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Abstract 
An abundance of clinical data has demonstrated that a subset of asthmatic patients present with 
a neutrophilic infiltrate that is anticipated to be implicated in the pathology of the disease. 
However, this assumption is based largely on circumstantial evidence and the exact role of 
neutrophils in the pathophysiology of asthma has not been extensively explored. The aim of 
this thesis therefore was to elucidate the role of neutrophils in asthma by utilizing the house 
dust mite (HDM) murine model of allergic airway disease (AAD). 
We demonstrated that administration of HDM to different inbred mouse strains yielded very 
different inflammatory and airway remodelling profiles culminating variable airway 
hyperresponsiveness (AHR). Pertinently, whereas HDM-exposed 129/S2 mice exhibited a 
hyper-eosinophilic response, Balb/c mice presented with a mixed granulocytic response with a 
prominent neutrophilic component, which was TLR-4 independent.  
Specific depletion of neutrophils in HDM-exposed Balb/c mice was not protective but actually 
resulted in increased Th2 inflammation, with elevated ILC2s, Th2 CD4+ T cells, Th2 cytokines 
and serum IgE and IgG1 antibody responses. This elevated type 2 inflammation in neutrophil 
depleted animals was dependent on augmented Th2 cytokine production by ILC2s and a 
monocytosis that gave rise to enhanced antigen presentation. G-CSF was substantially elevated 
in neutrophil depleted mice and directly promoted the Th2 cytokine production by ILC2 and 
drove the monocytosis by acting on progenitors in the bone marrow. This data demonstrates 
that neutrophils may play a regulatory role in restricting Th2 inflammation rather than being 
strictly pathological.  
The enzyme leukotriene A4 hydrolase (LTA4H) regulates two distinct pathways that 
reciprocally regulate neutrophil recruitment. Classically, LTA4H functions intracellularly to 
generate the pro-inflammatory lipid mediator and potent neutrophil chemoattractant 
leukotriene B4 (LTB4). Accordingly, pharmaceutical companies have developed LTA4H 
inhibitors for the treatment of asthma, but they have failed to demonstrate efficacy in the clinic. 
Rationalizing the failure of these inhibitors, my lab have previously demonstrated a secondary 
extracellular anti-inflammatory role for LTA4H in degrading neutrophil chemoattractant 
Proline-Glycine-Proline (PGP). We have now demonstrated that mice lacking the LTB4 
receptor, BLT1, showed reduced inflammation and AHR upon HDM exposure relative to wild 
type controls. Conversely, HDM treated lta4h-/- mice displayed an exacerbated airway 
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resistance relative to littermate controls, despite being incapable of generating LTB4 and 
displaying reduced Th2 inflammation. This exacerbated airway resistance in lta4h-/- mice was 
attributable to a novel, neutrophil-independent, role for PGP in the context of AAD in driving 
pathological airway remodelling, with a pronounced epithelial hypertrophy and mucus 
hypersecretion apparent.  
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1 Chapter 1: Introduction 
1.1 Neutrophil biology 
 Neutrophil development 
Neutrophil development or granulopoieses occurs within the bone marrow, which also 
subsequently acts as a reservoir for mature neutrophils1. Neutrophil development in the bone 
marrow is a sequential, step-wise process from the haematopoietic stem cell (HSC) lineage 
(Figure 1.1). Granulocytes and monocytes/macrophages share a similar progenitor called the 
Granulocyte-monocyte progenitor (GMP) during early stage differentiation from stem cells. It 
is believed that the default cell to arise from GMPs are macrophages2. Expression of 
transcription factors such as early growth response protein-1 (Egr1) and homeobox protein-7 
(HOXB7) along with different mediators and cytokines such as S100A8, S100A9 and 
Granulocyte-macrophage colony stimulating factor (GM-CSF) ensure the development of 
neutrophil committed progenitors2. The exact mechanisms by which the above proteins aid in 
neutrophil committed progenitor divergence from GMPs is less clearly understood. 
The first committed neutrophil progenitor after differentiation from GMPs is the myeloblast 
which subsequently differentiates into promyelocytes, myelocytes, metamylocytes, band and 
then finally terminally differentiated neutrophils (Figure 1.1). Transcription factors3 and most 
recently discovered microRNAs (mRNA)4 all work in a concerted manner at different stages 
of development to ensure the effective differentiation of neutrophils. Two key transcription 
factor families involved in the early stages of granulopoiesis are CCAAT-enhancer-binding-
proteins (C/EBPs) and PU.1. C/EBPs bind to deoxyribonucleic acid (DNA) as a homo or 
heterodimer protein5. C/EBP-α is critical in the development of neutrophils and C/EBP-α -/- 
mice lack neutrophils5. C/EBP-α has been shown to be important in the transition of GMPs to 
myeloblasts. Additionally C/EBP-α is important in restricting proliferation particularly at the 
myelocyte stage by directly6 or indirectly7 interacting with protein, E2F to restrict the 
transcription of proteins necessary for the S-phase of the cell cycle1,4. Other C/EBP types such 
as C/EBP-β, C/EBP-δ, C/EBP-ε are also important to neutrophil development particularly at 
the latter stages of development1,4,8. Hirai et al. have found that during emergency 
granulopoieses, C/EBP-β is critical to neutrophil production and functions in a similar capacity 
to that of C/EBP-α9. C/EBP-ε is usually expressed between the myelocyte to metamyelocyte 
differentiation stages where like its counterpart, C/EBP-α it restricts cell cycle progression4. 
Additionally C/EBP-ε appearance coincides with the appearance of neutrophil specific or 
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secondary  neutrophil granular proteins (Section 1.1.2) and mice lacking C/EBP-ε produce 
neutrophils that lack these respective granules8. 
PU.1 binds to DNA as a monomer4 and is implicated in monocyte differentiation.  However, it 
is important to note that deletion of PU.1 can severely reduce neutrophil numbers10. It is the 
balance between C/EBP-α and PU.1 that dictates the commitment to monocyte or granulocyte 
lineages1.  At the GMP stage lower levels of PU.1 are associated with promoting neutrophil 
lineage commitment, however from the promyelocyte stage onwards PU.1 along with its co-
activators c-jun and c-fos become important in the development of myelocytes and 
metamyelocytes1. 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Summary of neutrophil development.  
Neutrophils are derived from the HSC lineage where the neutrophil committed progenitor, the myeloblast is 
derived from the GMP. The myeloblast subsequently differentiates into promeylocytes, myelocytes, 
metamyselocytes, band cells and finally terminally differentiated neutrophil. Different neutrophil granules such 
as azurophil granules (red), specific granules (blue), gelatinase granules (green) and secretory vesicles (yellow) 
are produced during different stages of development. Different transcription factors namely, C/EBP-α, PU.1, Gf-
1, C/EBP-β, C/EBP-δ and C/EBP-ε all aid in neutrophil development at different stages. Adapted from: Cowland 
et al. Immunological Reviews (2016). 
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 Neutrophil granules 
Granules are a major feature of neutrophil appearance and function. Neutrophils are armed with 
pre-formed granules for fusion with phagocytic vacuoles (Section 1.1.7) or for expulsion from 
the cell by exocytosis11. Traditionally neutrophil granules were divided into peroxidase positive 
and peroxidase negative granules based upon the presence of myeloperoxidase (MPO)4. It has 
become clear that considerable heterogeneity within peroxidase-negative granules exist1,4. 
There are 3 types of granules identified in neutrophils namely azurophil, specific and gelatinase 
granules (Figure 1.2) that are all named according to their granule contents and the stages upon 
which they appear during terminal granulopoieses. 
Azurophil granules are peroxidase positive and are easily identifiable by histological staining. 
These granules are also termed primary granules as they are the first granule type detected 
during granulopoieses where their appearance occurs at the promyelocyte stage4. Although 
MPO is the defining protein of azurophil granules, these granules are armed with a myriad of 
other proteins that are primarily bactericidal and destructive to local tissue. These include 
proteins such as the serine proteases cathepsin G, neutrophil elastase, NSP4 and proteinase-3 
and cationic antimicrobial protein azurocidin4,12. Defensins and bactericidal permeability-
increasing protein have also been found to be present in azurophil granules13.  
Peroxidase negative granules are divided into specific granules and gelatinase granules. 
Specific and gelatinase granules are also termed as secondary and tertiary granules, 
respectively due to their sequential appearance during granulopoieses where they appear at 
myelocyte-metamyolcyte and band cell stages4. Many proteins found within these granules are 
similar and thus distinction initially proved problematic4. In 1993, however, neutrophil 
gelatinase associated lipocalin, NGAL, was identified to be uniquely found within gelatinase 
granules14. Specific granules contain an array of antibacterial proteins such as lysozyme, 
lactoferrin, haptoglobin and pentraxin-34,15. Additionally proteases such as collagenase, 
cystatins and small amounts of gelatinase are found within these granules4,15. Gelatinase 
granules primary source of gelatinases such NGAL but other proteins such as arginase-1 and 
lysozyme have also been shown to be present in within these granules1,4,15. 
Proteins expressed on the membranes of each granule type can also differ significantly and 
allows further distinction between granule subsets. Azurophil granules express significantly 
lower levels of CD11b and NOX2 proteins compared to the specific and gelatinase granules4. 
Specific and gelatinase granules, unlike their azurophil granule counterparts, possess higher 
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levels of the vesicle-associated membrane proteins (VAMP-2), a type of calcium sensitive v-
SNARE membrane fusion protein important in exocytosis16. The highest concentration of these 
proteins is in gelatinase granules and decreases in specific granules4. Therefore, upon 
stimulation and augmentation of intracellular calcium concentrations within the neutrophil, the 
gelatinase granules would primarily undergo exocytotosis, followed by the specific granules. 
Prolonged stimulation of the neutrophil would be required to cause the release or exocytosis of 
azurophil granules either extracellularly or into the phagocytic vacuole.  
Another membranous structure present within neutrophils are secretory vesicles. These 
vesicles are formed by endocytosis and are subsequently thought to carry an array of receptors 
to the surface membrane of neutrophils during exocytosis15. Secretory vesicles contain even 
higher concentrations of proteins associated with membrane fusion and exocytosis, such as 
CD11b and VAMP-2, than gelatinase granules and therefore are the first vesicles to channel to 
the membrane upon stimulation4,15,17.  
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Figure 1.2: Summary of neutrophil granules.  
Neutrophils possess 3 different granule subsets formed at different stages of granulopoieses and armed with 
different protein contents. Secretory vesicles are also prominently found within neutrophils that mainly carry cell 
surface proteins to the neutrophil membrane. Neutrophil granules and secretory vesicles exhibit different 
propensities for exocytosis dependent on the level of stimulation or activation by inflammatory and antigen 
signals. Adapted from: Pham, C.T. Nature Reviews Immunology (2006). 
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 Neutrophil mobilisation 
The bone marrow is a large source of neutrophils and accounts for up to 90% of these cells1,4. 
After development in the bone marrow, neutrophils are mobilised into the blood stream. Only 
1-2% of the total pool of neutrophils are present in the blood stream under homeostasis, 
indicating that certain factors are regulating neutrophil retention and egress from the bone 
marrow18. 
CXCL12 (SDF-1) has widely been acknowledged as being critical in retaining neutrophils in 
the bone marrow via interaction with the receptor, CXCR4 on the neutrophil19. CXCL12 is 
constitutively produced by stromal cells in the bone marrow including osteoblasts and 
endothelial cells20. In order for neutrophils to migrate out of the bone marrow, this CXCL12-
CXCR4 axis must be disrupted. Experiments with CXCR4 antagonist, AMD3100, have 
extensively been shown to mobilise neutrophils20. Under homeostatic conditions, Granulocyte 
Colony Stimulating Factor (G-CSF) has been shown to be important in disrupting the CXCL12-
CXCR4 axis and promoting neutrophil egress by a variety of mechanisms. Levesque and 
colleagues in 2003 showed that G-CSF triggers the release of neutrophil proteases that degrade 
CXCL1221. Additionally, other studies have demonstrated that G-CSF directly reduces the 
expression of CXCL12 in stromal cells within the bone marrow22. During neutrophilic diseases 
and infection, G-CSF is elevated and promotes neutrophil egress from the bone marrow and 
granulopoiesis20. 
Many diseases where neutrophilia has been implicated have consistently shown elevations in 
neutrophil chemokines in the blood. Within the bone marrow, chemokines are expressed by 
osteoblasts and endothelial cells which are released upon G-CSF treatment23. Martin et al. 
demonstrated that bone marrow CXCL12 can reduce neutrophil chemokine effects in the bone 
marrow19 suggesting a link between CXCR2 and CXCR4 where they may have antagonist 
effects on each other. 
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 Neutrophil recruitment 
In order to reach a target tissue, mature neutrophils will need to migrate to the area of 
inflammation and be able to extravasate from the vasculature into the interstitium. This 
transmigration of neutrophils is often described as a sequential cascade involving the neutrophil 
itself and the endothelium lining the blood vessels1. Recognised steps of the commonly 
described neutrophil recruitment cascade involve tethering, rolling, adhesion, crawling and 
finally transmigration into the tissue24 (Figure 1.3).  
Common cues initiating neutrophil migration to a tissue site include pattern associated 
molecular patterns (PAMPs) expressed or released by bacteria and other pathogens, damage 
associated molecular patterns (DAMPs) usually released from damaged and dying cells which 
subsequently trigger the release of neutrophil chemoattractants or cytokines from local stromal 
cells and macrophages25. DAMPs, PAMPs and neutrophil chemokines/chemoattractants drive 
the up-regulation of adhesion molecules, such as P-selectin and E-selectin, on the apical surface 
of endothelial cells, which subsequently bind to heavily o-glycosylated carbohydrates such as 
P-selectin glycoprotein ligand or E-selectin ligand-1 and CD44 present on the surface of 
neutrophils26,27. The tethering step of the neutrophil recruitment cascade involves the initial 
binding of these respective receptors and ligands, which initiates the slowing down of free 
flowing neutrophils in the vasculature. The transition from the initial neutrophil tethering to 
the endothelium to the rolling step is mediated primarily by E-selectin and E-selectin ligand-1, 
and that CD44 mediated the clustering of  P-selectin glycoprotein ligand and L-selectin to drive 
further slowing down of the neutrophils24,26. 
β2-integrins such as LFA1 and Mac-1 (also known as CD11b-CD18) are constituvely 
expressed on the surface of neutrophils24. Neutrophil adhesion to a specific site on the 
endothelium is mediated by LFA-1 binding to its ligand intercellular adhesion molecule-1 
(ICAM-1) on the surface of endothelial cells24. In order to efficiently function, both these 
integrins need to undergo conformational changes and translocation to the surface membrane 
of neutrophils to facilitate binding to their respective ligands. This process occurs after initial 
activation of the neutrophil following E-selectin and E-selectin ligand binding and the 
interaction of neutrophils with specific cytokines or chemoattractants28. This process of the 
upregulation of adhesion molecules post activation by selectin and cytokine binding is known 
as inside-out signalling.  
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Once neutrophils have adhered to the endothelium, they undergo a crawling process, whereby 
the cells elongate and probe surroundings24. The interaction of Mac-1 with ICAM-1, mediates 
the crawling of neutrophils to the site of transmigration by readily recycling Mac-1 to the 
leading edge of the cell29. Neutrophil transmigration can occur transcellularly, where the cell 
will pass through an endothelial cell, or paracellularly whereby the neutrophil will pass 
between two adjacent endothelial cells1,27. Paracellular migration of neutrophils is the most 
common route of transmigration and requires the breakdown of junctional interactions such as 
those formed by vascular-endothelial cadherins, and endothelial cell-selective adhesion 
molecules24,30. During transcellular migration the endothelium forms projections rich in 
adhesion molecules, such as ICAM-1, which surround the leukocyte and allow it to penetrate 
the cell and pass though1,24. A wide range of integrins and selectins have been suggested to be 
involved in the transendothelial migration step of neutrophil recruitment, including ICAMs, 
vascular cell adhesion proteins (VCAMs), platelet/endothelial cell adhesion molecule 
(PECAM-1), junctional adhesion molecules (JAMs) and CD991,24,27. Recent studies have 
demonstrated that neutrophils also possess the ability to migrate away from the site of 
inflammation termed as neutrophil reverse transmigration. The reason for physiological 
relevance for reverse transmigration remains incompletely understood but studies past and 
present have suggested that reverse transmigration may be linked to neutrophil clearance and 
downregulation of an inflammatory response31. 
Intravital microscopy of mesenteric vessels has enhanced our understanding greatly of 
neutrophil extravasation24, but it is however important to note that in the lung this mechanism 
may differ32. For example, the lung microvasculature is comprised mainly of capillaries within 
which neutrophils adopt different shapes to pass through the vessels. Additionally blood flow 
velocity is significantly lower in the lung microvasculature, therefore increasing neutrophil 
sequestration time through the lung32. Both of these factors have led to suggestion that 
neutrophils may be “mechanically trapped” in the lead up to neutrophil rolling and 
adhesion24,32. With the theory of “mechanical trapping” in mind, there has been questions as to 
whether selectins are actually required for recruitment of neutrophils into the lung tissue. Some 
papers have shown a critical requirement of selectins33 whereas this has been challenged in 
recent intravital microscopy studies24. 
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Figure 1.3: Summary of neutrophil transmigration through the endothelium.  
Neutrophils undergo a sequential cascade at the endothelial bed to enter the site of inflammation.  These steps 
involve the initial formation of bonds between integrin and selectin molecules present on the surface of neutrophils 
and endothelial cells. Neutrophils then adhere to the endothelium, and crawl to the site of transmigration where 
they pass through via paracellular or transcellular migration. Adapted from Kolaczkowska and Kubes, Nature 
reviews Immunology (2013). 
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 Neutrophil clearance 
In steady state and diseased conditions, neutrophils spontaneously undergo apoptotic death 
programs34 and are cleared via the liver, spleen and bone marrow. In the liver, apoptotic 
neutrophils are thought to be taken up by Kuppfer cells upon P-selectin upregulation in 
sinusoids35. Red pulp macrophages have been shown to be important in the clearance of 
neutrophils in the spleen, however, whether there are other cell types involved in neutrophil 
clearance remains speculative34. Bone marrow homing receptor, CXCR4 is thought to be 
crucial in homing ‘senescent’ neutrophils back to the bone marrow for uptake by stromal 
macrophages18. 
 Neutrophil chemoattractants 
To ensure effective neutrophil recruitment to a particular site in response to infection or tissue 
damage, a multitude of inflammatory and stromal cells work in a coordinated manner to 
produce chemokines that establish gradients to facilitate the direction of neutrophil migration. 
A multitude of cells can produce these chemokines such as neutrophils themselves, 
macrophages and lymphocytes36. Additionally stromal cells such as epithelial and endothelial 
cells can produce these chemokines37. Neutrophil chemokines can set up long ranging 
chemokine gradients by binding to glycosaminoglycans (GAGs) found in the extracellular 
matrix38. Additionally, these chemokines can line the walls of the endothelium to ensure 
neutrophil transmigration24. Table 1.1 summarises the wide range of neutrophil chemokines 
identified in mouse and human. These chemokines belong the CXC family which has four 
cysteine residues at the N-terminus of the molecule36,37. These chemokines are characterised 
by the presence of a glutamic acid-leucine-arginine (ELR) motif before the CXC sequence37. 
The most prominently studied neutrophil chemokine found in humans is IL-8 (CXCL8), which 
binds to CXCR1/2 abundantly expressed on the surface of the neutrophil. Other well defined 
neutrophil chemokines in humans are GRO-α (CXCL1), GRO-β (CXCL2) and GRO-γ 
(CXCL3), which selectively bind CXCR225. In mice, key neutrophil chemokines include 
keratinocyte chemokine (KC or CXCL1) and macrophage inhibitory protein-2 (MIP-2 or 
CXCL2) which both bind to receptor CXCR225. CXCL5 or lungkine is another neutrophil 
chemokine that is elevated in bacterial challenge models and binds to CXCR239.  
In addition to the commonly described neutrophil chemokines, other peptides, cytokines and 
eicosanoids (summarised in Table 1.2) can induce neutrophil recruitment and activation. N-
formyl peptides such as fMet-Leu-Phe (fMLP) function as an early stage neutrophil 
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chemoattractant during tissue injury or infection. Whilst fMLP  is classically viewed as bacteria 
derived, it can additionally be released from necrotic cells via disruption of the 
mictochondria40. Complement factor proteins, C5a and C3a function as neutrophil 
chemoattractants by binding to receptors C5aR and C3aR abundantly expressed on 
neutrophils25.  
Eicosanoids are lipid mediators that are generated by the metabolism of cell wall component 
arachidonic acid, resulting in the generation of an array of pro-inflammatory and anti-
inflammatory molecules41. An important neutrophil chemoattractant derived from the 
arachidonic acid pathway is leukotriene B4 (LTB4), which binds to G-coupled protein receptors 
(GPCRs), BLT-1 and -242. Similar to CXCL8 family chemokines, cells such as neutrophils, 
macrophages and lymphocytes produce LTB437. LTB4 can also amplify neutrophil 
chemoattractive effects and is discussed in more detail in Section 1.2.2. Another cytokine 
implicated in the recruitment of neutrophils is interleukin-17 (IL-17). This cytokine is produced 
commonly by T cells from the adaptive immune response. The exact mechanism by which IL-
17 induced neutrophil recruitment remains unclear with direct and indirect actions of the 
cytokine on neutrophils being described (discussed further in Section 1.3.4.4). 
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Nomenclature Receptor 
General Human Murine 
Human 
neutrophils 
Mouse 
neutrophils 
CXCL1 GRO-α KC CXCR2 CXCR2 
CXCL2 GRO-β MIP-2 CXCR2 CXCR2 
CXCL3 GRO-γ n/a CXCR2 n/a 
CXCL5 ENA-78 LIX CXCR2 CXCR2 
CXCL6 GCP-2 n/a CXCR1/CXCR2 n/a 
CXCL7 NAP-2 NAP-2 CXCR1/CXCR2 CXCR2 
CXCL8 IL-8 n/a CXCR1/CXCR2 CXCR2 
CXCL12 SDF1A SDF-1A CXCR4 CXCR4 
Table 1.1: Summary of neutrophil chemokines.  
There are a variety of neutrophil chemokines described to date in mouse and human. The chemokines have 
different nomenclatures in mouse and human. Adapted from: Sadik et al. Trends in Immunology (2011). 
 
 
 
 
 
 
 
 
 
 
Table 1.2: Summary of non-chemokine neutrophil chemoattractants.  
Different protein mediators and eicosanoids have been shown to possess chemoattractive properties to neutrophils 
by binding to their respective receptors. Adapted from: Sadik et al. Trends in Immunology (2011). 
 
Nomenclature Receptor 
Peptide/Protein 
C5a C5aR 
C3a C3aR 
Formylated peptides (e.g. fMLP) FPR1 
Proline-Glycine-Proline (PGP) CXCR2 
LL37 FPR2 
Eicosanoids 
Leukotriene B4 BLT-1 
Platelet activating factor (PAF) PAFR 
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 Neutrophil killing mechanisms 
Neutrophils provide anti-microbial activity by either phagocytosing and killing the invading 
organism or by the release of anti-microbial contents into the extracellular environment by 
degranulation11. During the process of phagocytosis, FCγR-rich pseudopod extensions from 
the neutrophil are formed which engulf the antigen and bring it into the cytoplasm forming a 
phagosome43. Neutrophils are particularly efficient phagocytes and can internalise a target as 
quickly as 20 seconds43. The internalised organism in the phagosome is then destroyed after 
fusion with intracellular lysosomes to form phagolysosomes44. Neutrophils can destroy 
microbes either by oxidative measures, through the generation of reactive oxygen species 
(ROS), or by non-oxidative measures, through the use of anti-microbial peptides and proteases. 
These oxidative species and peptides are either released extracellularly or are leached into the 
phagolysosome. 
Generation of ROS by neutrophils is mediated by the enzyme nicotinamide adenine 
dinucleotide phosphatase oxidase (NADPH oxidase)3,24. NADPH oxidase was the first enzyme 
identified to be able to generate ROS. Upon neutrophil activation, the NADPH complex is 
assembled from components within the cytoplasm and membrane3. Key components of this 
enzyme are cytosolic proteins p47phox, p67phox and p40phox, which associate with membrane 
bound proteins gp91phox (NOX2) and p22phox45. Upon assembly, NADPH functions as an 
electron transferase, transporting electrons into the phagosome lumen and converting oxygen 
into superoxide45. Superoxide dismutases form hydrogen peroxide, which can disrupt protein 
structures and cell membrane integreity44. Azurophil granules also fuse with the phagosome 
and allow the entry of MPO into the phagosome. MPO catalyses the conversion of hydrogen 
peroxide into hypochlorous acid (HOCl) with the help of chloride ions. In-vitro studies have 
highlighted the potent anti-microbial activity possessed by HOCl46. Neutrophils are also a 
source of reactive nitrogen species derived from nitric oxide (NO). NO is usually formed by 
the action of nitric oxide synthase (NOS) on L-arginine47. Reaction of NO with reactive 
superoxides subsequently form nitrogen dioxide and reactive hydroxyl radical ions that aid in 
the breakdown of the antigen within the phagosome47. 
In addition to oxidative measures, neutrophils also contain an array of antimicrobial proteins 
that are efficient at killing specific pathogens3. α-Defensins such as human neutrophil peptides 
(HNPs)  are expressed mainly by neutrophils and are shown to be antibacterial in function 
although the exact mechanism of action remains unknown13. Defensins can reach very high 
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concentrations within the phagosome of neutrophils upon fusion with azurophil granules, and 
there is also evidence that defensin proteins can be released into the extracellular environment3. 
Neutrophils are also a source of serine proteases that can be released intracellularly into the 
phagosome or extracellularly by degranulation11. Neutrophil elastase (NE) is one such serine 
protease that cleaves a variety of bacterial virulence factors44. NE has previously been shown 
to disrupt membrane integrity resulting in cell death of Escherichia coli11. Cathepsin-G is 
another serine protease expressed by neutrophils that displays anti-microbial properties. 
Cathepsin-G has been shown to cleave bacterial proteins such as flagellin, thus contributing to 
antigen destruction within the phagosome48. Serine protease, proteinase-3 (PR3) is known to 
function in the cleavage of cathelicidins to their bioactive forms48. Cathelicidins are proteins 
produced by neutrophils that upon cleavage into bioactive forms can mediate a wide range of 
anti-microbial and pro-inflammatory responses44. Common active forms of cathelicidins 
include human antibacterial cathelicidin protein or hCAP and LL-371.  
Another strategy by which neutrophils can destroy microbial targets is via the formation and 
release of neutrophil extracellular traps (NETs). These antimicrobial structures were first 
described in 2004 by Brinkmann et al.49, who demonstrated that NETs are composed of granule 
and nuclear constituents that are able to bind both gram negative and gram positive bacteria 
and degrade their virulence factors. It has subsequently been demonstrated that NET scaffolds 
are composed of fibres with a diameter between 15-17 nm and consist primarily of DNA and 
histones50,51. Various factors have been shown to induce NETosis of neutrophils such as 
interleukin-8 (IL-8), tumour necrosis factor-α (TNF-α) and lipopolysaccharide (LPS)52. It has 
recently been shown that neutrophils can directly interact with microbes to induce NETosis, 
with the size of the microbe important in defining the decision to trigger NETosis instead of 
phagocytosis. Thus it is has been shown that large fungal hyphae structures trigger NETosis 
but smaller fungal spores readily induce phagocytosis by neutrophils50. The molecular 
mechanism by which neutrophils produce NETs has been further established, with Fuchs et al. 
suggesting that neutrophils undergo a novel cell death program to form NETs53. It was 
demonstrated that a collapse of nuclear and granule membranes occur within the neutrophil 
allowing the mixing of granule contents and chromatin before the cell membrane is ruptured 
to release NETs53. Furthermore, it has been shown that neutrophil elastase translocation to the 
nucleus to promote chromatin decondensation is a key initial step in triggering NETosis54. 
MPO has also been shown to be a key protease in triggering NETosis in a synergistic manner 
with neutrophil elastase54. 
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 Neutrophils in respiratory disease 
Neutrophils are armed with an array of anti-microbial and destructive enzymes and proteases 
and if neutrophil recruitment and clearance is perturbed, significant bystander or collateral 
damage will ensue at the site of inflammation. Accordingly, dysregulated neutrophil 
recruitment  is associated with the pathology of many lung diseases, such as chronic obstructive 
pulmonary disease (COPD)55, acute respiratory distress syndrome (ARDS)56, asthma57, 
bronchiectasis58 and cystic fibrosis (CF)58.  
Studies on COPD patients have consistently demonstrated that the number of neutrophils in 
the alveolar space is linked with loss of lung function, regardless of current smoking status55. 
A long term study of tobacco smokers revealed that the number of airway neutrophils increased 
on an annual basis along with a gradual decline in lung function59. Studies have shown that the 
concentration of BALF neutrophils are increased in ARDS and correlates with poor patient 
outcome and disease severity56. Likewise in CF, neutrophil derived products often correlate 
with disease severity and is commonly used as a biomarker for disease progress and decline in 
lung function58. Neutrophil-derived proteases are thought to be instrumental in driving the 
pathology in COPD and other lung diseases. NE and PR-3 are capable of degrading 
extracellular matrix (ECM)  elastin contributing to lung architecture collapse and an 
emphesyma-like phenotype60,61. In degrading elastin, NE can also liberate elastin fragments 
that are chemotactic for monocytes and thus further perpetuate inflammation62. Neutrophils are 
also a rich source of matrix metalloproteinases (MMPs) that can degrade multiple components 
of the ECM that maintain the architecture of the lung63, as well as possessing 
immunoregulatory  functions that can further promote neutrophil migration64. MMP-9 is a 
prominent protease in neutrophilic diseases, whereby its excessive production is associated 
with pathology through degradation of ECM components such as collagen and laminin55,65. 
Matrix Metalloproteinase-8 (MMP-8) or neutrophil collagenase is another MMP released by 
neutrophils and implicated in pathology of disease. MMP-8 is capable of degrading collagen64 
and  has been found at elevated levels in patients with COPD and pulmonary fibrosis66,67.  
MPO is also linked with disruption of the lung architecture, with elevated levels of MPO 
reported in neutrophilic inflammatory conditions68–70. MPO has been shown to modulate the 
function of chemokines by enhancing their release and function63. O’Donnell et al. in 2010 
showed that MPO product, 3-Chlorotyosine, was increased in the sputum of COPD patients 
suggesting an active role of this protease in the disease71. Accordingly, administration of MPO 
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inhibitor provided by Astra Zeneca, AZ1, to guinea pigs abrogated emphysema and provided 
partial protection in a model of pulmonary hypertension72. 
 Methods to study neutrophils 
An abundance of circumstantial evidence suggestive that neutrophils are important in the 
development and progression of a variety of diseases. However, it is important to define the 
specific role neutrophils play in driving pathology. Subsequently, a multitude of methods have 
been developed to specifically deplete neutrophils in in-vivo animal models of disease.  
Classically, pharmacological agents such as cyclophosphamide and vinblastine have been 
utilised to target neutrophils. These chemotherapeutic agents have been shown to induce 
neutropenia in patients by supressing myelopoiesis73. Cyclophosphamide in particular has been 
used in a multitude of studies to delineate neutrophil specific effects73. However despite being 
potent at inducing neutropenia and mirroring the outcome of patients on chemotherapy, 
cyclophosphamide has been shown to deplete other cell populations such as lymphocytes and 
monocytes74. De Vooght et al. also showed that cyclophosphamide administration depleted 
most key effector cell types in a mouse model of allergic airway disease (AAD) highlighting 
it’s unspecific myelo-suppressive capacity75. 
With pharmacological agents becoming increasingly unreliable for defining neutrophil-specific 
actions, neutrophil-depleting antibodies have subsequently been developed. Fleming et al. in 
1993 were one of the first to describe a monoclonal antibody to granulocyte receptor-1 (Gr-1), 
RB6-8C5, that was able to deplete neutrophils76. Subsequently, this antibody has been 
extensively used to deplete neutrophils, but in recent years its cell specificity has been 
questioned. The RB6-8C5 antibody recognises cell surface antigens Ly6C and Ly6G and whilst 
Ly6G is neutrophil specific, it has been shown that Ly6C is expressed on many other leukocyte 
populations such as monocytes77 and plasmacytoid DCs78. CD8+ T cells have also been shown 
to express Ly6C and be depleted upon RB6-8C5 administration79. This led to the possible 
exploration of utilising Ly6G-specific monoclonal antibody, 1A8, to deplete neutrophils. The 
ligand for Ly6G, a protein that structurally belongs to the urokinase plasminogen (uPAR) 
family remains unknown80,81.  Wang et al. in 2012 were able to show that administration of 
high doses of this antibody resulted in specific depletion of neutrophils80. These authors also 
suggested that the depletion was caused by a β2-integrin dependent mechanism80 though this 
has been contested81, with a recent  study showing that Ly6G binding on the surface of 
neutrophils may increase their chances of being phagocytosed by local macrophages81. Whilst, 
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the exact function of Ly6G has yet to be determined,  genetic deletion of Ly6G in mice failed 
to alter neutrophil development or recruitment82. 
1.2 Leukotriene A4 hydrolase (LTA4H) 
 LTA4H biology 
Leukotriene A4 hydrolase (LTA4H) classically functions in a pro-inflammatory capacity in an 
intracellular environment, whereby it operates as an epoxide hydrolase to catalyse the 
hydrolytic conversion of leukotriene A4 (LTA4) into pro-inflammatory lipid mediator LTB4 
(Figure 1.4; Section 1.2.2). However, LTA4H is a highly unusual enzyme as it also operates in 
anti-inflammatory capacity in an extracellular environment as an aminopeptidase to degrade 
tri-peptide and neutrophil chemoattractant, Proline-Glycine-Proline (PGP) (Figure 1.4; Section 
1.2.3)83. LTA4H generally resides in the cytosol of most leukocytes with high levels of LTA4H 
detected within neutrophils and monocytes whereas eosinophils and lymphocytes possess 
relatively low amounts of LTA4H84,85. Various stromal cells such as fibroblasts, endothelial 
cells, keratinocytes and airway epithelial cells have also been demonstrated to express LTA4H 
despite lacking of the enzymatic machinery required to generate classical substrate LTA484. 
The function of LTA4H within these stromal cells remains unclear.  
LTA4H has been cloned and demonstrated to have a molecular mass of around 69kDa84. The 
crystal structure of LTA4H has revealed that the protein is folded to form 3 domains: N-
terminal, catalytic terminal and C-terminal86. The active site of this protein is found at the 
interface of all 3 domains and forms an L-shaped cleft (Figure 1.5).  The opening part of this 
cleft, near the protein surface, is wider and highly hydrophilic before narrowing into a 
predominantly hydrophobic tunnel that penetrates deeper into the protein86. LTA4H contains 
one zinc atom that is critical to its dual function, and is located within the hydrophilic wider 
region of the active site and co-ordinated with amino acid residues His-295, His-299 and Glu-
31885. Computational structural based studies have revealed that LTA4 occupies the entire 
binding pocket, with its epoxide moiety co-ordinating with the Zn and its long hydrophobic tail 
sitting within the narrow hydrophobic cavity87 (Figure 1.5 A). Conversely, it is believed that 
the wider hydrophilic region of the active site can bind to peptides such as PGP and is the site 
of the enzyme’s aminopeptidase activity (Figure 1.5 B)87. Mutational studies have 
demonstrated that all the zinc binding amino acids are critical for both activities of LTA4H, 
with other residues also identified as being specifically important for either the hydrolytic or 
aminopeptidase functions. Glu-29688 and Tyr-38389 have been demonstrated to be critical to 
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the aminopeptidase function (functioning as a general base and proton donor, respectively) 
without being necessary for the epoxide hydrolase activity of the enzyme . Conversely, 
Rudberg et al. found that Asp-375 is specifically important for the epoxide hydrolase function 
of the enzyme90. Similarly, Arg-563 has been identified as another key amino acid residue in 
the epoxide hydrolase function of LTA4H91. 
 
Figure 1.4: The dual roles of LTA4H. 
LTA4H possesses two opposing inflammatory roles, a pro-inflammatory hydrolytic role limited to the intracellular 
compartment of leukocytes and an extracellular aminopeptidase anti-inflammatory role. In a variety of leukocytes, 
membrane phospholipids can be broken down and form different bioactive lipid mediators by a sequence of steps 
involving different enzymes. Arachidonic acid is an upstream membrane phospholipid derivative that leads to the 
production of various lipids that modulate the inflammatory response. Arachidonic acid is converted into 
Leukotriene A4 (LTA4) by 5-lipoxygenase, an enzyme that requires to be activated by FLAP. LTA4 can then be 
converted in cysteinyl leukotrienes (LTC4, LTD4 and LTE4) by LTC4 synthase enzyme. Alternatively, LTA4 can 
be converted into lipoxin lipids, mediated by lipoxygenases. LTA4 can also be converted into leukotriene B4, a 
powerful pro-inflammatory lipid mediator. This production occurs within the intracellular compartment of 
leukocytes by an enzyme called Leukotriene A4 Hydrolase (LTA4H). LTA4H also possesses an anti-inflammatory 
role where extracellularly, this enzyme can degrade PGP, a tri-peptide and neutrophil chemoattractant formed by 
the breakdown of collagen by enzymes MMP-8/9 and Prolylendopeptidase. 
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 Leukotriene B4 
LTB4 is a powerful pro-inflammatory lipid mediator, capable of driving the recruitment and 
activation of an array of immune cells. LTB4 exerts its activity by binding to two receptors, 
BLT-1 and BLT-2. BLT-1 is the high affinity receptor for LTB4 and is expressed on the surface 
of a variety of leukocytes92, including neutrophils, eosinophils, mast cells, dendritic cells, T 
cells and B cells93. Additionally, stromal cells such as smooth muscle cells, endothelial cells 
and neural stem cells also express BLT-1. BLT-1 is a GPCR coupled to Gi and G16 proteins 
and downstream signalling from BLT-1 receptor binding leads to increases in intracellular 
calcium and a variety of signalling responses92 which ultimately enhance chemotaxis94, 
upregulation of transmigration adhesion molecules95 and activation and priming for 
degranulation96. There have been suggestions that other eicosanoids including 12-HETE and 
Resolvin E1 can bind to BLT-1, however at considerably lower affinities than LTB497,98.  
BLT-2 exhibits approximately 20-fold less affinity for LTB4 compared to its counterpart, BLT-
1. The expression of BLT-2 is also more ubiquitous compared to BLT-1 and is widely 
expressed in multiple organs across the body. BLT-2 is most abundantly expressed in the 
spleen, other organs such as liver, muscle and heart also express BLT-293. BLT-1 is expressed 
more on leukocytes compared to BLT-2 but eosinophils have been shown to express low levels 
of BLT-299. Numerous eicosanoids having been shown to bind to BLT-297. Okuno et al. have 
shown that 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic  acid (12-HTT) possesses a higher 
affinity than LTB4 for BLT-2 and may represent the more physiological ligand for this 
Figure 1.5: The active site of LTA4H. 
The active site of LTA4H is an L-shaped binding pocket with a hydrophobic tunnel located on one side of the 
active site (Site A), and a Zinc motif located at the hydrophilic catalytic site on one side (Site B). LTA4 (A) 
occupies both sites A and B, whereas PGP (B) PGP occupies just Site B. 
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receptor100. Chiba et al. have shown that BLT2 is important in maintaining barrier function by 
mediating effective actin polymerisation in keratinocytes with 12-HHT used as the agonist101. 
Thus recent indications point to a more regulatory role of BLT-2 relative to BLT-1. This 
regulatory role of BLT-2 was also highlighted in a mouse model of AAD102. BLT-2 deficient 
mice developed a robust Th2 inflammation accompanied with an increase in AHR102 compared 
to respective wild type mice. It was discussed that agonist 12-HHT was able to impose this 
regulatory function via its interaction with BLT-2102.  
LTB4 is one of the most potent neutrophil chemoattractants and activators known, and can also 
potentiate neutrophil responses to other mediators103. Afonso et al. in 2012 showed that 
neutrophils produce LTB4 in an autocrine fashion at the leading edge of the cell to ensure 
forward migration to fMLP molecules104. They also showed that neutrophils relay LTB4 signals 
during different stages of recruitment while migrating to the target tissue104. In a model of 
sterile-induced injury, local neutrophils lacking the receptor for LTB4 were able to migrate to 
the site of injury but distant neutrophils were unable to migrate to the site suggesting LTB4 is 
important in driving persistent and sustained neutrophil recruitment105. LTB4 also has effects 
other cell types.  LTB4 is a potent chemoattractant for immature mast cells from the bone 
marrow106. Furthermore, LTB4 has been demonstrated to induce the migration and activation 
of monocytes, dendritic cells and eosinophils107,108. In 1998, Huang et al. demonstrated the 
chemoattractive effects on LTB4 on eosinophils and other leukocytes alike109. They 
demonstrated that LTB4 receptor expression increased in eosinophils, neutrophils and 
macrophages upon stimulation and addition of LTB4 leads to an augmentation in intracellular 
calcium, thus hinting at a cellular response109. LTB4 has been shown to be important in 
eosinophil action against parasites whereby eosinophil accumulation around nematodes was 
dependent upon paracrine LTB4 signalling110. Other studies have highlighted the importance 
of LTB4 on dendritic cells, another cell type important in inducing allergenic responses. 
Transfer of DCs lacking the receptor of LTB4 to wild type mice markedly attenuated allergen-
induced airway hyperresponsiveness (AHR)111. The receptor of LTB4 is abundantly present on 
all T cell subsets112,113. LTB4 has been shown to be chemotactic for T-helper cell 1 (Th1) and 
T-helper cell 2 (Th2) cells upon stimulation114. Furthermore, LTB4 facilitates the recruitment 
of T cells from the bloodstream by aiding in cell adhesion to the endothelium112. Recently, 
Wonyong et al. have demonstrated that LTB4 is particularly important in inducing the 
migration of T-helper cell 17 (Th17) cells in a mouse model of autoimmune 
encephalomyelitis115. Cytotoxic CD8+ T cells express the receptor of LTB4, with LTB4 
Chapter 1: Introduction 
47 
 
promoting chemotaxis and integrin up-regulation of CD8+ T cells  and thus aiding in the 
recruitment of  these cells116. 
Given its wide functions on a variety of inflammatory cell type, LTB4 is indeed a critical 
mediator in providing immunity. However, LTB4 is also implicated in pathology of a wide 
range of inflammatory conditions. LTB4 has been extensively studied in the context of allergic 
disease. LTB4 is anticipated to be important in neutrophil, eosinophil and Th2 cell migration 
into skin lesions of patients with atopic dermatitis and Reilly et al. demonstrated that LTB4 is 
elevated in skin biopsies from atopic dermatitis patients117. Furthermore, LTB4 is also elevated 
in allergic rhinitis and Tanou et al. have shown that neutrophils isolated from peripheral blood 
from allergic rhinitis patients were able to produce more LTB4 upon calcium ionophore 
stimulation118. LTB4 has also been implicated in allergic conjunctivitis, whereby LTB4 has 
been shown to be a critical mediator in driving mast cell degranulation119and eosinophilic 
infiltration into the conjunctiva of guinea pigs120. 
LTB4 has been implicated in a wide array of chronic pulmonary inflammatory diseases.  There 
has been extensive literature implicating LTB4 in asthma pathophysiology and this will be 
discussed in depth later (Chapter 5)121. Hubbard et al showed that LTB4 is important in 
neutrophil chemo-attraction in patients with emphysema due to alpha 1-antitrypsin 
deficiency122. Likewise, in COPD, LTB4 has been found in exhaled breath condensates of 
patients and levels of LTB4 significantly increased post exacerbations123. LTB4 has been shown 
to be elevated in the sputum124 and broncheoalveolar lavage fluid (BALF)125 of cystic fibrosis 
patients. Additionally LTB4 has been shown to be elevated in scleroderma lung disease126.  
 Proline-Glycine-Proline (PGP) and matrikine biology 
The ECM is the non-cellular component of tissues that provides a scaffold for constituent cells 
and is critical in the provision of biological cues that dictate development, homeostasis, 
inflammation and repair. Degradation of the ECM can liberate biologically active fragments, 
termed matrikines, which can dictate the progression of inflammation and injury seen in 
chronic lung diseases 127. Collagen-derived peptides have been shown to possess chemotactic 
potential for monocytes and fibrolasts128. Senior et al. demonstrated that elastin fragments 
generated by the action of NE and matrix metalloproteinase-12 (MMP-12) could be 
chemoattractants for monocytes128. MMP-12 deficient mice were subsequently protected from 
cigarette smoke-induced emphysema due to the inability of these mice to generate these elastin 
fragments129.  
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The tripeptide PGP is a matrikine derived from the proteolytic degradation of ECM collagen. 
PGP was discovered in the 1990s from a series of ophthalmology studies. Application of alkali 
to the eyes of rabbits elicited an injury that was driven by in influx of neutrophils into the 
cornea130. Subsequent digestion and mass spectrometry analysis of alkali treated corneas 
identified low-molecular weight peptides PGP and N-acetyl PGP as the instigators of 
neutrophil recruitment131. Subsequently, Weathingon et al. showed that PGP functioned by 
mimicking key sequences found in classical ELR+ CXC neutrophil chemokines and binding to 
CXCR1 and CXCR2132. They also demonstrated that blocking CXCR2 in-vitro and in an in-
vivo LPS model suppressed PGP-mediated neutrophil chemoattraction132.  
In 2008, Gaggar et al. more clearly delineated the proteolytic cascade required for PGP 
generation133. Initial cleavage of native collagen by MMP-8 or MMP-9 liberated fragments that 
were a suitable substrate size for the enzyme prolylendopeptidase (PE), which specifically cuts 
out the PGP motif133 (Figure 1.4). Neutrophils can release PE134 and recently  another study 
demonstrated that PE can also be released from airway epithelium via TLR4 activation135. 
Thus, neutrophils are capable of a creating a self-sustained vicious cycle of neutrophilic 
inflammation by releasing MMPs and PE that generate PGP that essentially lead to further 
neutrophil recruitment.  PGP, once generated can undergo further modification by acetylation. 
Reactive aldehydes within cigarette smoke can acetylate PGP (to form AcPGP) in a dose 
dependent manner83. Although physiologically mechanisms by which PGP becomes acetylated 
remains unknown, it could be speculated that reactive aldehydes that are formed during 
inflammation and stress could lead to acetylation of PGP but further studies are required to 
depict this. 
PGP has been extensively linked with pathology in neutrophilic airway diseases such as COPD 
and cystic fibrosis. Houwelingen. et al. showed that administration of PGP alone to the airways 
of mice can induce common emphysema-like changes such as alveolar enlargement and right 
ventricular hypertrophy that was reversed when mice were administered competitive PGP 
antagonist, RTR136. Similarly, in a murine model of cigarette smoke-induced emphysema, 
PGP/AcPGP was demonstrated to accumulate coinciding with neutrophilic inflammation and 
pathology; with neutrophilia ameliorated by RTR treatment137. Additionally, valproic acid, a 
PE inhibitor, reduced cigarette-smoke induced inflammation and PGP generation138. Studies 
have also shown elevated PGP/AcPGP in BALF samples of COPD patients132. O’Reilly et al. 
identified elevated sputum and serum PGP levels in COPD patients that correlated with 
neutrophil biomarker, MPO levels139. Subsequently, O’Reilly et al. demonstrated that 
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azithromycin treatment  reduced sputum PGP and MPO levels and coincided with an 
improvement in clinical outcomes140. Cystic fibrosis is another disease where PGP has been 
identified to be present141. One study found that 8 out of 10 patient CF sputum samples 
contained significant quantities of PGP compared to the sputum samples of healthy controls 
where no samples contained detectable levels of PGP133. Hardison et al. identified an increase 
in PGP and PGP generating enzymes, PE and MMP-9 in the BALF of bronchiolitis obliterans 
syndrome after lung transplantation142. 
In 2010, Snelgrove et al. observed that BALF from influenza treated mice was able to degrade 
PGP and that this activity was attributable to a previously unrecognised activity of the enzyme 
LTA4H in an extracellular environment83. PGP degradation by LTA4H was subsequently 
demonstrated to be the norm in episodes of acute pulmonary inflammation and critical to the 
efficient resolution of the neutrophilic response. It was subsequently shown that mice lacking 
LTA4H and infected with Haemophilus influenzae b developed significant neutrophilic 
inflammation caused by accumulation of PGP as a result of being unable to degrade the 
tripeptide143. Interestingly, Snelgrove et al. demonstrated that N-acetyl PGP was resistant to 
degradation by LTA4H and that chemicals within cigarette smoke were able to further perturb 
the aminopeptidase function of LTA4H83. In 2014, Wells et al. set out a study to investigate the 
LTA4H and PGP pathway in COPD patients and showed that sputum from smokers with COPD 
had elevated levels of PGP, concomitant with aberrant LTA4H aminopeptidase activity144. 
1.3 Asthma 
 Asthma epidemiology 
Asthma is one the most common chronic inflammatory diseases with more than 300 million 
people suffering from the condition worldwide145. The disease is particularly prevalent in 
developed western countries with an incidence of up to 10%145. However, asthma is 
increasingly being recognised as a global condition with asthmatics also found in developing 
countries albeit at a far lower prevalence145.  
Multiple epidemiological studies have shown a close association between asthma and 
hypersensitivity. Retrospective assessment of medical records of children have revealed that 
50% of children diagnosed with asthma by the age of 3 are atopic146. This study also 
demonstrated that 80% of children diagnosed with asthma by the age of 6 are atopic 
highlighting a clear link between asthma and atopy146. Gender studies have also revealed trends 
whereby asthma is more common amongst boys in early childhood. However, during 
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adolescence, boys are likely to undergo disease remission and girls are likely to develop the 
disease, thus the sex ratio reverses146,147. 
Severe asthma, characterised by the inability to respond to conventional asthma therapies such 
as inhaled corticosteroids present the most problematic asthma patient cohort148. Although only 
5-10 % of asthmatics present with a disease that can be classified as severe, these patients cause 
the greatest economic healthcare burden148,  with severe asthmatics estimated to contribute to 
up to 50 % of the healthcare costs of asthma as a whole149. 
 Asthma pathophysiology 
Persistent airway inflammation is a prominent feature in most asthmatic patients. Allergy 
occurs in up to 80% of asthmatic children and the majority of adult asthmatics and is classically 
characterised by type-2 inflammation145,146,150. This type of asthma is associated with 
sensitisation to environmental agents particularly pets, pollen, fungi and house dust mites 
(HDM)145,150. Allergen sensitisation requires the processing of allergen by antigen presenting 
cells such as dendritic cells (DCs) and subsequent presentation of the processed allergen 
peptides by major histocompatibility complex II (MHC II) to T cells in local draining lymph 
nodes151 (Figure 1.6). This ultimately invokes the development of Th2 cells that secrete 
cytokines such as Interleukin-3 (IL-3), Interleukin-4 (IL-4), Interleukin-5 (IL-5), Interleukin-9 
(IL-9) and Interleukin-13 (IL-13)150 (Figure 1.6). Furthermore, T cells can differentiate into T-
follicular helper cells, which subsequently migrate to the B cell follicles to initiate 
Immunoglobulin E (IgE) class switching and production152.   
Once sensitised, chronic exposure to allergen subsequently leads to long-term inflammation 
which may in turn lead to downstream remodelling changes to the airway which is discussed 
below. Allergens are recognised by IgE antibodies which subsequently activates local mast 
cells via binding to high affinity FC receptor, FCεR1150 (Figure 1.6). IgE-dependent mast cell 
degranulation involves the release of cysteinyl leukotrienes, prostaglandins and histamine 
which lead to bronchoconstriction and airway oedema subsequently leading to the early 
asthmatic response or EAR. Additionally, some Th2 cells migrate to the site of allergen 
exposure and exacerbate the ongoing inflammatory response through the release of their 
respective pathological cytokines to promote type 2 inflammation, eosinophil recruitment and 
airway remodelling (Section Section 1.3.3 and Section 1.3.4)145. Perros et al. demonstrated that 
this movement of Th2 cells to the airway mucosa is dependent of CCR4 ligands secreted by 
activated dendritic cells at the site of allergen exposure153. There is also a late-phase response 
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characterised by further bronchoconstriction that occurs a few hours post the EAR and is linked 
to inflammatory cell infiltration and cysteinyl leukotriene production.  
Airway remodelling is another key pathological feature of asthma (Figure 1.7). Typical 
remodelling features of asthma include epithelial cell damage, thickening of the basement 
membrane due to enhanced collagen deposition, airway smooth muscle hypertrophy, neuronal 
proliferation, angiogenesis and goblet cell metaplasia that leads to excessive mucus 
production145,154. In 1989, substantial remodelling of the basement membrane was first 
observed in asthmatic patients. Excessive deposition of collagen types I, III, V and VI in the 
basement membrane is brought about by mediators such as periostin and osteopontin155–157.  
Epithelial cell damage is another key feature of the airway remodelling and pathological 
appearance of asthmatic airways. Creola body formation formed by the dissociation of 
columnar cells from basal cells is a hallmark feature of epithelial damage in asthma145. 
Sustained release of oxygen radicals and inflammatory mediators contribute to epithelial 
damage158. Furthermore, many allergens contain enzymatic components that can directly 
damage epithelium and invoke cell death159. Perturbation of the epithelium can lead to release 
of DAMPs, alarmins and cytokines which are chemotactic for inflammatory cells159.  
Excessive mucus production is another hallmark feature of asthma and can form plugs in 
smaller airways leading to compromised airflow, air trapping and hyperinflation145. It has been 
anticipated that inflammation drives goblet cell metaplasia with studies showing that Th2 
cytokine levels in asthmatics correlate with increased mucus production160,161. Disruption of 
the epithelium can activate cells within the epithelial mesenchymal trophic unit composed of 
epithelial cells, fibroblasts and myofibroblasts162. These cells collectively are a potent source 
of members of the epidermal growth factor family that drive fibrosis and smooth muscle 
proliferation163. This unit can release factors such as periostin162 which leads to excessive 
collagen deposition, as detailed above. Recently the epithelial mesenchymal trophic unit has 
been shown to promote neuronal proliferation and angiogenesis by the release of 
neurotrophins164 and endothelial growth factors respectively165. Subepithelial microvascular 
pericytes and myofibroblasts have been linked with inducing muscle hyperplasia and 
angiogenesis145,166.  
Despite these responses being characterised in humans and animal models alike, this model of 
persistent inflammation does not apply to all cases of asthma with considerably heterogeneity 
found to exist amongst asthmatic patients, which will be explained in further detail in later 
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sections (Section 1.3.5). In fact, recent studies have noted that inflammation and remodelling 
are not always interlinked in asthmatic patients167. Thus, it is possible that genetic and 
environmental factors may alone be sufficient to drive airway remodelling and subsequent 
symptomology associated with asthma. One example of a factor that could delineate 
inflammation and remodelling is ADAM33168.  Disintegrin and metalloproteinase domain-
containing protein 33 (ADAM 33) is a glycoprotein commonly found in cell matrix interaction 
sites, thus its association with inflammatory cells is limited168.  In fact, polymorphisms 
associated with ADAM33 have been found in many asthmatic patient subgroups, particularly 
patients that do not respond to therapy targeting inflammation168. Furthermore, polymorphisms 
in children has been linked with the increased development of pre-school wheeze, AHR and 
decline in lung function with age169. The soluble fragment of ADAM33 possesses the capability 
to drive angiogenesis and myogenesis in vitro169. Thus a dysregulated role of ADAM33 may 
be sufficient to drive airway remodelling independent of airway inflammation. Like ADAM33 
gene, it is possible that other factors are indeed important in inducing inflammation-
independent remodelling. 
AHR is another key characteristic of asthma pathophysiology. Smooth muscle cells 
surrounding the airways contract after interaction with agents such as histamine which 
ultimately lead to narrowing of airways. Cysteinyl leukotrienes such as LTC4 and LTD4, largely 
derived from inflammatory cells are also important in inducing AHR150. Asthmatics display an 
AHR phenotype where this response to increasing doses of agonists is strikingly augmented 
ultimately leading to restrictive airflow170,171. Remodelling features such as increased smooth 
muscle and collagen deposition are considered to be important factors driving this exacerbated 
bronchoconstrictive activity of the asthmatic airways145. Inflammatory cell infiltrate and 
release of inflammatory mediators have also been associated with the AHR145.  
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Figure 1.6: Classical allergen sensitisation and challenge pathway in the lung. 
Allergens initially interact with antigen presenting cells such as dendritic cells which take up the allergen and 
migrate to local nodes. Upon entry into the lymph node, allergen peptides are presented to naïve T cells which 
eventually lead to the development of Th2 cells and expansion of local B-cell populations. The activated B-cells 
then begin to make IgE antibodies specific for the allergen. These antibodies bind allergen and subsequently 
activate local inflammatory cells such as mast cells. Th2 cells also migrate into the lung tissue, usually with the 
help of CCR4 ligands secreted by dendritic cells near the mucosal site that encounter allergen. Adapted from 
Hoffmann, F. et al. Frontiers in Immunology (2016) 
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Figure 1.7: Summary of asthma remodelling. 
Remodelling to the airways is a prominent feature of asthma. Common remodelling features include basement 
membrane thickening and smooth muscle hyperplasia. Most asthmatics tend to display inflammation around the 
airways. Adapted from, Olin, J.T. and Wechsler, M.E. BLJ (2014). 
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 Inflammatory cells in asthma 
Type-2 inflammation associated with asthma is mainly composed of Th2 cell and eosinophil 
infiltration into the airways145,150. Cells such as mast cells, neutrophils, macrophages, basophils 
and monocytes are also linked with the type-2 response150. 
1.3.3.1 Mast cells 
Mast cells were first described in 1878 by Paul Ehrlich and are commonly found at mucosal 
surfaces such as the airways172. Previous studies have shown a significant increase in the 
number of mast cells in asthmatics compared to healthy control patients173. Although mast cells 
are classically activated by cross-linking of FCεR1 receptors with IgE , they also possess a 
wide range of receptors to other inflammatory stimuli such as proteases174, complement175 and 
neuropeptides176. Mast cells are key effector cells in asthma and upon degranulation release 
histamine and serotonin that can cause smooth muscle contraction, enhanced vascular 
permeability and mucus hypersecretion177. Furthermore mast cells produce prostaglandins and 
cysteinyl leukotrienes such as Prostaglandin E2 (PGE2) and LTC4 which consequently lead to 
bronchoconstriction and remodelling172,177. Mast cells are also a source of cytokines that 
promote airway inflammation177. For example, Ho et al. demonstrated that Interleukin-33 (IL-
33) can trigger IL-13 production from mast cells by binding the ST2 receptors178. Mast cells 
have also been shown to be sources of IL-4 which is important in T cell recruitment and 
antibody production179.  
1.3.3.2 Eosinophils  
Eosinophils are granulocytes derived from the bone marrow that are considered to be a 
hallmark of the classical type 2 inflammation observed in asthma. IL-5 (Section 1.3.4.3) and 
eotaxin proteins (Section 1.3.4.6) are key regulators of eosinophil recruitment and activation180. 
Eosinophils are a source of cationic granule proteins that induce microvascular permeability 
and promote inflammatory responses181. Additionally eosinophils are a source of cysteinyl 
leukotrienes which as explained earlier, induce bronchospasms181. In allergen models, 
eosinophils have also been shown to drive Interleukin -18 (IL-18)182 and Interleukin-25 (IL-
25) production which activates Th2 cells via inducing the release of thymic stromal 
lymphopoietin (TSLP) (discussed in Section 1.3.4.5)183. Although it has been disputed in 
mouse eosinophils, human eosinophils have been widely acknowledged as sources of Th2 
cytokines, IL-4, IL-5 and IL-13184. Additionally, eosinophilic components such as major basic 
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protein and eosinophils peroxidase have been shown to be increased in asthma185,186, although 
manipulation of these genes had minimal effect in the mouse ovalbumin (OVA) model of 
AAD187,188. In-vivo models delineating the specific roles of eosinophils in AAD have displayed 
conflicting results. Utilisation of an anti-CCR3 depleting antibody and strains of mice that fail 
to develop eosinophils, PHIL and ΔdblGATA all exhbited abrogated eosinophilia upon HDM 
exposure. Despite all 3 strategies resulting in a loss of eosinophils, HDM-induced Th2 cytokine 
and antibody production and airway remodelling and hyperresponsiveness were unaffected 
relative to control animals189. In 2004, however, another study highlighted that ΔdblGATA 
mice were protected from OVA-induced inflammation and remodelling190. 
Sputum eosinophils were traditionally used to stratify asthmatic patients into groups since they 
were widely believed to be a suitable predictor of corticosteroid sensitivity191. Wenzel et al. in 
1999 reported that significant proportions of asthmatics display eosinophilia192. Asthmatic 
patients with significant eosinophilia have increased lymphocytic and mast cell infiltration 
accompanied with augmented basement membrane thickening compared to non-eosinophilic 
asthmatics. These findings have been further supported by various studies which also report 
reduced forced expiratory volume in 1 second (FEV1) levels and increased AHR193.  
1.3.3.3 T cells 
T cells are integral to providing immunity to a wide range of pathogens. T cells are derived 
from lymphoid tissues and several subsets of T cells exist. Each T cell subset is commonly 
identified by the cytokines and transcription factors each subset expresses or secrete. For 
differentiation into a particular T cell subset, naïve T cells require certain cytokine signals 
which are highlighted in Figure 1.8. 
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Figure 1.8: Summary of T cell subsets. 
There are different effector T-helper cell subsets that can be formed after differentiation from naïve T cells. For 
differentiation into a particular subset, naïve T cells require certain cytokine signals. Each T cell subset also 
produce cytokines unique to each subset. Th1 cells usually require IL-12 for formation and secrete cytokines 
such as IFN-γ and TNF-α. Th2 cells require IL-4 for their generation and these cells secrete cytokines IL-4, IL-
5 and IL-13 amongst others. Th9 cells require TGF-β for formation and secrete IL-9. Th17 cells usually require 
cytokines IL-1, IL-23 and IL-6 for their generation and commonly secrete cytokines IL-17, IL-23 and GM-CSF. 
Tregs require IL-4 and TGF-β for formation and secrete cytokines IL-10 and TGF-β. 
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Th2 cells are a hallmark feature of the classical inflammatory response associated with asthma, 
and key sources of IL-4, IL-5 and IL-13194. Th2 cells were identified in in asthmatic samples 
as early as the 1980s with  increased ‘CD4 helper-like T cells’ identified in the peripheral blood 
of asthmatic patients, which were reduced upon steroid treatment195. Robinson et al. 
subsequently described elevated levels of IL-4 and IL-5 in asthmatic patient’s BALF, with 
these cytokines predominantly produced by T cells196.  
Other CD4+ T cell subsets have also been implicated in asthma pathophysiology. Th1 cells, 
producing interferon-γ (IFN-γ), have been found in increased numbers in BALF of asthmatic 
patients197. Th17 cells, known for their ability to secrete IL-17A, have also been found to be 
increased in the lungs of asthmatics, particularly in patients with a severe and refractory 
phenotype of asthma198,199. The exact role of IL-17 in asthma and in inducing neutrophil 
recruitment is discussed in (Section1.3.4.4). T-regulatory cells or Tregs are a class of CD4+ T 
cells that possess largely regulatory and suppressive roles for inflammatory cell infiltrate. Tregs 
supress inflammation by a variety of ways, such as the secretion of anti-inflammatory cytokines 
interleukin-10 (IL-10) and transforming growth factor-β (TGF-β)200. Tregs possess surface 
markers that are crucial for mediating their suppressive roles on inflammatory cells. For 
example, cytotoxic T-lymphocyte-associated protein 4 (CLTA-4) on Tregs is crucial in the 
downregulation of co-stimulatory molecules, CD80 and CD86 on DCs200. Tregs have  been 
found in lower proportions in pro-inflammatory diseases such as asthma201,202. Recently, 
studies have found CD8+ T cells in lung tissue and BAL samples of asthmatics, particularly 
those with severe disease203. Adoptive transfer of sensitised CD8+ T cells in an OVA model of 
asthma reduced serum IgE concentrations and led to a reduction in AHR upon challenge204. 
Whilst CD8+ T cells are classically a source of type-1 cytokine IFN-γ, some studies have 
demonstrated CD8+ T cell to also be a  source of Th2 cytokines in ovalbumin sensitised 
mice205,206.  
1.3.3.4 Innate lymphoid cells (ILCs) 
ILCs are defined as cells with lymphoid morphology but lacking the classical lineage cell 
markers commonly ascribed to other lymphoid cells207. To date, 3 subsets of ILCs have been 
described; as defined by their transcription factors and cytokine profile. ILC1s are defined by 
their ability to produce cytokines IFN-γ and TNF-α and are important in providing immunity 
to bacteria208. ILC3s like their ILC1 counterparts promote antibacterial immunity and are 
implicated in tissue repair and chronic inflammation through the production of cytokines IL-
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17A, IL-17F and GM-CSF207,208. As discussed previously ILC2s, like their T cell counterparts 
are key sources of Th2 cytokines and have been tightly implicated in allergic responses150. The 
epithelium is recognised to be critical to the recruitment of ILC2s by the release of alarmins in 
response inflammatory stress, infection or allergens209. ILC2s have been shown to produce up 
to 40-fold more IL-5 and 10-fold more IL-13 compared to cultured Th2-cells210. A recent study 
by Halim. et al. in 2015 showed an interesting interplay between ILC2s, dendritic cells and 
Th2 cells whereby early IL-13 release from ILC2s invoked CCL17 release from local dendritic 
cells that subsequently attracted Th2 cells to the airways after administration of the protease, 
papain211. ILC2s have been shown to be increased in the BALF of severe asthmatics212. A study 
by Nagakumar et al. in 2015 reported increased numbers of ILC2s in the BAL, sputum and 
blood of children with severe therapy resistant asthma212.  
 Effector cytokines in asthma 
A multitude of cytokines have been detected in lung and airway samples of asthmatic patients. 
Most asthmatic patients and animal models of AAD exhibit robust Th2 inflammation. This has 
facilitated the dissection of the roles of specific cytokine networks in the pathology of AAD 
(Figure 1.9). 
1.3.4.1 Interleukin-4 
IL-4 signals through the IL-4R, which exists in two complexes namely type 1 and type 2. 
Receptor type 1 is found primarily on hematopoietic cells such as T cells, B cells, macrophages 
and mast cells213. Type 2 receptor is found on stromal cells such as airway smooth muscle cells 
and epithelial cells214. Autocrine signalling of IL-4 is anticipated to be the major mechanism 
by which T cells acquired a Th2 phenotype, however multiple studies have now identified other 
cellular sources of IL-4 such as NK cells215, mast cells216 and ILC2s208. 
IL-4 has been detected in the BALF of both asthmatic children and adults217,218. Batra et al. 
recruited asthmatic and non-asthmatic patients for a bronchial allergen challenge study and 
identified increased BALF IL-4 levels post challenge in asthmatic patients219. In-vivo studies 
have helped establish an important role for IL-4 in antibody production, with Finkelmann et al. 
demonstrating that administration of an anti-IL-4 neutralizing antibody to Balb/c mice 
immunised with anti-IgD  resulting in a diminished IgE response220. Subsequently, IL-4 -/- 
mice also exhibited significantly reduced eosinophilia and peribronchial inflammation in an 
OVA model of allergic airway inflammation in221. 
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1.3.4.2 Interleukin-13 
IL-13 shares structural homology to IL-4 and like IL-4 binds to the type-2 IL-4 receptor and 
induces downstream STAT6 signalling222. The fact that the type-2 IL-4 receptor is abundantly 
expressed on structural cells supports a possible pro-remodelling role of IL-13 in AAD, and 
animal models have supported this assertion223. Neutralisation of IL-13, with a monoclonal 
antibody, in the HDM model of AAD  resulted in a significant reduction in goblet cell 
metaplasia and airway remodelling224. Transgenic mice that selectively express IL-13 in Clara 
cells within the epithelium  develop augmented inflammation, mucus hypersecretion and 
airway fibrosis223. Townley et al. demonstrated that IL-13 administration to mice sensitised 
and challenged with ovalbumin resulted in an AHR that was corticosteroid resistant225. 
IL-13 is increased in the BALF of asthmatic patients after bronchial allergen challenges219. 
Similarly, Huang et al.  also found increased BALF IL-13 protein levels and IL-13 mRNA 
levels from isolated cells in a bronchial challenge study in asthmatic patients226. IL-13 mRNA 
levels were found to be increased in the bronchial biopsies of asthmatic patients227.  
1.3.4.3 Interleukin-5 
The IL-5 receptor is expressed on basophils and a subgroup of B cells but maximal expression 
of the IL-5 receptor is found on eosinophils228. As such, various studies have highlighted the 
importance of IL-5 in the development, recruitment and survival of eosinophils229. Clutterbuck 
et al. demonstrated that recombinant human IL-5 selectively induced eosinophil maturation in 
bone marrow cultures compared to other cytokines such as IL-1, IL-3, IL-6 and GM-CSF230. 
Lopez  et al. in 1988 were one of the first to show the selective effects of IL-5 on the activation 
status of eosinophils, whereby IL-5 stimulation of cultured eosinophils induced morphological 
changes and reactive oxygen species generation228.  
Likewise, in-vivo models of allergic diseases showed similar pro-eosinophilic effects of IL-5. 
IL-5 receptor deficient mice displayed reduced numbers of eosinophils compared to respective 
wild type mice in an OVA model of AAD231. In 1997, Humbert et al. assessed mRNA levels 
from bronchial biopsies and identified significant increases in mRNA levels of IL-5 from the 
atopic patients recrutied227. Furthermore, a bronchial challenge study also reported increased 
levels of BALF IL-5 levels in asthmatic patients232. 
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1.3.4.4 Interleukin-17 
IL-17 is commonly produced by Th17 cells and binds to a receptor complex composed of IL-
17RA and IL-17RC subunits, which are commonly expressed on fibroblasts, endothelial and 
epithelial cells233. In-vivo models and cell based studies have demonstrated that IL-17 has an 
indirect effect on neutrophil recruitment by triggering the release of neutrophil chemokines 
from structural cells234,235. Additionally, It is believed that IL-17 may have a role in inducing 
neutrophil survival and activation235,236. Animal models of AAD have highlighted the 
importance of cells producing IL-17 such as Th17 cells in the recruitment of neutrophils and 
induction of AHR234,237. IL-17 is a cytokine that is consistently linked with asthma and 
particularly the severe forms of the disease238,239. Several clinical studies have highlighted 
correlations between IL-17 levels and the number or neutrophils retrieved from sputum, BAL 
and blood238,240,241.  
1.3.4.5 Epithelial-derived cytokines 
IL-33 is a key cytokine expressed by epithelial cells within different mucosal tissues, although 
it can also be produced by macrophages, monocytes and dendritic cells, albeit at lower levels242. 
IL-33 is found both intracellularly, within the nucleus, and extracellularly and to fulfil different 
roles dependent upon location242. The nuclear role of IL-33 highlights an anti-inflammatory 
role of the cytokine whereby IL-33 has been shown to bind to transcription factors such as NF-
κβ and histones within the nucleosome that result in the reduced expression of IL-4R and IL-
6242. Extracellular IL-33 binds to receptor ST2 that is commonly expressed on the surface of 
Th2 cells and ILC2s243. IL-33 has been linked with promoting ILC2 recruitment and 
activation208, with administration of recombinant IL-33 to the airways of mice inducing 
significant ILC2 infiltration and increased levels of BALF IL-4, IL-5 and IL-13209. Full length 
IL-33 is bioactive, but its bioactivity can be increased 10-fold through cleavage by neutrophil 
elastase or cathepsin-G243. IL-33 staining of bronchial sections has revealed significant 
augmentation of IL-33 expression in asthmatic samples244.  
TSLP is another cytokine derived from the epithelium. The receptor of TSLP, TSLPR, is 
expressed on dendritic cells, NK cells, monocytes, eosinophils and Th2 cells, with TSLP 
driving the  activation of the latter245. In an OVA model of AAD, TSLP receptor -/- mice 
exhibited reduced inflammation and remodelling changes246, which could be reconstituted by 
administration of TSLP246. Additionally, airway epithelial cells from asthmatics have been 
Chapter 1: Introduction 
62 
 
shown to produce increased TSLP when stimulated with double stranded RNA247, and 
polymorphisms of the TSLP gene have been linked with asthma246. 
IL-25, also known as IL-17E, is expressed by airway epithelial cells, Th2 cells, eosinophils, 
mast cells and basophils. Administration of allergens containing proteases such HDM can 
trigger the transcription of IL-25248. Administration of IL-25 to mice results in the increased 
mRNA expression of IL-4, IL-5 and IL-13249. Clinical studies have also reported the increased 
presence of IL-25 in asthmatic samples, with increased IL-25 levels in BAL and epithelial 
airway brushes of asthmatic patients243. 
1.3.4.6 Eotaxins 
In 1994, it was identified that BALF from sensitised guinea pigs challenged with ovalbumin 
was potent at inducing localised eosinophil recruitment when intradermally injected into naïve 
guinea pigs250,251. BALF from sensitised guinea pigs was purified utilising high performance 
liquid chromatography and subsequent microsequencing revealed a novel protein which was 
called eotaxin251. Subsequent injections of this isolated protein into the skin revealed that this 
protein was highly potent at inducing eosinophil recruitment251.  
CCR3 is prominently expressed on eosinophils and  is the receptor for eotaxin chemokines, 
eotaxin-1 (CCL11), eotaxin-2 (CCL24) and eotaxin-3 (CCL26)252. Multiple cells can produce 
eotaxins such as macrophages, eosinophils and stromal cell populations including epithelial 
cells, smooth muscle cells and fibroblasts, although certain types of eotaxin proteins are limited 
to certain cell populations252. 
Eotaxin antibody neutralisation studies significantly reduced lung eosinophilia and AHR in a 
cockroach mouse allergen challenge model253. Clinical studies have also shown that eotaxin 
levels are elevated in asthmatic patients. Ying et al. found increased expression of eotaxin 
mRNA and protein levels in bronchial mucosa of mild asthmatic patients254. Furthermore, 
Coleman et al. observed increased expression of eotaxin-2 and eotaxin-3 mRNA from airway 
epithelial cell brushings from mild and severe asthmatic patients compared to normal 
controls255. Intriguingly eotaxin expression also correlated with severity of disease, asthma 
exacerbations and reduced FEV1 measurements255. 
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Figure 1.9: Summary of asthma pathophysiology. 
The series of events that occur in the progression and development of asthma is a rather complex process which 
may or may not involve inflammation. This figure represents the series events that mostly occur in asthmatic 
patients with a predominant Th2 inflammation. Upon allergen sensitisation or allergen-mediated epithelial 
damage, Th2 cells and ILC2s are recruited towards the lung mucosa. These cells then produce Th2 cytokines such 
as IL-4, IL-5 and IL-13 amongst others. This cytokine production drive eosinophil recruitment, Th2 polarisation 
and development of antibodies. These cytokines also mediate remodelling around the airways by causing goblet 
cell hyperplasia and smooth muscle cell metaplasia. Adapted from Lambrecht, B. and Hammad, H, Nature 
Immunology (2015) 
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 Asthma heterogeneity 
Asthma was classically recognised as a Th2 dominant disease. This concept originated from 
studies utilising mouse models and limited patient samples, which portrayed a disease 
characterised by a profound eosinophilic infiltrate, and Th2 cells producing cytokines such as 
IL-4 and IL-5256. However, treatment strategies designed to specifically inhibit these Th2 
cytokines and limit CD4+ T cell recruitment initially displayed disappointing results during 
large-scale clinical trials257. Furthermore, many patients were found to be resistant to inhaled 
corticosteroids, which non-specifically ameliorate Th2 inflammation148. The development of 
more efficient and safer sampling methods such as bronchial biopsies, BAL and induced 
sputum has permitted more extensive analysis of patient samples. Subsequently, asthma has 
undergone a paradigm shift with heterogeneity becoming widely appreciated257. It is now 
recognised that it is important to stratify patients into subgroups in order to develop suitable 
and personalised treatment strategies. Additionally stratifying patients can further enhance our 
understanding of the disease, by identifying subgroup specific pathological mechanisms, 
biomarkers and genetic associations256.  
Many attempts have been made to sort patients into subgroups based on phenotype – defined 
as the observable characteristics of patients as a result of genetic and environmental cues257. 
Initially, biased approaches to phenotyping patients were utilised whereby asthmatics were 
classified based on a small number of clinical or physiological variables. For example, patients 
were grouped according to allergic status. Up to 50% of adult patients possess intrinsic asthma 
or extrinsic (allergic) asthma, commonly defined by a positive skin prick test to common 
allergens or elevated antibody titers150. Furthermore, allergic asthma is even more prevalent in 
children, where disease commonly persists or progresses onto adulthood257. Many studies have 
associated non-allergic asthma with older patient groups, obesity and female gender257. Various 
clinical studies have shown that these patients have exacerbated lung function and more 
frequent disease-related hospital visits258.  
Discrepancies between separate studies and a failure to consider underlying cellular 
pathophysiology led to criticism of these biased approaches to categorise patients. 
Subsequently, studies utilizing statistical based approaches were planned that would limit study 
bias. Accordingly, clustering analysis were performed on a variety of cohort studies whereby 
patients were grouped based on clinical characteristics such as age-of-onset, sex, induced 
sputum inflammatory profiles, FEV1 measurements and responsiveness to steroids257,259. One 
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large scale study in America and 2 other studies in Europe all yielded similar findings, with 
age-of-onset identified as a key characteristic to distinguish asthmatic subgroups257. These 
analyses demonstrated that patients with early-onset disease were more likely to be allergic and 
displayed increased responsiveness to steroid treatment. Late-onset asthmatic patients were 
identified to be predominantly female, obese and were primarily non-atopic. Interestingly late-
onset asthmatic patients also had increased numbers of neutrophils in induced sputum 
samples259.  
More recently, there has been a shift to categorise asthmatic patients into groups on the basis 
of underlying disease pathology instead of patient characteristics. Accordingly, assigning 
patients into cohorts based on inflammatory profiles (immunophenotyping) has been 
performed and revealed a further need to sub-stratify patient groups. Based on this strategy, 
many classical subclinical asthma groups can be defined as a “Th2 high” phenotype with 
augmented eosinophilia and elevated Th2 cytokine levels. Patients with early onset asthma 
display elevated Th2 cytokine levels concomitant with  atopy, high IgE and sensitivity to 
inhaled corticosteroids191,260–262. Patients with late-onset asthma that display “Th2 high” 
inflammation is often associated with reduced allergic sensitisation192. Patients with exercise-
induced asthma also present with a significant Th2 component, and symptomology is often 
associated with eosinophil and mast cell infiltrate257. Similarly, aspirin exacerbated respiratory 
disease, whereby patients display reversible airflow due to aspirin sensitivity, also exhibit 
significant Th2 inflammation263. There is also a cohort of asthmatic patients that display a 
persistent eosinophilic inflammation and frequent exacerbations despite corticosteroid 
therapy192,193,257.  
Whilst Th2 inflammation has classically been associated with asthma pathology, it is now 
apparent that only 50 % of symptomatic asthmatics display elevated sputum eosinophilia264,265. 
The Asthma Clinical Research network reported that within a cohort of 995 patients, 64 % of 
patients not taking corticosteroids and 83 % of patients taking corticosteroids reported with 
lower than 2 % sputum eosinophils266. Thus, many patients with symptomatic asthma lack the 
typical eosinophilic and Th2 inflammation traditionally viewed as to be a hallmark of the 
disease. A cluster analysis performed on induced sputum from 423 patients revealed the 
presence of 4 distinct clusters based on inflammatory cell profile267. Patients in clusters A and 
B had mild disease and consisted of a paucigranuloytic and eosinophil-dominant inflammatory 
phenotypes, respectively. Clusters C and D consisted of patients with more severe asthma, and 
interestingly both clusters displayed a neutrophil-dominant sputum profile. Patients in Cluster 
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D presented with a mixed-granulocytic phenotype with increased eosinophil and neutrophil 
numbers and presented with a severely compromised lung function. This study is one of many 
to show the co-existence of eosinophils and neutrophils in asthmatics268,269.  
Studies have highlighted the difficulty in treating non-eosinophilic asthmatics. For example, 
asthmatics with lower than 3 % sputum eosinophils are more likely to respond poorly to inhaled 
corticosteroids270,271. Patients with non-eosinophilic asthma exhibit variable inflammatory and 
physiological parameters272. Non-eosinophilic patients may display neutrophilic airway 
inflammation or normal levels of neutrophils and eosinophils (paucigranulocytic)266. Triggers 
for non-eosinophilic asthma include exercise, occupational irritants, smoking, obesity and 
recurrent infection or endotoxin exposure, all of which intriguingly are linked with inducing 
neutrophilic inflammation273.  
 Neutrophils in asthma 
As early as 1921, Rackemann identified asthmatic patients with a mixed granulocytic infiltrate 
composed of eosinophils and neutrophils274. However it was anticipated that this neutrophilic 
inflammation was merely a consequence of bacterial colonisation in these patients274. With an 
increase in more efficient and safer sampling methods, there now exists an abundance of 
evidence that neutrophils are a common component of the cellular infiltrate found in the 
asthmatic lung. In 1997, Wenzel et al. demonstrated the presence of neutrophils in BAL, endo-
bronchial and trans-bronchial biopsies from asthmatic patients with severe asthma requiring 
high glucocorticoid steroid treatment275. Recently, a study performed by Demarche et al. 
analyzing sputum samples from 833 recruited asthmatics, revealed that a high proportion of 
patients displayed significant sputum neutrophilia269. Furthermore, studies have highlighted the 
presence of neutrophil chemoattractants, IL-8 and LTB4 in BALF275 and induced sputum from 
asthmatics276. Another study found increased peripheral blood neutrophil numbers which 
displayed an enhanced migratory capacity to neutrophil chemoattractant, PAF277. Wood et al. 
performed a large-scale study on induced sputum from 152 stable asthmatic patients and 83 
healthy controls, and found that neutrophils were increased in asthmatic samples and correlated 
with greater levels in neutrophil elastase and IL-8278. Thus the presence of neutrophils and their 
chemokines are found in a significant proportion of asthmatic patients. A multitude of studies 
have correlated neutrophils and their products with the severity of asthma and exacerbated 
symptoms of disease (summarised in Figure 1.10). Shaw et al. displayed a correlation between 
sputum neutrophil counts and reduced FEV1 measurements 279. Fahy et al. reported increased 
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sputum neutrophils post asthma exacerbations280, with a subsequent study observing increased 
neutrophil infiltration in bronchial biopsies of patients up to 4 hours after a fatal asthma 
exacerbation281. Further studies have also described increased BAL neutrophils in asthmatic 
patients requiring ventilation due to exacerbations282. Studies in mouse and man have also 
demonstrated elevated neutrophils and IL-8 levels after viral-induced exacerbations283,284.Thus, 
neutrophils and their chemoattractants are found in a significant proportion of asthmatic 
patients. 
As discussed previously, neutrophils are a rich source of proteases with the potential to induce 
extensive collateral damage to host tissues (Section 1.1.8). Barbaro et al. found elevated MMP-
9 levels in exhaled breath condensates of patients with severe asthma that inversely correlated 
with lung function285. Whilst MMP-9 may be produced by a variety of cells, Barbaro et al. 
demonstrated that levels were greater in those severe asthmatics with elevated neutrophilic 
inflammation, supporting the findings of a study by the European Network For Understanding 
Mechanisms of Severe Asthma (ENFUMOSA)285,286. Increased MMP-9 levels have also been 
reported in the induced sputum287, and bronchial biopsies of asthmatic patients288. BALF 
MMP-9 levels have also been reported to be elevated post allergen challenge in patients with 
persistent asthma symptoms289, and BALF MMP-9 levels are seemingly resistant to 
corticosteroid treatment290.  Neutrophil elastase is another protease involved in asthma 
pathophysiology, and has been reported to be elevated in asthmatics and inversely correlate 
with FEV157,291. Neutrophil elastase has been implicated in damage to airway epithelium, 
muscle hyperplasia, increases in vascular permeability and mucus hyper-secretion57. 
Lactoferrin is another neutrophil product that has been found to be elevated in asthmatic 
patients. Lactoferrin has been found in the sputum of asthmatic patients292 and also in increased 
amounts in the lung tissue post-fatal asthma exacerbations293.  Recent studies have highlighted 
the ability of lactoferrin to trigger cysteinyl leukotriene and ROS release from eosinophils294. 
Despite substantial circumstantial clinical evidence supportive of a pathological role for 
neutrophils in asthma, their exact role in the development and progression of disease remains 
poorly defined. Limited studies have been performed to dissect the roles on neutrophils in-vivo 
in animal models. Nabe et al. depleted neutrophils in an OVA model of AAD utilising the anti-
Gr-1 antibody, and reported a reduction in levels of MPO concomitant with an ablated LAR 
295. De Vooght et al. employed a similar neutrophil depleting strategy in a chemical-induced 
asthma model75, and reported  reduced AHR, epithelial damage and airway inflammation75. 
However, treatment strategies to ameliorate neutrophilic inflammation in asthmatic patients 
Chapter 1: Introduction 
68 
 
have yielded limited clinical benefit, raising doubts as to whether neutrophils are truly 
pathological in asthma (Section 1.4.7). There have also been suggestions that neutrophils are 
only present in severe asthmatics as a consequence of prolonged corticosteroid treatment296, 
with studies showing that corticosteroids can prevent apoptosis of neutrophils297. Smoking 
status and bacterial and viral lung infections may also be another consequence of the presence 
of neutrophils in subsets of asthmatic patients265. 
It is also impossible to rule out a potential beneficial role of neutrophils in asthma (summarised 
in Figure 1.10). McMillan et al. reported enhanced Th2 cytokine levels and persistence of Th2 
cells298 in an OVA model of AAD in mice lacking classical neutrophil protease MMP-9 
mice298. Corry et al. observed similar findings, whereby they demonstrated that MMP-9 may 
be important in degrading multiple Th2-relevant chemokines such as eotaxin and thymus and 
activation regulated chemokine (TARC)299. Interestingly, a recent report demonstrated that 
elevated intraepithelial neutrophil numbers in children with severe therapy resistant asthma 
correlated with improved lung function, suggestive of a possible beneficial role for 
neutrophils300. In support of this assertion, another study demonstrated that increased 
neutrophil chemokines in severe asthmatics was associated with improved lung compliance301. 
Furthermore, it has been shown that neutrophil proteases can degrade mucin polymers, 
suggestive that neutrophils may have a role mucus plug removal302. Neutrophils are also a large 
source of decoy receptors and can thus act as a scavenger for cytokines303,304. With such 
conflicting reports concerning the role of neutrophils, it is perhaps likely that the neutrophil 
exhibits pleiotropic and potentially conflicting roles in defining asthma pathophysiology – 
some almost certainly detrimental and some potentially beneficial – with context, timing and 
location all critical confounders. 
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 Mouse models of AAD 
In order to better dissect the inflammatory and remodelling phenotypes in asthma, animal 
models of AAD have been developed. A multitude of mouse models currently exist whereby 
hallmark features of AAD such as Th2 inflammation, airway remodelling and AHR can be 
recapitulated to varying degrees. 
Classically, antigen-sensitisation and challenge models have been utilised whereby mice would 
initially be peripherally sensitised with ovalbumin, followed by subsequent intranasal 
challenges with the same protein. This protocol results in a robust inflammation of the airways 
and lung parenchyma  composed of Th2 cells and eosinophils with  elevated levels of cytokines 
IL-4, IL-5 and IL-13 and an increase in OVA-specific IgE and Immunoglobulin G1 (IgG1)305. 
In most cases the adjuvant, aluminium hydroxide or alum, is administered with ovalbumin 
during sensitisation306. The exact immunological effect of alum remains unknown but one 
study demonstrated that alum administration to mice increased local uric acid production307. 
Figure 1.10: The enigmatic role of neutrophils in asthma. 
Neutrophils have been shown to possess a multitude of roles that are largely perceived to be detrimental in 
inflammatory diseases however it should be appreciated that neutrophils can modulate inflammation and promote 
a pro-resolving or beneficial effect to inflammatory conditions. The figure summarises the roles of neutrophils 
that may be beneficial (blue) or detrimental (red) to the pathophysiology of asthma.  
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Subsequent administration of uricase to these mice ablated Th2 inflammation and AHR in the 
OVA AAD model307. The physiological relevance of the OVA model has increasingly been 
questioned due to the non-specific action of the alum adjuvant305,308, and the use of peripheral 
sensitisation with an antigen not known to provide allergy in humans305. Another major 
criticism of the ovalbumin model is that upon cessation of protein administration the 
inflammation and remodelling is reversed305,309. 
In order to address these criticisms, researchers have developed allergen challenge models 
which involve the repeated intranasal challenge of mice with common physiologically relevant 
allergens306,310. Various allergens such as house dust mite (HDM), Aspergillus fumigatus311, 
cockroach antigens312 and ragweed extracts313 have been deployed in these models. HDM 
Dermatophagoides pteronyssinus is the most prevalent allergen that asthmatic patients are 
sensitised to305,306. Studies have shown that up to 50-85% allergic asthmatics possess IgE 
specific to HDM314,315.  
The HDM is an arthropod that lives in human habitations and ingests shed human skin. The 
dust mite itself contains considerable proteolytic activity. Major HDM allergen, derp1 is a 
cysteine protease which has been shown to break down epithelial tight junction protein, 
claudin-1316. Additionally intrinsic serine proteases within HDM faecal pellets can break down 
ZO-1 and occludin317. Epithelium and smooth muscle cells also contain cell surface protease 
activated receptors (PARs)159. Activation of these receptors by HDM can induce alarmin 
release and automatic cleavage of tight junctions318. Additionally, activation of PARs via 
proteases on smooth muscle cells can induce contraction and proliferation of this cell type319. 
Additionally, HDM allergen Dermatophagoides pteronyssi- Derp 2 (derp2) has been shown to 
be highly allergenic159. Derp2 belongs to the MD-2 lipid recognition domain protein family 
that are known to promote toll-like receptor 4 (TLR4) signalling159. Furthermore, HDM extract 
contains components that can be recognised by pattern recognition receptors such as LPS and 
β-glucans159,320.  
Johnson et al. were the first to demonstrate that repeated intranasal administration of HDM 
extract to mice promoted significant airway eosinophilia and effector T cell accumulation321. 
Additionally, these mice developed an increase in Th2 cytokines and HDM-specific IgE and 
IgG1. Subsequent studies utilising HDM extract at varying doses and administration regimens 
have consistently demonstrated augmented pulmonary eosinophil, neutrophil, CD4+ T cell and 
B cell numbers and increased levels of IL-4, IL-5 and IL-13322,323. More importantly, these 
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studies also recapitulate the airway remodelling and bronchial hyperreactivity seen in asthma 
patients320.  
HDM models have consistently demonstrated neutrophil infiltration into the lung and airway 
lumens305,321,322. Hongjia, J. et al. 2010 reported that 2 weeks of continuous HDM challenges 
produced a significantly higher neutrophilic inflammation relative to their in-house OVA 
model of AAD322. HDM has been shown to be a rich source of endotoxins that can promote 
neutrophilia159. Studies have revealed that HDM can activate TLR4 expressed on either stromal 
or haematopoietic lineages to promote eosinophilic and neutrophilic inflammation and 
AHR324,325. HDM-induced epithelial damage may also result in adenosine triphosphate (ATP) 
and uric acid release, which may in turn promote neutrophil recruitment and activation159,307. 
HDM extracts are also rich in chitins, a cell wall component of fungi found on mites,  which 
have been previously been demonstrated to regulate Th17 responses and ensuing 
neutrophilia326.  
1.4 Current and future therapeutics 
Classically, asthma was perceived as a disease of bronchoconstriction and thus treatment 
predominantly focused on the use of bronchodilators148. Bonchodilator therapy was originally 
based on herbs and salts, the active components of which were identified and modified to 
produce β2 agonists327. Further refinement has led to the development of longer acting β2 
agonists to be used once per day327. Chronic use of bronchodilators failed to completely 
ameliorate disease symptoms and with the recognition that inflammation is a key component 
of asthma pathogenesis, anti-inflammatory modulators were considered.  
 Inhaled corticosteroids 
Inhaled corticosteroids are currently the most effective anti-inflammatory treatment utilised in 
asthma. Glucocorticoids bind to the glucocorticoid receptor and translocate to the nucleus of a 
variety of cells mediating a wide range of anti-inflammatory effects328. Glucocorticoids 
mediate the transcription of β2-adrenergic receptors and anti-inflammatory proteins such as 
mitogen-activated protein kinase phosphatase-1 (MKP-1) and secretory leukoprotease 
inhibitor329. Glucocorticoids also suppress the transcription of pro-inflammatory transcription 
factors such as nuclear factor-κB (NF-κB) and activator protein-1 (AP-1)328.  
In asthma, glucocorticoids readily reduce the recruitment of key effector cells such as 
eosinophils, T-lymphocytes, mast cells and dendritic cells330. Gibson et al. in 2001 
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demonstrated that administration of budesonide reduced sputum eosinophilia and improved 
AHR within 6 hours331. With such rapid responses, it was speculated that inhaled 
corticosteroids may act on airway epithelial cells, and regular use of inhaled glucocorticoids 
has been associated with improved epithelial integrity332. 
However, it is important to recognise that such global anti-inflammatory strategies are not 
without risks.  
 Severe asthma and glucocorticoid resistance 
Despite steroids proving successful in the treatment of many asthmatics, not all patients exhibit 
clinical benefit. Glucocorticoid steroid resistance was first identified in 1968 in six asthmatic 
patients who displayed no changes in eosinophil numbers despite systemic steroid 
administration333. It was previously suggested that poor pharmacokinetic profiles in certain 
asthmatic patients may be a cause of this observation, but studies have  since disproven this 
theory334. Many molecular mechanisms have been suggested to contribute to glucocorticoid 
resistance328 such as defective receptor binding335, defective receptor translocation to the 
nucleus335, altered transcription factor activation336 and reduced expression of histone 
deacetylases in leukocytes336. Clinicians have also looked to reduce the doses of steroids 
administered to patients due to a multitude of side effects associated with long-term use, 
including osteoporosis, diabetes risk, pneumonia, hypertension and cataract risk329. 
Several studies have suggested that 10-15 % of asthmatics are unresponsive to even high doses 
of steroids148. Whilst this it is a relatively small proportion of asthmatic patients, these 
individuals are a significant economic burden due to the associated healthcare costs and 
absenteeism from work and school149. As discussed previously, considerable heterogeneity 
exists in severe asthmatics. Approximately 50 % of these severe asthmatic patients exhibit the 
prototypical Th2 inflammation. These Th2 high severe asthmatics are generally non-
atopic285,337 and it has been suggested epithelial derived cytokines may be central to driving the 
inflammation in this cohort of patients338. The other 50 % of severe asthmatics present with a 
non-eosinophilic or a mixed granulocytic inflammatory profile.  
 Anti-IgE antibody 
Omalizumab is an anti-IgE monoclonal antibody commonly used to treat asthmatic patients. 
Dujkanoic et al. in 2004 showed that omalizumab administration in atopic asthmatic patients 
reduced the number of tissue eosinophils and lymphocytes accompanied with an improvement 
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in AHR339. However, in large scale clinical trials, omalizumab did not provide improvements 
to all atopic asthmatic patients340,341. 
 Anti-IL-4/IL-13 antibodies 
Given the pathological roles of IL-4 and IL-13, various attempts have been made to specifically 
block the effects of these cytokines. Preliminary studies with antibodies targeting the type-1 
complex of the IL-4 receptor thus only preventing IL-4 functionality initially displayed 
disappointing results257. However, antagonism  of the type 2 complex, the shared receptor 
complex of IL-4 and IL-13 have shown some promising results in specific patient groups342. 
For example, patients with a “Th2 high” signature, identified by blood eosinophils, IL-13 
induced periostin and fractional exhaled nitric oxide (FeNO) biomarkers, all exhibited some 
clinical benefit from type 2 complex inhibition338,342. Corren et al. in 2011 performed a trial 
whereby 219 asthmatic patients that were poorly adherent to corticosteroids were administered 
anti-IL-13 antibody, Lebrikizumab. Interestingly, patients with high levels of periostin 
received maximal benefit from drug treatment over 12 weeks343. 
 Anti-IL-5 antibodies 
Anti-IL-5 antibody administration to asthmatic patients showed modest effects in initial large 
scale clinical trials257. However, patient phenotyping again led to the identification of 
subgroups of asthmatics that received therapeutic benefit from anti-IL-5 therapy. A multi-
centre 2 year trial was performed whereby patients with recurrent severe asthma exacerbations 
and significant eosinophilic inflammation received anti-IL-5 monoclonal antibody, 
mepolizumab. Mepolizumab treatment reduced the number of exacerbations in these patient 
groups and was tolerated throughout the 2 year trial344. A follow up study by  Ortega et al. in 
2014 identified that severe eosinophilic asthmatic patients administered mepolizumab were 
more adherent to corticosteroid therapy and required lower doses to achieve clinical benefit345. 
These studies highlight the clinical benefit of tailoring therapies to specific subsets of asthmatic 
patients. 
 Lipid mediator blockade 
Many lipid mediators are implicated in the pathogenesis of asthma. Cysteinyl leukotrienes have 
been intrinsically linked with inducing bronchoconstriction, mucus production, vascular 
permeability and cellular recruitment346,347. Subsequently, cysteinyl leukotriene antagonists 
such as montelukast have been developed. Montelukast reduces symptoms and improves lung 
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function in patients with mild asthma and is commonly used in combination with other 
therapies348. However, although montelukast improved lung function in a subset of severe 
asthmatics, the majority of these patients did not receive any improvement from this 
therapy349,350.   
As discussed previously, LTB4 is another lipid mediator anticipated to drive asthma 
pathophysiology, owing to its potent capacity to drive inflammatory cell recruitment and 
activation. Some drug compounds have been developed to limit the generation of cysteinyl 
leukotrienes but also limit the production of LTB4. For example,  Zileuton, a 5-lipoxygenease 
inhibitor that inhibits the generation of LTA4 thus limiting the production of downstream LTB4, 
lipoxins and cysteinyl leuktorienes351 (Figure 1.11).  5-Lipoxygenase-activating protein 
(FLAP) inhibitors target the activating protein for 5-lipoxygenase and thus prevent its function 
with similar downstream effects to Zileuton (Figure 1.11). FLAP inhibitor, GSK2190915 
caused a dose-dependent reduction in EAR and LAR in mild asthmatic patients post allergen 
challenge352. However, a subsequent phase II trial with GSK2190915 in severe asthmatic 
patients reduced levels of LTB4 but had no effect on sputum neutrophil counts or clinical 
endpoints353. While curtailing the generation of cysteinyl leukotrienes, it may be possible that 
these inhibitors inadvertently disrupt the production of anti-inflammatory and pro-resolving 
lipoxin lipids354.  
There have also been efforts to specifically target LTB4-mediated pathologies. Initially, BLT-
1 antagonists were trialled in asthmatic patients. BLT-1 antagonist, LY293111 administered to 
patients with neutrophilic asthma failed to improve EAR, LAR and AHR despite reducing 
neutrophil numbers355. Additionally, after allergen challenge, LY29311 treatment did not alter 
eosinophil numbers in the patients examined355. LTA4H inhibitors prevent the hydrolysis of 
LTA4 to form LTB4 and have been developed to specifically ameliorate LTB4 induced 
pathology. In pre-clinical studies, LTA4H inhibitors have shown impressive effects. A 
compound synthesised by Johnson & Johnson, JNJ-26993135, potently reduced neutrophil 
influx and oedema in an arachidonic acid-induced ear inflammation model and a zymosan-
induced peritonitis model. These effects were attributable to reduced LTB4 production and also 
increased synthesis of anti-inflammatory lipoxin A4 speculated to be as a result of the build-up 
of LTA4356. The same inhibitor was also potent at reducing airway inflammation and 
hyperresponsiveness in an OVA model of AAD354. Despite such great pre-clinical success, 
clinical trials showed disappointing results. Johnson & Johnson trialled LTA4H inhibitor, JNJ-
40929837 in a bronchial allergen challenge model in mild, atopic asthmatics357. JNJ-40929837 
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reduced whole blood and sputum LTB4 levels compared to placebo, but no clinical benefit was 
observed357. This could be attributable to the inadvertent inhibition of the anti-inflammatory 
PGP degrading activity of LTA4H, with PGP accumulation masking the beneficial effects of 
reduced levels of LTB483. Subsequently, it has be shown that JNJ-40929837 was indeed potent 
at preventing the aminopeptidase activity of LTA4H87. 
Figure 1.11: Lipid mediator blockade. 
Arachidonic acid metabolism involves a complex pathway where a multitude of inflammatory-
modulating lipid molecules can be generated. As such various strategies have been developed to inhibit 
specific arms of the arachidonic pathway to ameliorate their pro-inflammatory effects. LTA4 is 
generated from arachidonic acid via the concerted action of 5-lipoxygenase (5LO) and 5-lipoxygenase 
activating protein (FLAP). LTA4 is the precursor to spasmogenic cysteinyl leukotrienes LTC4, LTD4
and LTE4 and pro-inflammatory LTB4, and thus inhibitors of 5-LO (e.g. zileuton) and FLAP (e.g. 
GSK2190915) have been developed. However, the downside of these inhibitors is that they also reduce 
the levels of anti-inflammatory lipoxins. To specifically target cysteinyl leukotrienes, antagonists to 
their receptors (e.g. monteleukast) have been developed. The enzyme LTA4H converts to LTA4 to LTB4
and thus inhibitors of this enzyme (e.g. JNJ-40929837) have been developed to selectively target LTB4
generation.  
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 Strategies to target neutrophilic inflammation 
There has been the general consensus that neutrophils contribute to the pathology of severe 
asthma and thus there has been a concerted effort to ameliorate neutrophilic inflammation in 
this disease. In addition to inhibitors that target the LTB4 pathway, discussed above, CXCR2 
antagonists have also been explored as a method to ameliorate neutrophilic inflammation in 
asthma. Although this receptor is expressed by a variety of cell types in the lung such as 
fibroblasts, alveolar macrophages, airway goblet cells, eosinophils and monocytes358, 
neutrophils are known express the highest levels of CXCR225. CXCR2 antagonist, SCH 
527123, was administered to severe asthmatics with high neutrophil sputum counts over the 
course of 4 weeks359. Patients administered SCH 527123 displayed a significant reduction in 
sputum neutrophilia accompanied with fewer mild exacerbations and a trend towards 
improvement in the ACQ score. However, FEV1 measurements, sputum MPO and neutrophil 
elastase remained unchanged359.  
Macrolides are a class of antibiotics that have also been explored for the treatment of 
neutrophilic asthma. Macrolides such as azithromycin have been shown to possess anti-
inflammatory properties independent to their antibiotic potential. For example, azithromycin 
can inhibit the transcription of pro-inflammatory transcription factors NF-κB and AP1 in 
epithelial cells360. Another study demonstrated that different macrolide antibiotics were able to 
suppress the production of IL-8, regulated on activation, normal T cell expressed and secreted 
(RANTES), CXCL5 and other neutrophil chemoattractants from cells isolated from the sputum 
of COPD patients361. One trial in patients with severe neutrophilic asthma displayed reduced 
sputum neutrophilia, IL-8 and an improvement in symptoms upon azithromycin 
administration330.    
1.5 Hypothesis 
This thesis investigates the role of neutrophils, their proteases and   protease-derived matrikine, 
PGP, in defining airway inflammation and remodelling in the in-house HDM model of AAD. 
I hypothesise that neutrophils and their proteases are detrimental and drive pathological 
inflammatory and remodelling changes in AAD. Furthermore, I hypothesise that the beneficial 
effects of reducing LTB4 by targeting LTA4H in AAD will be masked by the adverse effects 
of causing PGP accumulation.   
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1.6 Aims 
1. To determine the levels of neutrophils and their proteases in different strains of mice, which 
may mimic the heterogeneity of asthma patients seen in the clinic. 
2. To dissect the specific role neutrophils in the HDM model of AAD utilising a neutrophil-
depleting monoclonal antibody. 
3. To investigate the dual roles of leukotriene A4 hydrolase in AAD. 
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2 Chapter 2: Materials and methods  
2.1 Mice 
2.1.1 Ethics statement and animal housing conditions 
This study was carried out in accordance with the recommendations in the Guide for the Use 
of Laboratory Animals of Imperial College London. All animal procedures and care conformed 
strictly to the UK Home Office Guidelines under the Animals (Scientific Procedures) Act 1986, 
and were approved by the Home Office of Great Britain. All experiments involving laboratory 
animals were performed in accordance with directive 2010/63/EU of the European Parliament. 
Mice were housed under specific-pathogen free (SPF) conditions in individually vented cages 
at 22 °C with a 12 hour light-dark cycle at Imperial College London. All mice received 
autoclaved food and water ad libitum. 
2.1.2 Mice for strain, neutrophil-depletion and LTA4H studies 
Female wild type 8-12 weeks-old Balb/c, C57BL/6 and 129/S2 mice were purchased from 
Harlan Olac Ltd (Oxon, UK). IL-13 gfp reporter mice362 on a Balb/c background were provided 
by Dr. Andrew McKenzie (MRC Laboratory of Molecular Biology, Cambridge, UK). LTA4H 
deficient (LTA4H -/-) mice and their littermate controls, on a 129 background, were provided 
Dr Y.M. Shim (University of Virginia, Charlottesville, VA) and subsequently bred in house. 
Wild type (WT) and deficient (BLT-1 -/-) mice on a C57BL/6 background were obtained from 
Jackson laboratories (California, USA) and bred in house. The transgenic mice used within the 
respective studies were also between 8-12 weeks of age and of female sex. Lta4h-/- and Blt1-
/- mice were genotyped by PCR on genomic DNA extracted using the Extract-N-Amp Tissue 
PCR Kit (Sigma-Aldrich). The WT expression of LTA4H was detected by primers oIMR1720 
(50-CGAATCCATGCT TAAAATTGC-30) and oIMR1721 (50-
GCGTTACGAACGTGAGACAA-30) to yield a product size of 128 bp, and Lta4h-/- mutated 
LTA4H was detected by primers oIMR6916 (50-CTTGGGTGGAGAGGCTATTC-30) and 
oIMR6917 (50-AGGTGA GATGACAGGAGATC-30) to yield a product size of 280 bp. 
Amplification was achieved by PCR (94 oC for 3min>35x2.5 min cycles (30 s at 94 oC>60s at 
60 oC>60s at 72 oC)>72 oC for 2min). The BLT1 expression was detected by primers 
oIMR8160 (50-ATAGCTTTGTAGTGTGGAGCATCCTGA-30), oIMR8161 (50-
TGGAAGACTTTATGCTCTTTGTTGGGA-30) and oIMR8162 (50-
TGGATGTGGAATGTGTGCGAG-30) to yield a product size of 433 bp for WT and 270 bp 
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for mutant. Amplification was achieved by PCR (94 oC for 3min>35x2.5 min cycles (30 s at 
94 oC>60 s at 64 oC>60 s at 72 oC)>72 oC for 2min). Amplification fragments were visualised 
on 2 % agarose gels. 
2.2 Induction of allergic airway inflammation and AHR 
2.2.1 Preparation of HDM extract 
Extracts of the HDM species Dermatophagoides pteronyssinus were purchased from GREER 
(Lenoir, NC, USA). Two different batches have been used throughout the course of this project: 
1. Lot No.: 228282; dry weight: 28.40 mg/vial; total protein weight: 7.37 mg/vial; 
DerP1 content: 406.89 µg/vial; endotoxin content: 390 EU/vial 
2. Lot No.: 290903; dry weight: 29.27 mg/vial; total protein weight: 6.4 mg/vial; 
DerP1 content: 287.96 µg/vial; endotoxin content: 927.5 EU/vial  
The lyophilised content of each HDM extract vial was reconstituted using sterile phosphate-
buffered saline (PBS; Life Technologies, Paisley, UK) to prepare a stock solution of 1 mg/ml. 
The HDM extract was reconstituted each time prior to an individual experiment and stored at 
4 ºC throughout the dosing timecourse. 
2.2.2 HDM induced AAD model 
For intranasal administration of HDM or PBS mice were transiently anaesthetised by inhalation 
of halogenated ether isoflourane. Mice were intranasally (i.n.) administered 25 µg of HDM 
extract (in 50 µl PBS) or 50 µl PBS, 3 times a week up to 3 weeks. Mice were harvested for 
downstream analysis at 1 week and 3 weeks, each time at 24 hours post the last dose of HDM 
(See Section 2.4). 
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2.3 Drug and antibody administrations 
2.3.1 Budesonide studies 
Budesonide (Bud) Respules (Breath Ltd. UK) at a concentration of 0.25 mg/ml were used 
during the relevant experiments. 12 µg of Budesonide (in 50 µl PBS) or PBS alone (vehicle) 
was administered i.n. 5 times a week during the course of the 3 week HDM timecourse. On 
days when mice received both PBS/HDM and budesonide/vehicle, HDM or PBS was 
administered at least 6 hours prior to the corresponding budesonide treatment. 
 
 
Figure 2.1: Standard HDM dosing protocol for establishment of AAD. 
Mice were i.n. administered HDM or PBS 3 times a week over the course of 3 weeks. Harvests were either carried 
out at 1 week or 3 week timepoints with different downstream analysis dependent on the timepoint. Harvests were 
performed 24 hours post the final HDM or PBS dose. 
Figure 2.2: Budesonide administration protocol. 
Mice were i.n. administered HDM or PBS 3 times a week over the course of 3 weeks. Mice also received intranasal 
administrations of budesonide or vehicle 5 times a week over the 3 week timecourse. Mice were harvested after 
3 weeks, 24 hours post the final HDM or PBS dose. 
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2.3.2 Neutrophil depletion studies 
Anti-Ly6G antibody, 1A8, and IgG2A isotype control antibody, 2A3, were obtained from 
BioXcell (New Hampshire, USA). Mice were administered either 100 µg 1A8 or 2A3 (in 200 
µl of PBS) intraperitoneally (i.p.) 24 hours prior to each HDM or PBS dose during respective 
timecourse experiments.  
 
2.3.3 Antigen presentation study with fluorescently tagged Ovalbumin 
As detailed above, 100 µg of 1A8 or 2A3 was administered to mice i.p. 24 hours prior to each 
HDM. Mice were administered the final dose of HDM in combination with 100 µg ovalbumin 
(Invivogen, San Diego, USA) tagged with Alexa Fluor 488. Ovalbumin was tagged with the 
fluorophore utilising an Alexa Fluor 488 Protein Labelling kit per manufacturer’s guidelines 
(ThermoFisher Scientific). A HDM timecourse of 1 week was used for this experiment. 
 
Figure 2.3: Neutrophil depletion protocol. 
Female Balb/c mice were administered HDM or PBS i.n. for up to 3 weeks. Neutrophil-depleting antibody, 1A8, 
or isotype control antibody, 2A3, was administered 24 hours prior to each HDM/PBS dose. Harvests were 
performed at 24 hour, 1 week and 3 week timepoints, 24 hours post the final HDM/PBS dose. 
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2.3.4 G-CSF studies 
Mice were administered 2.5 µg of recombinant G-CSF protein (Peprotech, New Jersey, USA) 
in 200µl PBS or PBS vehicle control i.p. on a daily basis for 4 consecutive days. Admixed with 
the G-CSF/PBS, mice were also administered either neutrophil depleting antibody, 1A8, or 
isotype control antibody, 2A3, as detailed in 2.3.3. Harvests were performed 24 hours post the 
final dose. 
 
 
Figure 2.4: Antigen presentation study. 
Female Balb/c mice were administered HDM or PBS i.n. for 1 week. Neutrophil-depleting antibody, 1A8, or 
isotype control antibody, 2A3, was administered 24 hours prior to each HDM/PBS dose. On the final HDM dose, 
mice were administered HDM mixed with Alexa Fluor 488-tagged ovalbumin protein. Harvests were performed 
at 24 hours post the final HDM/PBS dose 
Figure 2.5: G-CSF treatment protocol. 
Mice received PBS or recombinant G-CSF protein i.p. daily for 4 days. Neutrophil depleting antibody, 1A8, or 
control antibody, 2A3, was administered in combination with the PBS/G-CSF i.p. Harvests were performed 24 
hours after the final dose. 
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2.3.5 Anti-G-CSF study 
G-CSF neutralising antibody was obtained from Novus Biologicals (Abingdon, UK). 100 µg 
of 1A8 or 2A3 was admixed with either 100 µg anti-G-CSF or 2A3 and administered to mice 
i.p. 24 hours prior to each HDM or PBS. A HDM timecourse of 1 week was used for this 
experiment. 
 
2.4 Mouse sacrifice and downstream analysis 
2.4.1 Anaesthesia 
Terminal anaesthesia of mice was achieved by an anaesthetic overdose, whereby 100 µl of 
Pentoject (Merial, Woking, U.K.) per 10 g body weight was administered by peritoneal 
injection. Depth of anaesthesia was assessed by paw reflex assessment and death was 
confirmed by exsanguination from the femoral artery. 
For lung function assessment, surgical anaesthesia was induced in mice by an intramuscular 
injection of 100 mg/kg Ketamine (Fortdodge Animal Health, Southampton, UK) into the 
quadriceps femoris and an intraperitoneal injection of 50 mg/kg pentobarbitone (Sigma-
Aldrich).  Depth of anaesthesia was assessed by paw reflex assessment of the leg not subjected 
to the intramuscular injection. 
Figure 2.6: Neutrophil depletion protocol. 
Female Balb/c mice were administered HDM or PBS i.n. for 1 week. Neutrophil-depleting antibody, 1A8, or 
isotype control antibody, 2A3, was admixed with anti-G-CSF neutralising antibody or isotype control, 2A3 and 
administered 24 hours prior to each HDM/PBS dose. Harvests were performed at 24 hours post the final 
HDM/PBS dose. 
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2.4.2 Tracheotomy and Cannulation 
Upon successful induction of surgical anaesthesia or terminal anaesthesia, the mouse was 
placed on its back and the fur was soaked with ethanol. Skin and tissue was removed from the 
anterior section of the neck and salivary glands were separated to expose the trachea with the 
help of forceps. A small incision perpendicular to a visible cartilage ring was introduced using 
iris scissors. A blunt-ended 16 gauge cannula was inserted in the caudal direction and secured 
utilising a suture thread that was laced between the trachea and oesophagus.  
2.4.3 Assessment of lung function  
The Flexivent System (Scireq, Montreal, Canada) was used to measure dynamic airway 
resistance and lung tissue compliance as previously described363. Tracheotomised and 
cannulated mice were connected to the Flexivent ventilator. The following settings were used: 
tidal volume of 7 ml/kg body weight, 150 breaths per minute, positive end-expiratory pressure 
approximately 2 cm H20. Standardisation of lung volume history was achieved automatically 
by the machine by performing 2 deep lung inflations. Measurements of resistance and 
compliance were measured from a user-defined protocol by using the snapshot-150 
perturbation, which is a single-frequency waveform at a frequency equivalent to the ventilation 
rate of 2.5Hz.  
Changes in resistance, elastance and compliance in response to increasing doses of nebulised 
methacholine (0-300 mg/ml; Sigma-Aldrich) were measured by snapshot perturbation 
measurements via the forced oscillation technique364. Airway resistance was expressed as 
cmH2O/mL/s and compliance was expressed as mL/cmH2O. 
2.4.4 Blood collection and processing 
Upon mouse sacrifice, the femoral artery of the mouse was exposed with the help of surgical 
scissors and forceps. The femoral artery was subsequently cut and blood collected. In lung 
function experiments, a cardiac puncture was performed to collect blood. For downstream flow 
cytometry analysis, 200 µl of blood was immediately pipetted into a 15 ml falcon tube 
containing red blood cell lysis buffer (See Media and Buffers list, Table 2.6) for 5 minutes. 
The lysis buffer was then neutralised with R10F (See Media and Buffers list, Table 2.6) and 
centrifuged at 160 xg for 5 minutes at 4 ºC (Hettich Rotina 420R centrifuge (Hettich)).  For 
isolation of serum, blood was collected into a 1.5ml Eppendorf tube and allowed to clot at 4 
ºC. The tubes were then centrifuged at 6000 xg in an Eppendorf 5415 D centrifuge (Eppendorf, 
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Hamburg, Germany) for 10 minutes to separate the serum from other blood components. The 
serum was stored frozen at -80 ºC for further analysis. 
2.4.5 Bone Marrow isolation 
To isolate bone marrow cells, the femur and the tibia from both hind legs were removed and 
freed of soft tissue attachments, and the extreme distal tip of each extremity cut off. PBA (See 
Media and Buffers List, Table 2.6) was forced through the bone with a syringe. After dispersing 
cell clumps and passage through a 100 µM sieve (BD labware, New Jersey), red blood cells 
were lysed by re-suspending pellets in 3 ml red blood cell lysis buffer (See Media and Buffers 
list, Table 2.6) for 3 minutes. The erythrocyte-free cell pellet was then suspended with 2 ml 
PBA. 
2.4.6 Isolation of airway lumen cells 
The cells within the airway lumen of each mouse were obtained by BAL, whereby 0.4 ml of 
PBS (Life Technologies) was introduced endotracheally into the airway lumen of 
tracheotomised adult mice and recovered using a 1 ml syringe. This process was repeated a 
total of 3 times with separate 0.4 ml volumes and then pooled. The recovered BALF was 
centrifuged at 160 xg for 5 minutes at 4 ºC (Hettich Rotina 420R centrifuge (Hettich)). The 
supernatant of the BALF was collected and aliquoted and stored at -80 ºC for further analysis. 
The resultant cell pellet was re-suspended in R10F (Rosell Park Memorial Institute (RPMI; 
Life Technologies) supplemented with 10 % fetal calf serum (FCS; Life Technologies), and 
the resulting cell suspension stored on ice prior to subsequent downstream analysis. 
2.4.7 Processing of lung tissue 
The left lung lobe was finely chopped and incubated in 1 ml of R10F containing 0.15 mg/ml 
collagenase D (Roche, Burgess Hill, UK) and 25 µg/ml DNAse 1 (Roche) at 37 ºC for 30 
minutes with gentle agitation. The collagenase and DNase was inactivated by addition of 1 ml 
RPMI containing 100 mM Ethylenediaminetetraacetic acid (EDTA).  A single cell suspension 
was obtained by filtering the digested tissue through a 70 µm cell strainer (BD, Oxford, UK). 
Erythrocytes were removed by addition of 3 ml red blood cell lysis buffer (See Media and 
Buffers List, Table 2.6) for 3 minutes. The cells were then washed and the erythrocyte-free cell 
pellet was re-suspended in 2 ml R10F and stored on ice until further analysis. The accessory, 
middle and inferior lobes were snap frozen in liquid nitrogen and subsequently stored at -80 ºC 
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for downstream analysis.  The right caudal lobe was inflated with 10 % Neutral Buffered 
Formalin prior to being placed in a tube containing more of the fixative for histology analysis.  
2.4.8 Isolation of cells from the spleen 
Spleens were disrupted through a 70 µm cell strainer (BD) with the help of a 2 ml syringe 
plunger to obtain a single cell suspension. This suspension was centrifuged at 160 xg for 5 
minutes (Hettich Rotina 420R centrifuge (Hettich)) and the supernatant discarded. 
Erythrocytes were removed from the resultant cell pellet by addition of 3 ml red blood cell lysis 
buffer for a total of 3 minutes. The cells were washed and the erythrocyte-free cell pellet was 
re-suspended in 2 ml R10F media and stored on ice until further analysis. 
2.5 Flow Cytometry 
2.5.1 General extracellular staining protocol 
Up to 2 x 106 cells were loaded into wells of a 96 well plate (V-bottom; Corning, Wiesbaden, 
Germany). The plate was centrifuged at 400 xg for 2 minutes (Hettich Rotina 420R centrifuge 
(Hettich)) and the supernatant was decanted. To identify and exclude dead cells, 50 µl of 
LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit (Life Technologies) dye (diluted 1/1000 in 
PBS) was added to the cells for 15 minutes at 4 ºC. To avoid non-specific FC binding, the cells 
were incubated with a 1/200 dilution of anti-CD16/32 antibody (BD Pharmingen) in 1 % BSA 
in PBS with azide (PBA). The cells were then washed in PBA and incubated with a 
combination of antibodies conjugated to different fluorophores (Table 2.1) in 30 µl PBA for 
30 minutes at 4 ºC. The cells were subsequently washed 3 times with PBA before fixation. The 
cells were fixed in 100 µl 2 % PFA (Sigma-Aldrich) in PBS for 15 minutes at room 
temperature. The cells were subsequently washed and stored in 200 µl PBA for flow cytometry 
analysis. Flow cytometry was performed utilising a BD Fortessa flow-cytometer. Gating 
strategies for flow cytometry analysis were determined with the use of Fluorescence Minus 
One controls (FMOs). 
2.5.2 General intracellular staining protocol 
For intracellular cytokine analysis, cells were stimulated with a mix of 40 ng/ml PMA (Sigma-
Aldrich), 3 µg/ml Ionomycin (Millipore, Watford, UK) and 10 µg/ml brefeldin A (Sigma-
Aldrich) in R10F at 37 ºC / 5 % CO2 for 3 hours, and surface extracellular markers were stained 
as described in 2.5.1. 
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To subsequently stain for intracellular cytokines, the cells were permeabilised with 50 µl 
saponin buffer (1 % bovine serum albumin (BSA) in PBS containing 1 % saponin from quillaja 
bark (Sigma-Aldrich) and 0.01 % sodium azide) (See Media and Buffers, Table 2.6) at 4 ºC for 
10 minutes. The samples were then incubated with respective antibodies (Table 2.1) in saponin 
buffer at 4 ºC for 30 minutes. After staining, the cells were washed two times in saponin buffer 
prior to a final wash and suspension in 200 µl PBA. Flow cytometry was performed utilising a 
BD Fortessa flow-cytometer. All samples for intracellular staining underwent flow cytometry 
measurements within 2 hours of staining. 
2.5.3 Gating strategy for lymphocytes  
2.5.3.1 Gating strategy for T cells, NK cells and B cells 
Dead cells were initially excluded based on positive staining with a live dead dye (A). A 
defined ‘lymphocyte gate’ (B) was drawn based on characteristic cell size (FSC-A) and cell 
granularity (SSC-A) and this gate served as the basis for subsequent analysis. Cells positive for 
CD3 and CD4 markers were recorded as CD4+ T cells (C). Cells positive for CD3 and CD8 
were recorded as CD8+ T cells (D). Cells negative for CD3 and positive for NKp46 were 
recorded as NK cells (E). Cells negative for CD3 and positive for CD19 were recorded as B 
cells (F).  
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Figure 2.7: Gating strategy for T cells, B cells and NK cells by flow cytometry. 
All gating strategies were drawn with the help of FMOs. 
Chapter 2: Materials and methods 
89 
 
2.5.3.2 Gating strategy for ILCs 
Dead cells were initially excluded based on positive staining with a live dead dye (A). A 
defined ‘lymphocyte gate’ (B) was drawn based on characteristic cell size (FSC-A) and cell 
granularity (SSC-A) and this gate served as the basis for subsequent analysis. Cells were 
analysed for the expression of haematopoietic lineage (Lin) markers CD3, CD11b, CD45R, 
TER-119 and Gr-1 expression (C). Cells negatively stained for these markers (Lin-) were 
further analysed for the expression of ICOS and CD45 (D). Lin-, CD45+ ICOS+ cells were 
defined as ILCs (D). ILC populations were then examined for the expression of T1ST2 (E), 
IL-13 (F) and IL-17 (G) with gating defined by respective FMOs. 
2.5.3.3 Gating strategy for Th1, Th2 and Th17 cells 
Dead cells were initially excluded based on positive staining with a live dead dye (A). A 
defined ‘lymphocyte gate’ (B) was drawn based on characteristic cell size (FSC-A) and cell 
granularity (SSC-A) and this gate served as the basis for subsequent analysis. Cells within the 
lymphocyte gate that were positive for CD3 and CD4 were identified as CD4+ T cells (C). 
Further analysis of intracellular cytokines was performed to identify respective T cell subsets. 
CD4+ T cells positive for either T1ST2 (D) or IL-13 (E) were recorded as Th2 cells. CD4+ T 
cells positive for IL-17 were recorded as Th17 cells (F). CD4+ T cells positive for IFN-γ were 
described as Th1 cells (G).   
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Figure 2.8: Gating strategy for defining ILCs by flow cytometry. 
All gating strategies were drawn with the help of FMOs. 
Chapter 2: Materials and methods 
91 
 
 
 
 
 
 
Figure 2.9: Gating strategy for CD4+ Th1, Th2 and Th17 cells by flow cytometry. 
All gating strategies were drawn with the help of FMOs. 
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2.5.4 Gating strategy for myeloid cells 
2.5.4.1 Gating strategy for myeloid cells 
Dead cells were initially excluded based on positive staining with a live dead dye (A). A CD11c 
vs. CD11b plot was drawn from which CD11c+ cells and CD11b+ CD11c- cells were gated (B). 
CD11c+ cells were subsequently analysed for expression of F4/80 and Siglec-F, with those that 
were F4/80+ and Siglec-F+ defined as alveolar macrophages (C). CD11b+ CD11c- cells were 
subjected to further analysis for identification of additional myeloid cell populations. Firstly, 
expression of Siglec-F was assessed, with CD11b+ CD11c- Siglec-F+ cells defined as 
eosinophils (D). CD11b+ CD11c- cells that were Siglec-F- were further analysed for F4/80 and 
Ly6C expression. CD11b+ CD11c- SiglecF- cells that were F4/80+ and expressed low levels of 
Ly6C were defined as Ly6Clow monocytes, whereas those that express high levels of Ly6C 
were recorded as Ly6Chigh monocytes (E). Cells that were CD11b+ CD11c- SiglecF-F480- but 
express intermediate levels of Ly6C were putatively recorded as neutrophils (E). Neutrophils 
were further confirmed as Ly6G positive w henever possible (F). All myeloid cell populations 
were further validated by characteristic FSC-A and SSC-A profiles. 
2.5.4.2 Gating strategy for monocytes 
Monocytes are classically identified by the expression of csfr1 or CD115365, however our in-
house lung digestion protocols and supplementation of media with serum cause an unavoidable 
down-regulation of CD115 expression thus necessitating the use of an alternative staining 
strategy independent of CD115.  Dead cells were initially excluded based on positive staining 
with a live dead dye (A). A CD11c vs. CD11b plot was drawn from which CD11b+ CD11c- 
cells were gated (B) and further analysed for the expression of markers within an in-house 
lineage cocktail (Lin; consisting of markers CD3, CD19, Nkp46, SiglecF and Ly6G) (C). Cells 
negative for these lineage markers (Lin-) were subsequently analysed for the expression of 
F4/80. CD11b+ CD11c- Lin- F480+ cells were defined as monocytes (D). Monocytes were 
further subdivided into subsets based on the relative expression of markers Ly6C and MHC2 
as previously described366 (E). Ly6Clow MHC2low cells were recorded as Ly6Clow monocytes 
(Q1). Ly6Chigh MHC2low cells were recorded as Ly6Chigh monocytes (Q2). Ly6Chigh and 
MHC2high cells were identified as Ly6Chigh MHC2+ve monocytes (Q3). Ly6Clow MHC2high cells 
were identified as Ly6Clow and MHC2+ve monocytes (Q4). 
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2.5.4.3 Gating strategy for lymph node DCs 
Dead cells were initially excluded based on positive staining with a live dead dye (A). MHC2+ 
cells that were lineage negative were gated (Lin; consisting of markers CD3, CD19, CD90.2, 
Nkp46, SiglecF and Ly6G) (B). DCs were then identified from the Lin- MHC2+ gate by the 
expression of CD11c (C).  Two DC subsets, namely monocyte-derived DCs (MoDCs) and 
CD11b+ cDCs have been identified as being crucial to inducing antigen presentation in the 
HDM model320. Both subsets are CD11b+ but are further distinguished by CD64 expression, to 
which MoDCs are positive for the marker (D)320.  
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Figure 2.10: Gating strategy for myeloid cells by flow cytometry.   
All gating strategies were drawn with the help of FMOs. 
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Figure 2.11: Gating strategy for monocyte subsets by flow cytometry. 
All gating strategies were drawn with the help of FMOs. 
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Figure 2.12: Gating strategy for lymph node dendritic cells by flow cytometry. 
All gating strategies were drawn with the help of FMOs. 
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2.5.5 Isolation and sorting of epithelial cells, endothelial cells and CD45+ 
cells from lung tissue 
Lung epithelial cells, endothelial cells and CD45+ leukocytes were isolated from the lung with 
the help of flow sorting. Lungs of the mouse were inflated with 1.5 ml of dispase solution 
(5mg/ml Dispase (Sigma-Aldrich) in PBS, See Media and Buffers, Table 2.6) via the trachea. 
The lungs were allowed to collapse before 0.5 ml of 1 % low melting point agarose (Sigma-
Aldrich) was injected into the lung and the trachea was tied off. Ice was placed over the chest 
cavity to ensure the agarose solidified before the whole lung was dissected and incubated in 2 
ml of dispase solution for 40 minutes at room temperature. The tissue was then shredded using 
a pair of forceps and incubated with 50 µg/ml DNAse in DMEM containing 25 mM Hepes 
(Gibco) for 10 minutes on a shaker. The cells were then passed through a 70 µm cell strainer 
(BD) and centrifuged at 160 xg for 5 minutes at 4 ºC (Hettich Rotina 420R centrifuge 
(Hettich)). Erythrocytes were removed by addition of 3 ml red blood cell lysis buffer (See 
Media and Buffers List, Table 2.6) for 3 minutes. The cells were then washed and the 
erythrocyte-free cell pellet was re-suspended in 2 ml R10F and stored on ice until extracellular 
staining. The lung cells were stained as previously mentioned in section 2.5.1, but PBS with 1 
% BSA was utilised instead of PBA and cells were not fixed. For identification of the different 
cell types by flow cytometry, epithelial cells were identified as EpCAM+ and CD45-, CD45+ 
leukocytes were identified as EpCAM- and CD45+ while endothelial cells were identified as 
EpCAM- CD45- CD31+. The different cell populations were collected by fluorescence-
activated cell sorting (FACS) after which the cells were centrifuged 160 xg for 5 minutes at 4 
ºC (Hettich Rotina 420R centrifuge (Hettich)) and re-suspended in 350 µl RLT buffer (Qiagen, 
Hilden, Germany) and stored at -80 ºC until further use. 
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Antigen Clone 
Conjugated 
Fluorophore Dilution Manufacturer 
CD11b M170 PerCP/Cy5.5 1:400 eBioscience 
CD11c HL3 APC 1:200 BD Pharmingen 
CD11c N418 FITC 1:200 eBioscience 
F4/80 BM8 PE 1:50 eBioscience 
F4/80 BM8 PE-DAZZLE 1:50 Biolegend 
Ly6G 1A8 FITC 1:200 BD Pharmingen 
Ly6G 1A8 PE 1:200 BD Pharmingen 
Ly6C AL-21 PE/Cy7 1:200 BD Pharmingen 
Ly6C HK1.9 Alexa Fluor 700 1:100 Biolegend 
Siglec-F E50-2440 PE 1:200 BD Pharmingen 
Siglec-F E50-2440 BV421 1:100 BD Horizon 
CD64 X54-5/7.1 PE/Cy7 1:50 Biolegend 
CD103 2E7 APC 1:100 Biolegend 
C-Kit 2B8 PE/Cy7 1:100 Ebioscience 
Flt3 A2F10.1 PE-DAZZLE 1:100 BD Horizon 
CD115 AF598 APC 1:50 Biolegend 
MHC2 M5/114.15.2 BV421 1:100 Biolegend 
CD3 145-2C11 PE/CY7 1:200 eBioscience 
CD3 145-2C11 PE 1:200 eBioscience 
CD3 17A2 eFluor 450 1:100 eBioscience 
CD4 RM4-5 PeCP/Cy5.5 1:200 BD Pharmingen 
CD8 53-6.7 APC 1:200 BD Pharmingen 
CD19 ID3 FITC 1:100 BD Pharmingen 
CD19 ID3 PE 1:100 eBioscience 
Nkp46 29A1.4 PE 1:200 eBioscience 
CD45 30-F11 PeCP/Cy5.5 1:100 eBioscience 
ICOS C398.4A PE/Cy7 1:100 Biolegend 
Haematopoietic 
lineage marker 
cocktail   eFluor 450 1:30 eBioscience 
T1ST2 DJ8 FITC 1:100 MD Bioproducts 
IL-13 13A PE 1:50 eBioscience 
IL-17A 17B7 APC 1:50 eBioscience 
IFN-γ XMG1.2 PE/Cy7 1:50 eBioscience 
CD44 IM7 PE-DAZZLE 1:200 Biolegend 
CD279 (PD1) 29F.1A12 PE-Cy7 1:100 Biolegend 
Ki-67 SolA15 PE-Cy7 1:200 eBioscience 
CD86 GL-1 APC 1:100 Biolegend 
CD90.2 53-2.1 PE 1:100 eBioscience 
CD326 (EpCAM) G8.8 PE 1:100 eBioscience 
CD31 390 APC 1:100 Biolegend 
Table 2.1: Flow cytometry anti-mouse antibodies utilised for cell identification. 
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Antigen Clone 
Conjugated 
Fluorophore 
Dilution Manufacturer 
Haematopoietic 
lineage marker 
cocktail 
  BV510 1:200 Biolegend 
CD161 DX12 APC 1:100 
BD 
Pharmingen 
CD127 
HIL-7R-
M21 
APC 1:100 
BD 
Pharmingen 
CD294 BM16 APC 1:100 
BD 
Pharmingen 
C-kit YB5-B8 APC 1:100 
BD 
Pharmingen 
IL-13 JES10-5A2 APC 1:100 
BD 
Pharmingen 
Table 2.2: Flow cytometry anti-human antibodies utilised for human ILC2 purfication 
 
2.6 Assessment of soluble mediators 
2.6.1 Preparation of lung tissue homogenates  
Lung tissue homogenates were prepared to allow the measurement of specific soluble 
mediators. Snap frozen middle and inferior lobes were weighed and homogenised in PBS (Life 
Technologies) at a concentration of 50 mg/ml utilising a glass tissue grinder (ThermoFisher 
Scientific) in PBS. The ground tissue was then centrifuged at 800 xg for 10 minutes, and 
aliquoted and stored at -80 ºC for further analysis. 
2.6.2 Enzyme-linked immunosorbant assay (ELISA) 
2.6.2.1 General ELISA protocol 
The concentrations of selective cytokines and mediators were assessed by commercially 
available ELISA kits, according to manufacturer’s instructions (Table 2.3).  
In the case of IL-4 and IL-5, it was necessary to develop an in-house protocol.  Capture and 
detection antibodies and recombinant standards were obtained individually (Table 2.4) and the 
following general protocol applied. High binding affinity 96-well plates were coated with 
respective purified capture antibodies in PBS (VWR) (ELISAs from R&D) or 0.1 M NaHCO3 
(for ELISAs from eBioscience) and left overnight at 4 ºC (for IL-4, IL-5 and eBioscience 
ELISA kits) or at room temperature (for R&D ELISA kits). The plates were washed 3 times 
with wash buffer composed of 0.05 % Tween-20 (Sigma-Aldrich) in PBS and subsequently 
blocked with 1 % BSA in PBS for 1 hour. After 3 washes, the standards (consistent of 8 serially  
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diluted standard curve points, in duplicate) and samples were loaded onto the plate and 
incubated overnight at 4 C. The plates were again washed for a total of 3 washes and 
biotinylated detection antibodies were added to each well and incubated at room temperature 
for 2 hours. Wells underwent a further 5 washes before the addition of streptavidin-horseradish 
peroxidase (HRP) diluted 1:200 in 1 % BSA in PBS and incubation at room temperature for 
30 minutes. The plates were washed a further 5 times prior to the addition of K-blue substrate 
(Neogen Corporation, Michigan, US) to each well. The reaction was allowed to develop for 15 
minutes at room temperature and was subsequently stopped by the addition of 0.19 N H2SO4. 
The absorbance values were recorded at a wavelength of 450 nm (reference wavelength: 540 
nm) using a Tecan sunrise plate reader (Tecan, Männedorf, Switzerland).  
2.6.2.2 Serum Immunoglobulin ELISAs  
Concentrations of total immunoglobulins IgE and IgG1 in serum were measured using the 
general protocol described above for IL-4 and IL-5 (Section 2.6.2.1). The concentrations of the 
capture, standard and detection antibodies used are in Table 2.4. To measure HDM-specific 
antibodies in the serum, an in-house methodology was devised. Briefly, high affinity binding 
96-well plates (Corning) were coated with 50 µg/ml HDM extract in 0.1M NaHCO3 (pH = 9.6) 
and incubated overnight at 4 oC. HDM-specific IgG1 and IgE were subsequently assessed 
following the general protocol described in 2.6.2.1, utilizing the reagents described in Table 
2.4. Allergen-specific antibody levels were expressed as absorbance values recorded at 450 
nm.  
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ELISA Name of kit Manufacturer 
IL-13 Mouse IL-13 ELISA Ready-Set-Go eBioscience 
MCPT-1 Mouse MCPT-1 ELISA Ready-Set-Go eBioscience 
TNF-A Mouse TNF-A ELISA Ready-Set-Go eBioscience 
IL-6 Mouse IL-6 ELISA Ready-Set-Go eBioscience 
IL-17A Mouse IL-17A ELISA Ready-Set-Go eBioscience 
KC Mouse CXCL-1/KC DuoSet ELISA R&D Systems 
MIP-2 Mouse CXCL-2/MIP-2 DuoSet ELISA R&D Systems 
Eotaxin-2 Mouse CCL24/Eotaxin Duoset ELISA R&D Systems 
MMP-9 Mouse MMP-9 DuoSet ELISA R&D Systems 
MPO Mouse MPO DuoSet ELISA R&D Systems 
MDC Mouse MDC/CCL22 DuoSet ELISA R&D Systems 
C5a Mouse C5a DuoSet ELISA R&D Systems 
IL-33 Mouse IL-33 DuoSet ELISA R&D Systems 
G-CSF Mouse G-CSF DuoSet ELISA R&D Systems 
MCP-1 Mouse MCP-1 DuoSet ELISA R&D Systems 
Fractalkine Mouse CX3CL1/Fractalkine DuoSet ELISA R&D Systems 
Albumin Mouse Albumin ELISA Quantitation Set Bethyl Laboratories 
Table 2.3: Commercially available ELISA kits utilised. 
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ELISA Antibody type Catalogue 
number 
Clone Standard Curve range 
IL-4 Coating 
(1:250) 
554434 11B11 
1000 pg/ml - 15.625 
pg/ml 
Standard 
(1:5000) 
550067 Recombinant 
Mouse IL-4 
Detection 
(1:1000) 
554390 BVD6-24G2 
IL-5 Coating 
(1:250) 
554393 TRFK5 
2000 pg/ml - 31.25 
pg/ml 
Standard 
(1:5000) 
554581 Recombinant 
Mouse IL-5 
Detection 
(1:250) 
554397 TRFK4 
IgE Coating 
(1:250) 
553413 R35-72 
400 ng/ml – 6 ng/ml 
Standard 
(1:250) 
557079 C38-2 
Detection 
(1:250) 
553419 R35-118 
IgG1 Coating 
(1:250) 
553445 A85-3 
10 ng/ml - 0.156 ng/ml 
Standard 
(1:250) 
557273 MOPC-31C 
Detection 
(1:250) 
553441 A85-1 
Table 2.4: Components of in-house developed ELISAs. 
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2.6.3 Western blot  
12 µl BALF samples were combined with 3 µl LDS loading buffer (Novex, Life Technologies) 
and 3 % mercaptoethanol (Sigma-Aldrich) and incubated at 95 ºC for 5 minutes before 
separation on 4-12 % CriterionTM XT Bis-Tris precast polyacrylide gels (BIORAD, 
Hertfordshire, UK). The proteins were subsequently transferred (using a Bio-Rad CriterionTM 
Blotter machine (BIORAD, Hertfordshire, UK) onto polyvinylidene difluoride membranes 
(ThermoFisher Scientific, Paisley, UK). Membranes were blocked in PBS (VWR) containing 
5 % milk (Dried skimmed milk, Marvel, London, UK) and 0.1 % Tween-20 for two hours at 
room temperature. The membranes were then incubated with 20 µg/ml rabbit-anti-mouse PE 
antibody (synthesised by EZ Biolab (Westfield, IN) against a synthetic peptide representing 
residues 190-219 of mouse PE) diluted in PBS/ 5 %milk / 0.1 % Tween-20 overnight at 4 ºC. 
The membranes were then washed in PBS/0.1 % Tween-20 3 times and then incubated with 
goat anti-rabbit IgG-HRP (Cell Signalling, Massachusetts, US) diluted 1:500 in 5 % milk in 
TRIS-buffered saline solution. Reactivity was detected utilising the ECL2 Western Blotting 
Substrate chemiluminescent kit (ThermoFisher Scientific) according to manufacturer’s 
instructions. The membrane was then exposed to film (GE Healthcare, Buckinghamshire, UK) 
for 2 minutes and developed utilising an automatic X-Ray film processor (JPi Healthcare 
Solutions, New York, USA). 
2.6.4 Proteome Profiler  
A proteome profiler (R&D systems, Minneapolis, USA) was utilised to determine the 
expression of a multitude of cytokines, chemokines and growth factors in lung tissue 
homogenate and serum samples. Nitrocellulose membranes, pre-spotted with control and 
capture antibodies to the various mediators, were primarily incubated in the manufacturer 
supplied block buffer for 1 hour at room temperature on a rocking shaker. 200 µl of neat serum 
samples was diluted in manufacturer supplied assay diluent to a final volume of 1.5 ml and 
subsequently incubated with the membrane overnight at 4oC on a rocking shaker. Membranes 
were then washed for a total of 3 times using a wash buffer provided by the manufacturer. After 
washing, a detection antibody cocktail was incubated with the membranes at room temperature 
for 1 hour on a rocking shaker. The membranes were washed a further 3 times prior to the 
addition of streptavidin-HRP for 30 minutes at room temperature on a rocking shaker. 
Membranes were again washed 3 times and developed using a chemi-reagent mix provided by 
the manufacturer. The membrane was then exposed to film (GE Healthcare, Buckinghamshire, 
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UK) for 5 minutes and developed utilising an automatic X-Ray film processor (JPi Healthcare 
Solutions, New York, USA). 
2.6.5 Quantitative real time PCR (qPCR) 
Different cell populations were collected by FACs. The cells were centrifuged at 160 xg for 5 
minutes at 4 ºC (Hettich Rotina 420R centrifuge (Hettich)), and immediately re-suspended in 
300 µl RLT buffer (Qiagen, Hilden, Germany) containing 1 % B-Mercaptoethanol (Sigma-
Aldrich) and stored at -80 ºC until time of use. The RNA was then purified utilising an RNeasy 
Plus Micro Kit (Qiagen) according to manufacturer’s protocol. The RNA yield was quantified 
using a nanodrop spectrophotometer (ThermoFisher). 1 µg of RNA was reverse transcribed 
into cDNA utilising a High-capacity cDNA reverse transcription kit (Life Technologies) 
according to manufacturer’s protocol. A Veriti 96-well thermal cycler (ThermoFisher) was 
utilised for the cDNA reverse transcription. The cDNA was diluted 1/4 with dH2O before being 
stored at -20 ºC until time of use. For the qPCR, a reaction mixture (6 µl total volume) was 
made containing 3 µl Taqman Fast Advanced Master Mix (ThermoFisher), 0.3 µl Taqman 
primer, 0.3 µl dH2O and 2.4 µl cDNA. The contents were pipetted into a 384-well plate (Life 
Technologies) and run on a Viaa7 Real-Time PCR System (ThermoFisher). The program 
followed on the PCR system was 2 minutes at 50 ºC, then 20 seconds at 95 ºC, followed by 40 
cycles of 1 second at 95 ºC and 20 seconds at 60 ºC. RNaseZap decontamination solution 
(ThermoFisher) was used throughout the procedure to ensure all items were RNase free. Each 
target gene expression was normalised to housekeeping genes Hprt and Gapdh. Data was 
expressed when detected as a fold-change relative to PBS control mice administered 2A3. The 
list of Taqman primers utilised in the project are listed in Table 2.5. 
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2.6.6 PGP degradation experiments  
LTA4H aminopeptidase activity within BALF samples were assessed by measuring the 
capacity of the BALF to degrade exogenous PGP.  Specifically, BALF (diluted 1/10 in PBS) 
was incubated with 0.4 mM PGP (BACHEM, USA) at 37 oC and 5 % CO2 for 2 hours. 
Concentrations of PGP remaining were quantified by electrospray ionization (ESI)–liquid 
chromatography (LC)/mass spectrometry (MS)/MS (section 2.6.7) by comparison with PGP 
standards. The percentage of peptide degraded was determined relative to control samples of 
0.4 mM PGP alone.  
An aliquot was taken from the aforementioned PGP degradation experiments for the 
measurement of free proline released following cleavage from the N-terminus of the peptide. 
Specifically, aliquots from PGP degradation experiments were diluted 1 in 10 in PBS (to a final 
volume of 250 µl). Glacial acetic acid (250 µl) was then added, followed by 250 µl of ninhydrin 
solution (25 mg/ml in acetic acid / 6 M phosphoric acid; heated at 70 ºC to dissolve). The 
reaction mixture was heated at 100 ºC for 60 min, allowed to cool to room temperature and the 
proline containing fraction was extracted with 500 µl of toluene and optical density measured 
at 520 nm using a spectrophotometer (Jenway, Staffordshire, UK). 
2.6.7 PGP quantification 
Mass spectrometry (Electrospray ionization-Liquid Chromatography-mass spectrometry or 
ESI–LC/MS/MS technique) was utilised to determine the concentration of PGP. PGP 
quantification within BALF was determined using a MDS API-4000 spectrometer Sciex 
(Applied Biosystems, Foster City, CA) equipped with a Shimadzu HPLC (Columbia, MD). For 
peptide quantification from degradation experiments, PGP was measured using a Thermo 
Gene Catalogue number 
Gapdh Mm99999915_g1 
Hprt Mm03024075_m1 
IL-4 Mm00445259_m1 
IL-5 Mm00439646_m1 
IL-13 Mm00434204_m1 
Table 2.5: List of Taqman primers. 
Gapdh: Glyceraldehyde-3-Phosphate Dehydrogenase; Hprt: Hypoxanthine Phosphoribosyltransferase 1.  
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Accela Pump and Autosampler coupled to a ThermoTSQ Quantum Access. In both cases, 
HPLC was performed using a 2.0x150-mm Jupiter 4u Proteo column (Phenomenex, Torrance, 
CA) with A: 0.1 % HCOOH and B: MeCN+0.1 % HCOOH: 0-0.5 min 5 % buffer B/95 % 
buffer A, then increased over 0.5-2.5 min to 100 % buffer B/0% buffer A. Background was 
removed by flushing with 100 % isopropanol/0.1 % formic acid. Positive electrospray mass 
transitions were at 270-70, 270-116 and 270-173 for PGP. 
2.6.8 LTB4 quantification 
The concentration of LTB4 in the BALF was quantified using a MDS Sciex API-4000 
spectrometer (Applied Biosystems, Foster City, CA) equipped with a Shimadzu HPLC 
(Columbia, MD).  HPLC was performed using a 2.1 x 100 mm Kinetex column (Phenomenex, 
Torrance, CA) with A: 10 mM NH4OAc and B: MeCN + 10 mM NH4OAc: 0 min-0.5 min 5% 
buffer B/95 % buffer A, then increased over 0.5-5 min to 100 % buffer B/0 % buffer A.  
Negative electrospray mass transitions were at 335-195, 335-151 and 335-123 for LTB4. 
2.7 Human cell culture experiments 
2.7.1 Air Liquid Interface (ALI) culture 
Primary human normal bronchial epithelial cells (Lonza, Basel, Switzerland) were cultured to 
air liquid interface on transwell inserts using an adaptation of a previously described method367. 
Cells were cultured for expansion in a 25 cm3 flask (Corning) using Lonza Bronchial Epithelial 
Growth Medium (BEGM). Once 80 % confluence was achieved, the cells were removed with 
the help of Trypsin (TrypLETM Express Enzyme, Gibco) and seeded onto inserts in a 12-well 
plate (Corning) at a density of 82,500 cells per insert. The cells were fed apically and 
basolaterally for 2 weeks, every two days with 50 % BEGM (Lonza) + 50 % high glucose 
DMEM (Life technologies) + 5 x 10-8 M retinoic acid (Sigma-Aldrich). After two weeks, the 
apical media was removed and the cells were exposed to air, but cells continued to be fed 
basolaterally as described above. Experiments were performed 2-4 weeks after cilia were first 
observed. AcPGP (Anaspec peptides, Fremont, CA) at a concentration of 10 μg/ml or media 
control (50 % BEGM (Lonza) + 50 % high glucose Dulbecco's Modified Eagle's medium 
(DMEM; Life Technologies)) was added basolaterally on a daily basis for 7 days. Apical 
supernatant was collected by washing the apical side of the transwell with 100 μl PBS on day 
1 and 7 and stored at -80 ºC for subsequent analysis. 
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2.7.2 JuliStage Real-Time analysis 
Primary human normal bronchial epithelial cells (Lonza, Basel, Switzerland) were cultured for 
expansion in a 75 cm3 flask (Corning) using Lonza Bronchial Epithelial Growth Medium 
(BEGM). Once over 90 % confluence was achieved, the cells were removed with the help of 
Trypsin (TrypLETM Express Enzyme, Gibco) and plated onto a 96-well plate at a density of 
5000 cells per well. The cells were supplemented with BEGM or with BEGM containing either 
10 µg/ml, 1 µg/ml, 100 ng/ml or 10 ng/ml AcPGP. The cells were placed in an incubator for 4 
hours for acclimatisation and to avoid potential condensation on the lid. Snapshots of each well 
were subsequently recorded at 30 minute time intervals over 72 hours using the JuliStage Real-
Time Cell History Recorder (NanoEnTek Inc. Seoul, Korea). Percentage cell confluence was 
automatically recorded at every time point for each well. At the end of the experiment the cells 
were fixed in 10 % neutral buffered formalin (Sigma-Aldrich) for subsequent analysis. Ki-67 
staining was performed utilising a rat anti-mouse Ki-67 primary antibody diluted 1:500 
(eBioscience).  A Cy3-conjugated goat anti-rat antibody (Jackson ImmunoResearch, 
Baltimore, USA) diluted 1:500 was subsequently added to enumerate Ki-67 positively stained 
cells. The cells were then counterstained with a 4',6-diamidino-2-phenylindole (DAPI) dye 
(ThermoFisher) diluted 1:1000. The number of DAPI positive cells and the number of DAPI 
and Ki-67 double positive cells were counted to determine the percentage Ki-67 positive cells. 
2.7.3 Human ILC cultures 
ILC2s were enriched from whole blood using RosetteSepTM Human ILC2 Enrichment Kit 
(STEMCELL Technologies, Cambridge, UK) and further sorted by FACs as CD45+ Lineageneg 
(CD1a, CD3, CD4, CD5, CD8, CD11c, CD14, CD16, CD19, CD20, CD34, FceRI and CD123) 
(Biolegend), CD161+ (BD Pharmingen), CD127+ (BD Pharmingen), CD294+ (CRTH2+) (BD 
Pharmingen) and C-Kitvar (BD Pharmingen). ILC2s were bulk cultured in medium containing 
DMEM + 10 % FCS, IL-2 (5 ng/ml), IL-7 (5 ng/ml) and IL-33 (10 ng/ml) (eBioscience) and 
were replenished every 3-4 days until the experiment was performed. During the experiment, 
the cells were supplemented with media containing G-CSF at concentrations of 10 ng/ml and 
100 ng/ml. After 24 hours, the cells were intracellularly stained as per section 2.5.2 for IL-13 
(eBioscience) for flow cytometric analysis.  
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2.8 Histopathological analysis 
2.8.1 Differential cell counts 
Differential cell counts were performed on lung and BAL cell isolates in selected experiments. 
5x104 cells were pelleted onto microscope slides by centrifugation at 400 rpm for 5 minutes in 
a Shandon Centrifuge (Model Cytospin 3, ThermoFisher). The cells were the fixed with 100 
% methanol for 5 minutes and allowed to air dry. Cells were then stained with Wright-Geimsa 
(Sigma-Aldrich) for 8 minutes with frequent gentle agitation. Eosinophils, neutrophils and 
mononuclear cells were differentially counted at 200x magnification based on the morphology 
of the cells. A total of 200 cells were counted for each sample and the percentages of each cell 
type calculated. Images of selected cytospin slides were obtained utilising a LeicaDM2500 
microscope and QWin software (Leica Microsystems [UK] Ltd, Milton Keynes, UK). 
2.8.2 Preparation of histopathological sections 
The superior lobe of the mouse lung was inflated with 0.1 ml of 10 % neutral buffered formalin 
(Sigma-Aldrich).  Lung tissue was subsequently submerged in a further 2 ml of 10 % neutral 
buffered formalin for 24 hrs, before transfer to 70 % ethanol. Wax-embedding of lung 
specimens, sectioning (4 µm lung sections were cut for histological analysis), haematoxylin 
and eosin (H&E) staining and periodic acid-Schiff (PAS) staining was performed by Lorraine 
Lawrence (NHLI, Imperial College London). Images of selected sections were obtained 
utilising a LeicaDM2500 microscope and QWin software (Leica Microsystems [UK] Ltd, 
Milton Keynes, UK). Epithelial cell height around medium-sized conducting airways (150 and 
250 μm in diameter) were assessed, with 10 measurements made per airway and a minimum 
of 10 airways measured per section368. Data presented are an average per mouse.  
2.8.3 Evaluation of goblet cell hyperplasia 
PAS staining was used to enumerate goblet cells in lung sections. Goblet cell hyperplasia was 
analysed utilising a semi-quantitive scoring system as previously reported368. The scores were 
adjudged according to the percentage of positively stained (purple) mucous containing cells 
within the airway. The following scoring system was applied: 0= < 5 % goblet cells, 1= 5-25 
%, 2 = 25-50 %, 3=50-75 %, 4= >75 %. 15-20 airways were scored per lung section and the 
average score was calculated and expressed as a PAS score (arbitrary units). Images of selected 
sections were obtained utilising a LeicaDM2500 microscope and QWin software (Leica 
Microsystems [UK] Ltd, Milton Keynes, UK). 
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2.8.4 Immunohistochemistry  
4 µm paraffin embedded sections were cut by Lorraine Lawrence (NHLI, Imperial College 
London). The Sections were then dewaxed using Acquaclear clearing solution (Uckfield, UK) 
and rehydrated by soaking in sequentially lower concentrations of ethanol. To prevent 
unspecific binding of antibodies, a blocking step was performed by adding 10 % normal goat 
serum (Vector labs, Peterborough, UK) to the sections for 1 hour at room temperature. Sections 
were subsequently stained with rabbit anti-mouse α-smooth muscle actin (α-SMA) antibody 
(Thermo Fisher Scientific, Cheshire, UK) at a dilution of 1:1500 in 1 % normal mouse serum 
(Sigma-Aldrich) overnight at 4 ºC. After washing 3 times with a 1 % Tween Solution, the 
sections were then stained with a HRP-tagged secondary goat anti-rabbit antibody (Abcam, 
Cambridge, UK) diluted 1:500 1 % normal mouse serum (Sigma-Aldrich) for 1 hour at room 
temperature. Staining was developed using a DAB staining kit (Vector labs) following 
manufacturer’s protocol. Images of selected sections were performed utilising a LeicaDM2500 
microscope and QWin software (Leica Microsystems [UK] Ltd, Milton Keynes, UK).  Smooth 
muscle thickness around medium-sized conducting airways (150 and 250 μm in diameter) were 
assessed, with 10 measurements made per airway and a minimum of 10 airways measured per 
section368. Data presented are an average per mouse.  
2.8.5 ALI culture processing  
Upon completion of ALI culture experiments, the cells were fixed by addition of 4 % 
paraformaldehyde (Sigma-Aldrich) to the apical and basolateral compartments of the 
respective wells for 45 minutes. The inserts were then washed with PBS and cut out with the 
use of a scalpel. The inserts were subsequently sandwiched between two sponge biopsy pads 
and placed into histology cassettes.  Wax-embedding, sectioning (4 µm membrane sections 
were cut for histological analysis), haematoxylin and eosin (H&E) staining and periodic acid-
Schiff (PAS) staining were performed by Lorraine Lawrence (NHLI, Imperial College 
London). Images of selected sections were obtained utilising a LeicaDM2500 microscope and 
QWin software (Leica Microsystems [UK] Ltd, Milton Keynes, UK). 
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2.9 Statistical analysis 
The software, Graphpad Prism version 6 (Graphpad Software Inc, USA) was utilised 
throughout the entire course of the project. Two group comparisons were performed utilising 
a Mann-Whitney test. For multiple group analysis, a One-way ANOVA with a Bonferroni post 
hoc test was performed. Specific tests performed are mentioned in the respective figure legends 
within the results chapters (Chapters 3, 4 and 5). 
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Red Blood Cell 
Lysis Buffer 
155mM NH4Cl, 12mN NaHCO3, 0.1mM ethylenedieminetetraacetic acid 
(EDTA) in  autoclaved water 
PBA or FACs 
Buffer 
1% BSA (Sigma-Aldrich), 0.05% sodium azide (Sigma-Aldrich) in PBS 
(VWR) 
R10F 
RPMI 1640 (Life technologies supplemented with 10% fetal calf serum 
(FCS; Life Technologies) 
Buffer for sorting  1% BSA in PBS (Life Technologies) 
Saponin 
1% Saponin from quillaja bark (Sigma-Aldrich) , 1% BSA (Sigma-
Aldrich) and 0.05% sodium azide (Sigma-Aldrich) in PBS 
Dispase Solution 5 mg/ml Dispase II (Sigma-Aldrich) in PBS 
Table 2.6: Media and Buffers list. 
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3 Chapter 3: Strain studies 
3.1 Introduction 
As discussed previously (Section 1.3.5), asthma is now acknowledged to be a heterogeneous 
disease. The concept of a ‘one size fits all’ for asthma pathogenesis has largely been disproven 
in recent research studies and large scale clinical trials. Classically, asthma was largely thought 
to be a disease of a type 2 inflammatory background with significant eosinophilic infiltrate and 
detection of Th2 cytokines in patient BAL and induced sputum samples257. However, more in 
depth analysis of clinical samples revealed that the inflammatory cell infiltrate in the lung and 
airways can differ significantly amongst asthmatic patients. Accordingly, various large scale 
clinical trials initially aimed at inhibiting Th2 cell inflammation displayed disappointing 
results. It is thus important to develop personalised biomarkers and treatment strategies to help 
identify and treat specific asthma patient subsets.  
A variety of studies have shown that up to 50 % of asthmatic patients display little to no 
eosinophilic inflammation273,337,369. Intriguingly, a large proportion of these non-eosinophilic 
asthmatic patients display a robust neutrophil infiltration in their lungs and airways composed 
of either neutrophils alone or a combination of neutrophils and eosinophils272. The exact causes 
of neutrophil infiltration and the pathophysiological role of these granulocytes remains to be 
determined. Nonetheless, a significant proportion of severe asthmatics that inadequately 
respond to corticosteroid treatment display a significant neutrophil component260 with 
suggestions that corticosteroids may actually promote neutrophil survival257 .  
Due to this heterogeneity observed in asthmatic patients, it is important to develop animal 
models that faithfully mimic the inflammatory profile and immunopathology observed in 
specific patient subgroups so as to better understand the mechanisms that define disease 
progression, to identify potential biomarkers and to assess future therapeutic strategies. 
Multiple efforts have been deployed to develop mouse models of allergic airway inflammation 
that mimic the neutrophilic inflammation exhibited by some asthmatic patients. The classical 
OVA mouse model of AAD has been manipulated to induce neutrophilic inflammation. 
Additional instillation of LPS along with OVA during sensitisation and challenge phases was 
able to induce a robust neutrophil inflammation370. Some studies have suggested that infection 
by intracellular pathogens drives neutrophilic inflammation in asthma371,372. Subsequently, 
research groups have infected mice with a single administration of Chlamydia muridarum371 
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or Haemophilus influenzae372 during the sensitisation phase in a  OVA model of AAD to induce 
neutrophilia, largely believed to be mediated by TLR stimulation.  
The HDM model has also been manipulated to develop steroid resistant neutrophilic asthma. 
Raundhal et al. in 2015 developed a model whereby administration of cyclic-di-GMP to mice 
along with HDM was able to induce steroid resistant allergic airway disease with robust 
neutrophilia373. Sepehr et al. in 2017 challenged mice with HDM over the course of 8 weeks, 
which was sufficient to drive neutrophilic inflammation374. My lab  has also shown that the 
standard HDM model of allergic airway disease induces significant neutrophil recruitment into 
the lung and airways159. The exact mechanisms by which the HDM extract is driving neutrophil 
recruitment remains speculative. It has been suggested that the presence of TLR4 stimulatory 
components375, chitins and proteases within the HDM extract could drive neutrophilic 
inflammation159.   
Inbred laboratory mouse strains are highly divergent in the profile of their immune response as 
a result of inherent genetic mutations and polymorphisms. For example, neutrophilic 
inflammation was shown to greatly differ between Balb/c, 129/S2 and C57BL/6 mice in a 
cigarette smoke exposure model376. It may therefore be possible that these mouse strains 
display altered inflammatory and remodelling features upon induction of allergic airway 
disease – particularly pertinent given that transgenic lines, on multiple backgrounds, will be 
utilised within this thesis. Thus, one could rationalise that allergic inflammation and 
particularly the level of neutrophilic inflammation may differ amongst distinct mouse strains 
in the in-house HDM model of AAD thus partially recapitulating aspects of different asthmatic 
patient phenotypes. In order to probe the mechanisms that define neutrophilic inflammation in 
the allergic lung and understand the role played by neutrophils and their products in driving 
disease pathology, it is mandatory that we investigate the inflammatory profile in distinct 
mouse strains administered HDM so as to identify the optimum background in which to 
conduct my studies.  
3.2 Hypothesis 
I hypothesise that different mouse strains exhibit an altered inflammatory response during 
HDM-induced AAD, and thus specific strains will be better suited to probe the mechanisms 
that define neutrophilic pathogenesis and therapeutic options.  
Chapter 3: Strain studies 
114 
 
3.3 Aim 
The objective of this chapter is to characterise the inflammatory and remodelling profile of 
HDM-induced AAD in multiple mouse strains, with a particular focus on the neutrophilic 
infiltrate and assessing the sensitivity of HDM-induced neutrophilic inflammation to 
corticosteroid treatment. 
3.4 Results 
3.4.1 129/S2 mice exhibit greatest lung functional changes upon HDM 
administration. 
Balb/c, 129/S2 and C57BL/6 mice were intranasally administered HDM or PBS as a control 
three times a week for up to 3 weeks (Figure 3.1 A). It has previously been shown that this 
dosing protocol induces airway remodelling and inflammatory changes that lead to changes in 
AHR, a key lung function parameter of asthma368. Therefore, AHR to increasing doses of 
methacholine was assessed in different strains of mice exposed to PBS or HDM for 3 weeks. 
Administration of HDM to all strains of mice led to an increase in airway resistance and a 
reduction in lung compliance compared to relative PBS control mice (Figure 3.1 B-H). 
Although Balb/c and C57BL/6 mice developed an increase in AHR, 129/S2 mice developed a 
significantly greater increase in airway resistance (Figure 3.1 B) compared to the other strains. 
Lung compliance however was similar between all strains upon HDM administration (Figure 
3.1 F-H). 
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Figure 3.1: Augmented airway resistance in HDM treated mice. 
(A) Balb/c, 129/S2 and C57BL/6 mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 
weeks. (B) Airway Resistance (R) to increasing doses of methacholine (Mch) was measured 24 hrs post the final 
HDM/PBS exposure. (C) Airway Resistance to increasing doses of methacholine without data recorded from 
129/S2 mice. (D) Airway resistance at baseline. (E) Airway Resistance at 100 mg/ml methacholine. (F) Lung 
Compliance (C) to increasing doses of methacholine (Mch) was measured 24 hrs post the final HDM/PBS 
exposure. (G) Lung Compliance at baseline. (H) Lung Compliance at 100 mg/ml methacholine.  Results depicted 
as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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3.4.2 129/S2 mice exhibit the greatest increase in total cell infiltrate into the 
airways upon HDM administration. 
Lung and airway inflammation are prominent features of asthma and have been linked with 
inducing pathology in the disease377. As such, total cell infiltrate in the lung and airways (BAL) 
was assessed at both 1 week and 3 week timepoints. HDM exposure led to an increase in total 
cell infiltrate at both 1 week and 3 week timepoints in all strains of mice (Figure 3.2 A-D). 
HDM exposed 129/S2 mice exhibited a greater increase in total cells in the airways compared 
to the other strains of mice at 1 week and 3 weeks (Figure 3.2 B and D), in keeping with their 
augmented AHR. 
3.4.3 HDM exposed Balb/c mice exhibit the greatest neutrophil infiltration 
in lung and airways. 
Eosinophilia is a key inflammatory observation in asthma and particularly mouse models of 
allergic airway inflammation378. It is however becoming more appreciated that neutrophils are 
another granulocyte increasingly found in the lung and airways in a proportion of asthmatic 
patients particularly exhibiting severe forms of the disease257,337.  
Therefore lung and airway eosinophilia and neutrophilia was assessed at 1 week and 3 week 
timepoints. HDM administration lead to an augmentation in lung and airway eosinophilia at 
both 1 week and 3 weeks (Figure 3.3 A-H) in all strains of mice. Lung and airway eosinophil 
infiltration was most pronounced in HDM exposed 129/S2 mice compared to other strains of 
mice at both timepoints (Figure 3.3 A-H). HDM administration also led to an increase in 
neutrophil recruitment in the lung and airways in all mouse strains at 1 week and 3 weeks 
(Figure 3.4 A-H). Neutrophil infiltration however, was more prominent in Balb/c mice with 
significant increases in neutrophil numbers in the lung and BAL compared to other strains 
exposed to HDM (Figure 3.4 A-H). Thus whilst 129/S2 mice presented with a predominantly 
eosinophilic infiltrate in response to HDM exposure, Balb/c mice displayed a more mixed 
granulocytic inflammatory profile with significant eosinophil and neutrophil infiltration. 
HDM administration also affected other myeloid cell populations. HDM administration caused 
an increase in the number of monocytes expressing high levels of Ly6C (Ly6Chigh monocytes) 
and monocytes expressing low levels of Ly6C (Ly6Clow monocytes) in the lungs at both 1 week 
(Table 3.1) and 3 weeks (Table 3.3). Intriguingly, at 1 week, the number of both Ly6Chigh and 
Ly6Clow subsets were significantly higher in 129/S2 mice. At 3 weeks however the number of 
lung monocytes remained similar amongst all strains upon HDM administration. Although 
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alveolar macrophages were increased in the lung tissue, there was no change in the number of 
alveolar macrophages in the BAL upon HDM administration for 1 week (Table 3.1 and Table 
3.2) and 3 weeks (Table 3.3 and Table 3.4) in all strains of mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: HDM administration leads to an increase in total cell numbers in the lungs and BAL. 
Balb/c, 129/S2 and C57BL/6 mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 week 
and 3 weeks. At 24 hrs post final HDM/PBS exposure, total cell numbers in the lung and BAL were assessed by 
trypan blue exclusion. (A) Total cell numbers in the lung at 1 week. (B) Total cell numbers in the BAL at 1 week. 
(C) Total cell numbers in the lung at 3 weeks. (D) Total cell numbers in the BAL at 3 weeks. Results depicted as 
mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
 
Chapter 3: Strain studies 
118 
 
   
 
 
 
 
 
 
Figure 3.3: Administration of HDM induces eosinophil recruitment to the lungs and BAL in all strains of 
mice. 
Balb/c, 129/S2 and C57BL/6 mice were administered HDM or PBS intranasally (i.n.) 3 times per week for up to 
3 weeks. At 24 hrs post final HDM/PBS exposure, the number of eosinophils in the lung and BAL were assessed 
by flow cytometry. Number (A and C) and percentage (B and D) of lung eosinophils at 1 week (A and B) and 3 
weeks (C and D) of HDM exposure.  Number (E and G) and percentage (F and H) of airway eosinophils at 1 
week (E and F) and 3 weeks (G and H) of HDM exposure.  Results depicted as mean ± SEM. *P<0.05, **P<0.01 
using Mann–Whitney statistical test. 
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Figure 3.4: Administration of HDM for 3 weeks induces neutrophil recruitment to the lung and BAL in all 
strains of mice. 
Balb/c, 129/S2 and C57BL/6 mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 
weeks. At 24 hrs post final HDM/PBS exposure, the number of neutrophils in the lung and BAL were assessed 
by flow cytometry. Number (A and C) and percentage (B and D) of lung neutrophils at 1 week (A and B) and 3 
weeks (C and D) of HDM exposure.  Number (E and G) and percentage (F and H) of airway neutrophils at 1 
week (E and F) and 3 weeks (G and H) of HDM exposure. Results depicted as mean ± SEM. *P<0.05, **P<0.01 
using Mann–Whitney statistical test. 
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3.4.4 129/S2 mice display a pronounced Th2 inflammation upon HDM 
exposure. 
ILCs like their T cell counterparts are able to produce cytokines that modulate the inflammatory 
response to inhaled allergen150,207. Therefore, ILC numbers in the lung, identified by cytokine 
and cell surface marker expression, were assessed at 1 week and 3 week timepoints. T1ST2 
(Figure 3.5 A and D) and IL-13 (Figure 3.5 B and E) are markers for ILC2s and IL-17 (Figure 
3.5 C and F) is a marker for ILC3s. All strains of mice exposed to HDM displayed an increase 
in ILC numbers in the lung and airways upon HDM exposure at both timepoints. Interestingly, 
129/S2 mice displayed a predominant ILC2 infiltration after 3 weeks of HDM administration.   
T cell inflammation is a hallmark feature of asthma with numerous patient samples reporting 
an increase in various lymphocyte populations that modulate the allergic response. Therefore, 
different subsets of T cells identified by the cytokine and cell surface marker expression were 
assessed in the lung and BAL by flow cytometry at 1 week (Figure 3.6) and 3 weeks (Figure 
3.7) of HDM exposure. T1ST2 (Figure 3.6 A, E and Figure 3.7 A, E) and IL-13 (Figure 3.6 B, 
F and Figure 3.7 B, F) are markers for Th2 cells, IL-17 (Figure 3.6 C, G and Figure 3.7 C, G) 
is a marker for Th17 cells and IFN-γ (Figure 3.6 D, H and Figure 3.7 D, H) is a marker for Th1 
cells. 129/S2 mice particularly displayed an increase in Th2 cell infiltration in the airways 
compared to other strains of mice, in keeping with the prominent eosinophilia and abundant 
ILC2 infiltration. Administration of HDM also caused an increase in CD8+ T cells and B cells 
in the lung and airways at 1 week (Table 3.1 and Table 3.2) and 3 weeks (Table 3.3 and Table 
3.4). Interestingly, at 3 weeks C57BL/6 mice displayed a striking increase in the number of B 
cells in the lung and airways compared to other strains administered HDM. Other lymphocyte 
cell types were similar in number at 1 week and 3 week in all strains of mice. 
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Figure 3.5: HDM administration for leads to an increase in lung ILC subsets at 1 week and 3 week 
timepoints. 
Balb/c, 129/S2 and C57BL/6 mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 week 
and 3 weeks. At 24 hrs post final HDM/PBS exposure, the number of ILC subsets identified by cell surface or 
cytokine expression was identified by flow cytometry. Lung ILC2 subsets at 1 week and 3 weeks were identified 
by expression of T1ST2 (A, D) and IL-13 (B, E).  Lung ILC3 subsets at 1 week and 3 week were identified by 
expression of IL-17 (C, F). Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical 
test. 
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Figure 3.6: HDM administration for 1 week leads to an increase in lung and BAL Th1, Th2 and Th17 CD4+ 
T cell subsets. 
Balb/c, 129/S2 and C57BL/6 mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 
week. At 24 hrs post final HDM/PBS exposure, the number of CD4+ T cells subsets identified by cell surface or 
cytokine expression was identified by flow cytometry. Lung and BAL Th2 cells were identified by expression of 
T1ST2 (A, E) and IL-13 (B, F). Lung and BAL Th17 cells were identified by expression of IL-17 (C, G). Lung 
and BAL Th1 cells were identified by expression of IFN-γ (D, H). Results depicted as mean ± SEM. *P<0.05, 
**P<0.01 using Mann–Whitney statistical test. 
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Figure 3.7: HDM administration for 3 weeks leads to an increase in lung and BAL Th1, Th2 and Th17 
CD4+ T cell subsets. 
Balb/c, 129/S2 and C57BL/6 mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 
weeks. At 24 hrs post final HDM/PBS exposure, the number of CD4+ T cells subsets identified by cell surface or 
cytokine expression was identified by flow cytometry. Lung and BAL Th2 cells were identified by expression of 
T1ST2 (A, E) and IL-13 (B, F). Lung and BAL Th17 cells were identified by expression of IL-17 (C, G). Lung 
and BAL Th1 cells were identified by expression of IFN-γ (D, H). Results depicted as mean ± SEM. *P<0.05, 
**P<0.01 using Mann–Whitney statistical test. 
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3.4.5 129/S2 mice exhibit the most robust Th2 cytokine and antibody 
production upon HDM administration. 
Cytokines of a type 2 inflammatory background such as IL-4, IL-5 and IL-13 have been shown 
to contribute to Th2 inflammation and airway remodelling particularly in in-vivo models of 
AAD150. Thus, the levels of these soluble mediators were assessed in lung tissue homogenates 
and BALF samples at 1 week and 3 weeks.  
HDM administration led to an increased in IL-4, IL-5 and IL-13 in lung homogenates and 
BALF at both 1 week (Figure 3.8) and 3 weeks (Figure 3.9). 129/S2 mice displayed a more 
pronounced increase in the levels of these Th2 cytokines in the BALF, particularly after 3 
weeks of HDM exposure. Eotaxin-2 is an eosinophil chemoattractant and HDM administration 
led to an increase in the concentrations of eotaxin-2 in the lung homogenate and BALF at 1 
week and 3 week of all strains (Table 3.5 and Table 3.6). Again, 129/S2 mice administered 
HDM displayed a greater increase in eotaxin-2 compared to other mouse strains supportive of 
the exacerbated eosinophilic inflammation observed in this strain of mice. Additionally, IL-33 
which is important in the recruitment of ILC2s was strikingly increased upon HDM 
administration in all strains (Table 3.5 and Table 3.6). Albumin in the BALF is an indicator of 
oedema, endothelial and epithelial cell permeability, and damage to the airways linked with 
inflammatory cell infiltrate. Administration of HDM significantly increased the concentration 
of albumin detected in the BALF (Table 3.5 and Table 3.6). Although there was a trend towards 
129/S2 mice having the greatest levels of BALF albumin, there was no significant difference 
in BALF albumin between all strains upon HDM administration. As highlighted earlier, mast 
cell degranulation is an important feature leading up to exacerbations. Mast cell protease-1 
(MCPT-1) was measured in the serum and HDM administration led to an increase in the levels 
of MCPT-1 particularly after 3 weeks in 129/S2 and C57BL/6 mice (Table 3.6).   
Development of allergen-specific antibodies are integral for the development of an allergic 
response150. Therefore, levels of total and allergen-specific IgE (Figure 3.10 A, B) and IgG1 
(Figure 3.10 C, D) were measured in the serum of mice at 3 weeks. All strains of mice displayed 
an increase in total and HDM-specific antibodies upon HDM exposure. HDM-exposed 129/S2 
mice presented with a significant increase in antibody levels relative to other strains, in keeping 
with the more pronounced Th2 inflammation. Interestingly, PBS treated 129/S2 mice display 
an increase in total IgE but not HDM-specific IgE. 
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Figure 3.8: Administration of HDM for 1 week induces and increase in lung homogenate and BALF 
Th2 cytokines in all strains of mice. 
Balb/c, 129/S2 and C57BL/6 mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 
week. At 24 hrs post final HDM/PBS exposure, lung tissue and BALF was collected for detection of Th2 
cytokines. Levels of lung homogenate IL-4 (A) and BALF IL-4 (B), lung homogenate IL-5 (C) and BALF 
IL-5 (D) and lung homogenate IL-13 (E) and BALF IL-13 (F) were measured by ELISA. Results depicted as 
mean ± SEM. *P<0.05, **P<0.01, using Mann–Whitney statistical test. 
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Figure 3.9: Administration of HDM for 3 weeks induces and increase in lung homogenate and BALF Th2 
cytokines in all strains of mice. 
Balb/c, 129/S2 and C57BL/6 mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 
weeks. At 24 hrs post final HDM/PBS exposure, lung tissue and BALF was collected for detection of Th2 
cytokines. Levels of lung homogenate IL-4 (A) and BALF IL-4 (B), lung homogenate IL-5 (C) and BALF IL-5 
(D) and lung homogenate IL-13 (E) and BALF IL-13 (F) were measured by ELISA. Results depicted as mean ± 
SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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Figure 3.10: Administration of HDM for 3 weeks induces antibody production. 
Balb/c, 129/S2 and C57BL/6 mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 
weeks. At 24 hrs post final HDM/PBS exposure, serum was collected for detection of antibodies. Levels of total 
serum IgE (A) and HDM-specific IgE (B), total serum IgG1 (C) and HDM-specific IgG1 (D) were measured by 
ELISA. Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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3.4.6 Neutrophil chemokines and proteases are elevated upon HDM 
administration. 
Neutrophil chemokines are important in the recruitment of neutrophils and are found to be 
elevated in asthmatic patients. As such, levels of common mouse neutrophil chemokines KC 
and MIP-2 were measured in the lung and BALF at 1 week and 3 week timepoints (Figure 
3.11). Whilst KC and MIP-2 levels in BAL fluid and lung homogenate were increased in all 
strains of mice exposed to HDM relative to their PBS controls, the Balb/c strain possessed 
greater amounts of KC in keeping with the greater neutrophilic infiltrate in these mice. 
Complement factor 5a (C5a) is a complement derived neutrophil chemoattractant and is 
implicated in asthma154. HDM administration led to an increase in the concentrations of C5a in 
all strains of mice and was seemingly increased at 3 weeks compared to 1 week (Table 3.5 and 
Table 3.6). Although KC was elevated in Balb/c mice, the levels of C5a were comparable 
between all strains of mice administered HDM. 
Neutrophils mediate indiscriminate tissue damage by the release of proteases such as MMP-9 
and MPO. Although these proteases are released by other cell types, they are elevated in 
asthmatic patients and correlate with neutrophilic inflammation285,379. Therefore, lung 
homogenate and BALF MPO and MMP-9 levels were measured by ELISA at 1 week and 3 
week timepoints (Figure 3.12). HDM administration led to an elevation in the levels of MPO 
and MMP-9 in all strains compared to respective PBS control mice. Surprisingly no consistent 
intra-strain differences were observed despite clear contrasts in neutrophil infiltration. 
 
 
Chapter 3: Strain studies 
135 
 
  
 
 
 
 
 
Figure 3.11: HDM administration leads to the release of neutrophil chemokines into the lung and airways.
Balb/c, 129/S2 and C57BL/6 mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 
week and 3 week timepoints. At 24 hrs post final HDM/PBS exposure, lung tissue and BALF was collected for 
the detection of neutrophil chemokines.  Concentrations of lung homogenate and BALF KC and MIP-2 at both 
timepoints were measured by ELISA. (A) Lung homogenate KC at 1 week. (B) BALF KC at 1 week. (C) Lung 
homogenate KC at 3 weeks. (D) BALF KC at 3 weeks. (E) Lung homogenate MIP-2 at 1 week. (F) BALF MIP-
2 at 1 week. (G) Lung homogenate MIP-2 at 3 weeks. (H) BALF MIP-2 at 3 weeks. Results depicted as mean 
± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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Figure 3.12: HDM administration leads to the release of neutrophil proteases into the lung and airways. 
Balb/c, 129/S2 and C57BL/6 mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 week 
and 3 week timepoints. At 24 hrs post final HDM/PBS exposure, lung tissue and BALF was collected for the 
detection of neutrophil proteases.  Concentrations of lung homogenate and BALF MMP-9 and MPO at both 
timepoints were measured by ELISA. (A) Lung homogenate MMP-9 at 1 week (B) BALF MMP-9 at 1 week. (C) 
Lung homogenate MMP-9 at 3 weeks (D) BALF MMP-9 at 3 weeks. (E) Lung homogenate MPO at 1 week (F) 
BALF MPO at 1 week. (G) Lung homogenate MPO at 3 weeks (H) BALF MPO at 3 weeks. Results depicted as 
mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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3.4.7 HDM administration leads to an increase in airway remodelling which 
is greatest in 129/S2 mice. 
Airway remodelling features such as mucus production and epithelial and smooth muscle 
thickening are common features observed in asthmatic patients145. Therefore, lung tissue 
sections were prepared to visually assess and score the remodelling observed at 1 week and 3 
week timepoints in all strains of mice. Firstly, sections stained for H&E were observed to assess 
gross inflammation and remodelling. Inflammation around the airways was noticeable after 1 
week but inflammation and remodelling was more prominent after 3 weeks of HDM exposure 
in all strains of mice compared to PBS controls (Figure 3.13 A). Mucus production was 
assessed by visualising goblet cells with the help of PAS staining of sections at the 3 weeks 
timepoint. PAS staining was greatly augmented in HDM exposed Balb/c, 129/S2 and C57BL/6 
mice relative to controls (Figure 3.13 B-C). Airway remodelling and inflammation around the 
airways was particularly increased in the 129/S2 mice, in part mimicking the increased 
inflammation and cytokine production observed earlier. 
3.4.8 Prophylactic budesonide administration ablates HDM-induced AHR. 
Corticosteroid treatment is the most effective therapy available for the majority of asthmatic 
patients in the clinic today333. However, there are asthmatic patients that do not display any 
improvement in symptomology upon corticosteroid treatment and a large proportion of these 
refractory asthmatics tend to lack eosinophilia and display more neutrophilic immune 
profiles297,380.  
Therefore 129/S2 and Balb/c mice were administered HDM or PBS for 3 weeks concomitant 
with the administration of budesonide or vehicle, PBS (Figure 3.14 A). Administration of HDM 
expectedly led to an increase in airway resistance relative to controls in both strains of mice 
(Figure 3.14 B-G). Budesonide administration however, significantly reduced airway 
resistance in both HDM-exposed Balb/c and 129/S2 mice. Administration of HDM also led to 
a reduction in lung compliance in both strains of mice relative to PBS controls (Figure 3.14 H-
M), which was again abolished by budesonide treatment. 
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Figure 3.13: HDM administration leads to an increase in airway remodelling. 
Balb/c, 129/S2 and C57BL/6 mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 
up to 3 weeks. Lung sections from mice at 1 week or 3 weeks of HDM administration were stained with 
H&E (A). Lung sections from mice administered PBS or HDM for 3 weeks were stained with PAS (B) and 
scored (C). Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. (A, 
B) Scale bar = 50 µm 
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Figure 3.14: Budesonide administration attenuates HDM-induced lung function changes in Balb/c and 
129/S2 mice. 
Balb/c and 129/S2 were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks, along with 
budesonide or vehicle, PBS administered concomitantly 5 times per week (A). (B) Airway Resistance (R) to 
increasing doses of methacholine (Mch) was measured 24 hrs post the final HDM/PBS exposure in Balb/c mice. 
(C) Airway resistance at baseline in Balb/c mice. (D). Airway Resistance at 100 mg/ml methacholine in Balb/c 
mice. (E) Airway Resistance (R) to increasing doses of methacholine (Mch) was measured 24 hrs post the final 
HDM/PBS exposure in 129/S2 mice. (F) Airway resistance at baseline in 129/S2 mice. (G) Airway Resistance at 
100 mg/ml methacholine in 129/S2. (H) Lung Compliance (C) to increasing doses of methacholine (Mch) was 
measured 24 hrs post the final HDM/PBS exposure in Balb/c mice. (I) Lung Compliance at baseline in Balb/c 
mice. (J) Lung Compliance at 100 mg/ml methacholine in Balb/c mice. (K) Lung Compliance (C) to increasing 
doses of methacholine (Mch) was measured 24 hrs post the final HDM/PBS exposure in 129/S2 mice. (L) Lung 
Compliance at baseline in 129/S2 mice. (M) Lung Compliance at 100 mg/ml methacholine in 129/S2 mice. 
Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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3.4.9 Budesonide administration reduces total lung and airway cell 
infiltration. 
As previously observed, HDM administration resulted in an increase in lung and airway 
cellular infiltration in both strains of mice. Budesonide administration reduced total cellular 
infiltrate in both strains of mice (Figure 3.15 A-D) administered HDM with this reduction being 
more prominent in the Balb/c strain (Figure 3.15 A, B). 
 
3.4.10 Budesonide administration significantly reduces neutrophil and 
eosinophil numbers in HDM-exposed mice. 
Lung and BAL eosinophil numbers and percentages were determined by flow cytometry in 
both mouse strains (Figure 3.16 A-H). Budesonide administration significantly reduced 
eosinophila in both strains of mice exposed to HDM. Interestingly, this percentage reduction 
was more prominent in Balb/c mice in comparison to 129/S2 mice (Figure 3.16  B, F, D, H). 
Corticosteroids have previously been linked with promoting neutrophil survival297,380. 
Therefore, the total number and percentage neutrophils was determined in the lung and BAL 
by flow cytometry (Figure 3.17 A-H). HDM administration led to an increase in neutrophil 
infiltration in both strains of mice, however mice exposed to HDM and treated with budesonide 
exhibited reduced neutrophil numbers. This reduction in neutrophils was modest in the Balb/c 
strain and percentage neutrophils in the lung and airways were actually increased (Figure 3.17 
B and D).  
In addition to eosinophils and neutrophils, budesonide administration had an effect on other 
myeloid cell populations. Budesonide administration resulted in a reduction or trend towards a 
reduction in the numbers of alveolar macrophages, Ly6Clow and Ly6Chigh monocytes in the 
lung and BAL in both mouse strains (Table 3.7, Table 3.8, Table 3.9 and Table 3.10). 
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Figure 3.15: Budesonide administration reduces HDM-induced total cell infiltration. 
Balb/c and 129/S2 were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks. Budesonide 
or vehicle, PBS, were administered 5 times per week over the 3 week timecourse. At 24 hrs post final 
HDM/PBS exposure, total cell numbers in the lung and BAL were assessed by trypan blue exclusion. (A) 
Balb/c total cell numbers in the lung. (B) Balb/c total cell numbers in the BAL. (C) 129/S2 total cell numbers 
in the lung. (D) 129/S2 total cell numbers in the BAL. Results depicted as mean ± SEM. *P<0.05, **P<0.01 
using Mann–Whitney statistical test. 
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Figure 3.16: Budesonide administration reduces eosinophilia in HDM treated mice. 
Balb/c and 129/S2 were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks. Budesonide 
or vehicle, PBS, was administered 5 times per week over the 3 week timecourse. At 24 hrs post final HDM/PBS 
exposure, the percentage and number of eosinophils in the lung and BAL were assessed by flow cytometry. (A) 
Balb/c lung eosinophil numbers. (B) Percentage Balb/c lung eosinophils. (C) Balb/c BAL eosinophil numbers. 
(D) Percentage Balb/c BAL eosinophils. (E) 129/S2 lung eosinophil numbers. (F) Percentage 129/S2 lung 
eosinophils. (G) 129/S2 BAL eosinophil numbers. (H) Percentage 129/S2 BAL eosinophils. Results depicted as 
mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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Figure 3.17: Budesonide administration reduces neutrophil numbers in the lung and BAL of HDM treated 
mice. 
Balb/c and 129/S2 were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks. Budesonide 
or vehicle, PBS, was administered 5 times per week over the 3 week timecourse. At 24 hrs post final HDM/PBS 
exposure, the number of neutrophils in the lung and BAL were assessed by flow cytometry. (A) Balb/c lung 
neutrophil numbers. (B) Balb/c Percentage lung neutrophils. (C) Balb/c BAL neutrophil numbers. (D) Percentage 
Balb/c BAL neutrophils. (E) 129/S2 lung neutrophil numbers. (F) Percentage 129/S2 lung neutrophils. (G) 129/S2 
BAL neutrophil numbers. (H) Percentage 129/S2 BAL neutrophils. Results depicted as mean ± SEM. *P<0.05, 
**P<0.01 using Mann–Whitney statistical test. 
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3.4.11 Corticosteroid therapy reduces Th2 inflammation in HDM-exposed 
mice. 
The number of ILCs in the lungs of Balb/c (Figure 3.18 A-C) and 129/S2 (Figure 3.18 D-F) 
strains of mice expressing T1ST2 (Figure 3.18 A, D), IL-13 (Figure 3.18 B, E) and IL-17 
(Figure 3.18 C, F) were assessed by flow cytometry after 3 weeks HDM exposure. Both strains 
exhibited a reduction in HDM-induced ILC infiltration upon budesonide exposure. 
Budesonide administration also affected the number of lymphocytes in the lung and BAL of 
HDM-exposed mice. Budesonide led to a trend in reduction (albeit not statistically significant) 
in the number of CD8+ T cells, B cells and CD4+ T cells in both Balb/c and 129/S2 mouse 
strains administered HDM (Table 3.7, Table 3.8, Table 3.9 and Table 3.10). The number of 
different subsets of CD4+ T cells in the lung (Figure 3.19 A-H) and airways (Figure 3.20 A-H) 
were assessed by flow cytometry. T1ST2 (Figure 3.19 A, E and Figure 3.20 A, E) and IL-13 
(Figure3.19 B, F and Figure 3.20 B, F) are markers for Th2 cells. IL-17 (Figure 3.19 C, G and 
Figure 3.20 C, G) is a marker for Th17 cells and IFN-γ (Figure 3.19 D, H and Figure 3.20 D, 
H) is a marker for Th1 cells. All subsets of T cells were increased upon HDM administration 
in both strains relative to vehicle controls. Budesonide significantly reduced the infiltration of 
Th2 cell subsets in the lung and BAL of Balb/c mice. This reduction was less prominent in 
129/S2 mice with non-significant reductions observed in the lung. Budesonide administration 
led to a reduction in Th17 numbers in the lung and airways of both strains of HDM-exposed 
mice. Th1 cells were significantly reduced in the airways of HDM-exposed Balb/c and 129/S2 
mice treated with budesonide, but only in the lungs of 129/S2 mice. 
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Figure 3.18: Budesonide administration reduces the number of HDM-induced ILCs. 
Balb/c and 129/S2 were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks. Budesonide 
or vehicle, PBS, was administered 5 times per week over the 3 week timecourse. At 24 hrs post final HDM/PBS 
exposure, the number of ILC subsets defined by cell surface or cytokine expression was identified by flow. Lung 
ILC2 subsets were identified by expression of T1ST2 and IL-13.  Lung ILC3 subsets were identified by expression 
of IL-17. (A) Balb/c T1ST2+ ILCs. (B) Balb/c IL-13+ ILCs. (C) Balb/c IL-17+ ILCs. (D) 129/S2 T1ST2+ ILCs. 
(E) 129/S2 IL-13+ ILCs. (F) 129/S2 IL-17+ ILCs. Results depicted as mean ± SEM. *P<0.05, **P<0.01 using 
Mann–Whitney statistical test. 
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Figure 3.19: Budesonide administration reduces the number of Th2 cells in the lung. 
Balb/c and 129/S2 were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks. Budesonide 
or vehicle, PBS, was administered 5 times per week over the 3 week timecourse. At 24 hrs post final HDM/PBS 
exposure, the number of CD4+ T cells subsets defined by cell surface or cytokine expression was identified by 
flow cytometry. Lung Th2 cells were identified by expression of T1ST2 and IL-13. Lung Th17 cells were 
identified by expression of IL-17. Lung Th1 cells were identified by expression of IFN-γ. (A) Balb/c T1ST2+
CD4+ T cells. (B) Balb/c IL-13+ CD4+ T cells.  (C) Balb/c IL-17+ CD4+ T cells. (D) Balb/c IFN-γ+ CD4+ T cells. 
(E) 129/S2 T1ST2+ CD4+ T cells. (F) 129/S2 IL-13+ CD4+ T cells.  (G) 129/S2 IL-17+ CD4+ T cells. (H) 129/S2 
IFN-γ+ CD4+ T cells. Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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Figure 3.20: Budesonide administration reduces the number of Th2 cells in the airways. 
Balb/c and 129/S2 were administered HDM or PBS intranasally (i.n.) 3 times per week 3 week timepoints. 
Budesonide or Vehicle, PBS administered 5 times per week over the 3 week timecourse. At 24 hrs post final 
HDM/PBS exposure, the number of CD4+ T cells subsets identified by cell surface or cytokine expression was 
identified by flow cytometry. BAL Th2 cells were identified by expression of T1ST2 and IL-13. BAL Th17 cells 
were identified by expression of IL-17. BAL Th1 cells were identified by expression of IFN-γ. (A) Balb/c T1ST2+
CD4+ T cells. (B) Balb/c IL-13+ CD4+ T cells.  (C) Balb/c IL-17+ CD4+ T cells. (D) Balb/c IFN-γ+ CD4+ T cells. 
(E) 129/S2 T1ST2+ CD4+ T cells. (F) 129/S2 IL-13+ CD4+ T cells.  (G) 129/S2 IL-17+ CD4+ T cells. (H) 129/S2 
IFN-γ+ CD4+ T cells. Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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3.4.12 Budesonide treatment reduces the levels of BALF Th2 cytokines in 
129/S2 mice. 
Levels of IL-4, IL-5 and IL-13 cytokines were measured in the lung homogenate (Figure 3.21 
A-F) and BALF (Figure 3.22 A-F) of budesonide treated mice at the 3 week timepoint. HDM 
exposure led to a general increase in the levels of Th2 cytokines upon HDM exposure. The 
levels of these Th2 cytokines were significantly reduced in the BALF of both strains of mice 
by budesonide treatment and a general trend towards a reduction was observed in the lung 
homogenates. 
Budesonide administration also reduced HDM-induced eotaxin-2 levels in the lung 
homogenate of both strains of mice (Table 3.11 and Table 3.12). IL-33 was also reduced upon 
budesonide administration in keeping with ameliorated ILC2 numbers observed in both strains 
of mice administered HDM and budesonide (Table 3.11 and Table 3.12). Albumin levels in the 
BALF was also reduced albeit non-significantly in both strains of mice administered HDM and 
budesonide (Table 3.11 and Table 3.12). A similar trend was observed with MCPT-1 levels 
measured in the serum (Table 3.11 and Table 3.12). 
3.4.13 Budesonide administration effectively reduces antibody levels in mice 
administered HDM. 
To assess whether corticosteroid treatment influenced antibody secretion, total and HDM-
specific IgE and IgG1 levels in the serum was assessed in both strains of mice. HDM 
administration expectedly augmented the levels of total and HDM specific IgG1 (Figure 3.23 
A, B, C, D) and IgE (Figure 3.23 E, F, G, H). The levels of IgE and IgG1 were more pronounced 
in HDM-exposed 129 mouse strain as previously highlighted (Figure 3.23 B, D, F, H). 
Budesonide administration consistently reduced the levels of antibodies in both Balb/c mice 
and 129/S2 mice.  
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Figure 3.21: Budesonide administration does not effectively reduce lung homogenate Th2 cytokine 
concentrations. 
Balb/c and 129/S2 were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks. Budesonide 
or vehicle, PBS, was administered 5 times per week over the 3 week timecourse. At 24 hrs post final HDM/PBS 
exposure, lungs were collected for detection of Th2 cytokines. Lung homogenate from Balb/c (A-C) and 129/S2 
(D-F) mice was prepared to measure the concentrations of IL-4 (A and D), IL-5 (B and E) and IL-13 (C and F) 
by ELISA. Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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Figure 3.22: Budesonide treatment reduces the concentrations of Th2 cytokines in the BALF of 129/S2 mice. 
Balb/c and 129/S2 were administered HDM or PBS intranasally (i.n.) 3 times per week 3 week timepoints. 
Budesonide or Vehicle, PBS administered 5 times per week over the 3 week timecourse. At 24 hrs post final 
HDM/PBS exposure, BALF was collected for detection of Th2 cytokines. Lung homogenates from Balb/c mice was 
prepared to measure the concentrations of IL-4 (A), IL-5 (B) and IL-13 (C) by ELISA. Lung homogenates from 
129/S2 mice was prepared to measure the concentrations of IL-4 (D), IL-5 (E) and IL-13 (F) by ELISA. Results 
depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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Figure 3.23: Budesonide treatment reduced the development of allergen-specific antibodies in HDM 
exposed mice. 
Balb/c and 129/S2 were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks. 
Budesonide or vehicle, PBS, was administered 5 times per week over the 3 week timecourse. At 24 hrs post 
final HDM/PBS exposure, serum was collected for detection of antibodies. Total IgG1 in Balb/c mice (A) 
and 129/S2 mice (B), HDM-specific IgG1 in Balb/c mice (C) and 129/S2 mice (D), total IgE in Balb/c mice 
(E) and 129/S2 mice (F), and HDM-specific IgE in Balb/c mice (G) and 129/S2 mice (H) were measured by 
ELISA. Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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3.4.14 Budesonide administration reduces the concentration of neutrophil 
mediators upon HDM administration. 
Neutrophil chemoattractants, KC and MIP-2 were also measured in the lung homogenate and 
BALF of both strains of mice (Figure 3.24). KC and MIP-2 levels in BALF and lung 
homogenate of HDM-administered Balb/c mice were reduced upon budesonide treatment 
(Figure 3.24 A, B, E, F). KC and MIP-2 levels were significantly reduced in the BALF of 
129/S2 (Figure 3.24 D, H) mice administered budesonide and HDM, however this reduction 
was not observed in the lung homogenates of this strain of mouse (Figure 3.24 C, G). 
Neutrophil chemokine, C5a was also reduced albeit non-significantly in the lung homogenate 
of both strains of mice administered HDM and budesonide (Table 3.11 and Table 3.12). 
Budesonide exhibited a partial effect in depreciating neutrophil numbers, with an increase in 
neutrophil percentages actually observed in Balb/c mice administered HDM and budesonide. 
Therefore, neutrophil proteases MMP-9 and MPO were measured in the lung homogenate and 
BALF (Figure 3.25) of both strains of mice. Budesonide administration consistently reduced 
the levels of MMP-9 in both strains of mice administered HDM. MPO was reduced in the lung 
homogenate of both strains of mice and in the BALF of 129/S2 mice administered HDM and 
budesonide. BALF MPO levels in HDM exposed Balb/c mice was unaffected upon budesonide 
treatment.  
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Figure 3.24: Budesonide reduces the concentrations of KC in Balb/c mice. 
Balb/c and 129/S2 were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks. Budesonide 
or vehicle, PBS, was administered 5 times per week over the 3 week timecourse. At 24 hrs post final HDM/PBS 
exposure, lung homogenate and BALF was collected for detection of neutrophil chemokines by ELISA. (A) 
Balb/c lung homogenate KC. (B) Balb/c BALF KC. (C) 129/S2 lung homogenate KC. (D) 129/S2 BALF KC. (E) 
Balb/c lung homogenate MIP-2. (F) Balb/c BALF MIP-2. (G) 129/S2 lung homogenate MIP-2. (H) 129/S2 BALF 
MIP-2. Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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Figure 3.25: Budesonide administration reduces HDM-induced increases in MMP-9. 
Balb/c and 129/S2 were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks. Budesonide 
or vehicle, PBS, was administered 5 times per week over the 3 week timecourse. At 24 hrs post final HDM/PBS 
exposure, lung homogenate and BALF was collected for detection of neutrophil proteases by ELISA. (A) Balb/c 
lung homogenate MMP-9 (B), Balb/c BALF MMP-9. (C) 129/S2 lung homogenate MMP-9. (D) 129/S2 BALF 
MMP-9. (E) Balb/c lung homogenate MPO. (F) Balb/c BALF MPO. (G) 129/S2 lung homogenate MPO. (H) 
129/S2 BALF MPO. Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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3.4.15 Budesonide administration ameliorates tissue pathology. 
It has been observed that budesonide administration in most parts attenuates the inflammatory 
response. To assess whether budesonide administration has an effect on airway remodelling 
induced by HDM administration, lung sections stained with H&E (Figure 3.26 A) and PAS 
sections (Figure 3.26 B) were observed in both strains of mice. HDM administration led to an 
increase in inflammatory cell infiltrate around the airways relative to controls in both strains 
of mice as observed in H&E sections (Figure 3.26 A). This gross inflammation was reduced 
upon budesonide treatment in both strains of mice. Goblet cell metaplasia was scored on PAS 
stained sections (Figure 3.26 C-D). Despite PAS scores being increased in HDM exposed 
Balb/c and 129/S2 mice, this was significantly reduced upon budesonide treatment in both 
strains of mice. 
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Figure 3.26: Budesonide administration reduces the level of HDM-induced airway remodelling. 
Balb/c and 129/S2 were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks. Budesonide 
or vehicle, PBS, was administered 5 times per week over the 3 week timecourse. Representative lung sections 
from mice were stained with H&E (A). Lung sections were stained with PAS (B) and scored from Balb/c mice 
(C) and 129/S2 mice (D). Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical 
test. (A, B) Scale bar = 50 µm 
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3.4.16 Neutrophilic inflammation is not TLR4-dependent in the in-house 
HDM model. 
The components of HDM that specifically elicit neutrophilic inflammation remain poorly 
defined. It has previously been suggested that molecules within the HDM extract such as 
lipopolysaccharide can induce neutrophil recruitment via the activation of TLR4324,325. In order 
to interrogate this assumption in the AAD model, wild type mice and TLR4 -/- mice were 
administered HDM for 1 week, a timepoint previously been shown to induce peak neutrophil 
recruitment in the lung tissue and airways. Total (Figure 3.27 A, C) and percentage (Figure 
3.27 B, D) neutrophils were increased in the lung and BAL following exposure to HDM, as 
previously seen. Intriguingly, neutrophil numbers in the lung and airways remained similar 
between wild type and TLR4 -/- mice, thus suggestive that HDM-induced neutrophilic 
inflammation was independent of the TLR4-LPS axis in the in-house HDM model of AAD.  
PGP, is a collagen derived matrikine that has been shown to induce neutrophil chemoattraction. 
In mammals, PGP is readily degraded to resolve neutrophilic inflammation by the 
aminopeptidase activity of the enzyme LTA4H.  However, there is accumulating evidence that 
matrikines such as PGP may be primitive, evolutionarily conserved DAMPs and subsequently 
trigger an inflammatory response381. Similarly, it is anticipated that primitive aminopeptidases 
exist, analogous to mammalian LTA4H, which can degrade PGP382. Remarkably, we were able 
to reproducibly detect significant amounts of endogenous PGP in the HDM extract, when 
assessed by mass spectrometry (Figure 3.28 A). To assess whether HDM extract also contained 
an intrinsic aminopeptidase activity capable of degrading PGP, extract was incubated with 
large concentrations of exogenous PGP and the degrading activity assessed by measuring loss 
of peptide by mass spectrometry and release of free proline by Ninhydrin. HDM extract 
possessed an intrinsic capacity to degrade PGP, which was at least partially abrogated by 
treatment with metal chelator EDTA or heating (Figure 3.28 B-C) – suggestive that like LTA4H 
in mammals, a metalloproteinase is responsible. Thus, HDM extract seemingly contains PGP 
and presumably PGP-generating and PGP-degrading enzymes analogous to that observed in 
mammals. Whilst these findings are intriguing, future studies will be needed to ascertain 
whether this intrinsic PGP contributed to the HDM-driven neutrophilia. 
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Figure 3.27: HDM-induced neutrophil infiltration is unaltered in TLR4 -/- mice. 
Wild type and TLR4 -/- mice were administered PBS or HDM 3 times a week over the course of 1 week. At 24 
hours post the final PBS/HDM dose, lung tissue and BAL was collected to assess the level of neutrophilic 
inflammation by flow cytometry. The number (A and C) and percentage (B and D) of neutrophils in the lung (A
and B) and BAL (C and D) were determined. Results depicted as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 
using Mann–Whitney statistical test. 
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Figure 3.28: Endogenous PGP and a PGP-degrading activity is present in HDM extract. 
(A) HDM extracts were reconstituted in PBS at different concentration and PGP levels assessed by mass 
spectrometry. HDM extracts were assessed for the ability to degrade exogenous PGP by assessing loss of peptide 
by mass spectrometry (B) and free proline release by reaction with Ninhydrin (C). 
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3.5 Discussion 
The objective of this chapter was to identify the differences in inflammatory and remodelling 
changes that occur upon HDM administration in different inbred mouse stains, with a particular 
focus on neutrophilic inflammation. To achieve this, Balb/c, 129/S2 and C57BL/6 mice were 
administered PBS or HDM over the course of 3 weeks to induce AAD. Disease parameters 
were assessed 24 hours post the final allergen challenge. As highlighted earlier, application of 
HDM allergen to adult mice can induce asthma disease immune-physiological 
characteristics321,323 and avoids the use of adjuvant-supported antigen challenges like the OVA 
model. This chapter also aimed to dissect the effects of corticosteroid administration on 
different spectrums of HDM-induced inflammation. Therefore, mice were administered HDM 
or PBS over the course of 3 weeks, concomitantly with budesonide or vehicle, PBS. It has 
previously been shown that HDM administration can induce neutrophilic inflammation159,322, 
though the exact mechanisms by which it achieve this is less well understood. Therefore, we 
aimed to assess whether neutrophilia was triggered by TLR4-dependent mechanisms. To 
achieve this, wild type and TLR4-/- mice were administered HDM for 1 week and the number 
of neutrophils in the lung and airways was assessed 24 hours post the final HDM dose. 
3.5.1 Different mouse strains exhibit different immune-physiological 
responses upon HDM administration. 
Repetitive HDM exposure of adult mice resulted in the induction of AHR in all inbred strains 
with an increase in airway resistance and reduction in lung compliance - in keeping with 
previous literature321–323. Additionally, HDM administration led to an increase in overall 
inflammation in all strains of mice. Interestingly, 129/S2 mice exhibited the greatest AHR and 
inflammation upon HDM administration. Th2 inflammation was most prominent in 129/S2 
mice, with striking increases in Th2 CD4+ T cells and ILC2s. Th2 cytokines, notably IL-4, IL-
5 and IL-13, were also elevated in 129/S2 mice compared to Balb/c and C57BL/6 mice 
administered HDM. IL-33 was the highest in HDM-treated 129/S2 mice which may explain 
the increased recruitment of ILC2 cells. Hyper-eosinophilia was a prominent feature of the lung 
and airway inflammation observed in 129/S2 mice which correlates with the high levels of IL-
5 and eotaxin-2 detected in the lung homogenate and BALF of 129/S2 mice. Eotaxin-2 is noted 
to be a potent eosinophil chemoattractant251 and IL-5 is linked with eosinophil maturation, 
survival and function229. Levels of total and allergen specific, HDM specific IgE and IgG1 was 
also the highest in the serum of 129/S2 mice in comparison to other strains. These high antibody 
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concentrations could be linked to the increased levels of IL-4 detected in 129/S2 mice. IL-4 
has been shown to promote B cell function and antibody class-switching229. Observation of 
lung sections from all mouse strains revealed that 129/S2 mice also exhibited the greatest 
degree of remodelling and mucus production indicated by a PAS scoring system. A myriad of 
in-vivo studies have shown that IL-13 can invoke remodelling changes and mucus 
production229 pertinent given that this cytokine was significantly elevated in 129/S2 mice, as 
previously discussed.  
Balb/c mice displayed a mixed granulocytic response composed of significant recruitment of 
eosinophils and neutrophils in the lung and airways. This increased neutrophil recruitment in 
Balb/c mice may be promoted by the increased levels of neutrophil chemokine, KC, detected 
in the lung homogenate and BALF of these animals relative to other strains administered HDM. 
To assess neutrophil function, neutrophil proteases MPO and MMP-9 were measured. 
Interestingly despite MMP-9 and MPO being consistently utilised in clinical trials as measures 
of neutrophil function, MMP-9 and MPO levels were not significantly elevated in Balb/c mice 
compared to other mouse strains administered HDM. This may in part be due to the fact that 
MMP-9 can be synthesised by a variety of cells implicated in asthma383,384. It has also been 
shown that certain subsets of monocytes can produce MPO383. 
C57BL/6 mice displayed an intermediate inflammatory phenotype between that of 129/S2 mice 
and Balb/c mice. Inflammation was less profound at 1 week compared to the other strains of 
mice but after 3 weeks of HDM administration, various inflammatory parameters seemingly 
increase to a similar extent to that of Balb/c and 129/S2 mice. Thus, inflammation appears to 
have a delayed onset in C57BL/6 mice.  
Previous studies have highlighted alternate inflammatory profiles exhibited by different mouse 
strains in allergen models. For example, one study highlighted that 129/S2 mice displayed 
greater eosinophilic inflammation than C57BL/6 mice in an OVA model of AAD385. 
Furthermore, in contrast to the findings of the current study, Gueders et al. in 2009 reported 
that C57BL/6 had bigger neutrophil and eosinophil counts in the airways compared to Balb/c 
mice in an OVA model of AAD386. This difference may notably be in part due to the different 
dosing regimen and the use of the OVA model of AAD utilised by Gueders et al.386. It is also 
important to note the peripheral sensitisation that is utilised in the OVA model which may 
cause differential inflammatory responses upon challenge in comparison to the HDM model of 
AAD. 
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Inbred mouse strains display significantly divergent immune responses which may be as a 
result of inherent genetic mutations and polymorphisms. It is important to therefore place the 
certain immunological profiles exhibited by different strains of mice to HDM in the context of 
other literature to rationalise the disparate immunopathology. 129/S2 mice displayed a 
prominent Th2 inflammation noted by hyper-eosinophilia and augmented Th2 cytokines. 
Another notable feature observed in 129/S2 mice was the elevated IgE and IgG1 antibody 
levels in the serum. 129/S2 mice have been reported to exhibit polymorphisms in CD23387,388, 
which is a low-affinity receptor for IgE that is thought to function as a negative regulator to 
IgE production387. This may in part explain the high baseline levels of IgE but not HDM-
specific IgE observed in 129/S2 mice. The high concentrations of serum IgE has been 
associated with enhanced protection to parasitic infections by 129/S2 mice389,390, compared to 
other mouse strains. Yamashita et al. in 2007 demonstrated that 129/S2 mice exhibited enhance 
anaphylaxis compared to C57BL/6 mice, which was shown to be due to high levels of FcεR1 
detected on the surface of mast cells of 129/S2 mice391. This may explain the observation of 
elevated MCPT-1 in 129/S2 mice in the current study, indicative of mast cell degranulation 
caused by IgE cross-linking with FCεR1. 
It is evident from these conclusions that 129/S2 may partially mimic patients that display 
prominent Th2 inflammation and hyper-eosinophilia. This subgroup of patients have been 
noted to express elevated levels of periostin392,393 and TGF-β264 accompanied with excessive 
subepithelial remodelling264. It would be pertinent to assess these characteristics in the 129/S2 
mouse model. As mentioned previously, 129/S2 mice exhibit polymorphisms in CD23 which 
may subsequently alter the antibody response to HDM administration. Likewise, clinical 
studies have correlated polymorphisms such as SNP T2206C, in the gene encoding CD23 to 
promote excessive IgE production394,395. Elevated IgE is associated with an increased risk of 
exacerbation in patients396, thus mimicking in many aspects the exacerbated AHR in the 129/S2 
mice. 
Balb/c mice displayed a robust neutrophilic inflammation upon HDM administration compared 
to other strains of mice. Similarly, observations of enhanced neutrophilia in Balb/c mice were 
observed in a cigarette smoke study376,397, LPS model398 and allergen model399. This mouse 
strain also displayed increased levels of neutrophil chemokine KC, the murine counterpart to 
human CXCL1. The exact reason for the enhanced secretion of KC in Balb/c mice remains 
unknown. Common sources of this cytokine in the lung and airways include epithelial cells and 
alveolar macrophages. Thus, it would be of interest to assess the secretory properties of this 
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chemokine from these cell types from different strains of mice. Trifilieff et al., in 2000 noticed 
in their allergen model that neutrophil numbers were increased in Balb/c mice despite no 
changes in the number of alveolar macrophages399, though  it is feasible that alveolar 
macrophages are producing more chemokines on a per cell basis. Balb/c mice displayed a 
mixed granulocytic inflammation upon HDM administration with a prominent neutrophil and 
eosinophil influx observed in the lung and BAL. Many asthmatic patients display mixed 
granulocytic inflammation. This subset of patients often display increased levels of neutrophils 
and eosinophils269 accompanied by increased IL-8 levels400. Like in Balb/c mice, it may be 
interesting to assess the secretory potential of IL-8 from isolated macrophages from these 
respective patients. 
Polymorphisms associated with asthma have been identified in genes regulating neutrophilic 
inflammation. Polymorphisms in 5-Lipoxygenase and LTA4H, key enzymes in the generation 
of neutrophil chemoattractant LTB4, have been associated with asthma severity401. Thus, it 
would be important to assess if LTB4 generation is greater in Balb/c mice.  
3.5.2 Prophylactic budesonide administration reduces inflammation and 
remodelling in the HDM mouse model. 
Corticosteroids have for many years been a gold standard therapy for the treatment of asthma. 
Corticosteroids, as highlighted earlier, can inhibit inflammation via a variety of pathways329. 
However, there is a proportion of patients that do not adequately respond to corticosteroid 
therapy and display worsened symptomology and represent an enormous economic burden329. 
These patients commonly display a non-eosinophilic inflammation with a prevalent 
neutrophilic component. Steroids have been previously shown to prolong the survival of 
neutrophils402 and as such it has been perceived that observations of neutrophilia in steroid 
resistant patients might be as a consequence of high dose therapy. Therefore, it is important to 
assess the responsiveness of HDM-driven inflammation and remodelling in Balb/c and 129/S2 
mouse strains to corticosteroid administration. 
This study highlighted that prophylactic budesonide administration elicited a striking reduction 
in AHR and total cellular infiltrate into the lungs and airway in both strains of HDM-exposed 
mice. In agreement with previous literature, it was observed that steroid treatment reduced 
eosinophil infiltrate and Th2 cytokines in both strains of mice upon HDM administration. 
However, whilst total neutrophil numbers were decreased in the Balb/c strain of mice by 
budesonide treatment, the reduction was relatively modest and the percentage of neutrophils 
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was actually augmented. In keeping with the partial effect of budesonide on neutrophil 
numbers, levels of KC were only modestly reduced by corticosteroid treatment. With the 
observed increases in percentage neutrophils, it would be of interest to assess the degree of 
neutrophil apoptosis in this model. Since budesonide administration only partially ameliorated 
neutrophilic inflammation in Balb/c mice and yet ablated AHR, it questions the assumed 
pathological contribution of neutrophils in establishment of AAD, which will be dissected 
further in the next chapter. It is also noteworthy that budesonide was only administered 
prophylactically in these studies. Prophylactic administration of corticosteroids may be more 
effective than a therapeutic strategy where the disease and prominent neutrophilia and allergen 
sensitisation is already established. Furthermore, a prophylactic strategy is not relevant to how 
patients presenting with disease are treated in the clinic. Therefore, in future it will be important 
to assess the outcome of budesonide administration after disease is established in this HDM 
model of AAD. 
3.5.3 HDM-induced neutrophilic inflammation is not TLR4-dependent in 
the in-house HDM model. 
HDM extract has been shown to contain a variety of components with the capacity to trigger 
neutrophilic inflammation. Components such as chitins, proteases and lipopolysaccharides can 
induce neutrophilic inflammation and have been found in HDM extract. With little known as 
to what is driving neutrophil recruitment, it is important to ascertain the key components within 
the extract that may trigger this effect.  
A common consensus is that LPS within HDM extract may be an important instigator of 
neutrophilic inflammation. To test this, I administered HDM to wild type and TLR4 -/- mice 
for 1 week, a timepoint highlighted for peak neutrophil recruitment in all strains of mice. 
Importantly, neutrophils were comparable in the lung and BAL of wild type and TLR4 deficient 
animals - thus a TLR4-independent mechanism is driving neutrophil recruitment in the in-
house HDM model. This finding conflicts with previous findings by Hammad et al. and 
McAlees et al. that showed HDM induced neutrophilic inflammation was by a TLR4-
dependent mechanism324,325. This difference may again be attributable to the variable dosing 
regimens deployed by both studies. These previous studies both administered 100 µg of HDM 
extract to mice by the intratracheal route - significantly higher than the 25 µg utilised in the 
model. Furthermore, in these previous studies mice were administered 3 doses of 100 µg HDM 
over 2 weeks as opposed to 1 week period. House dust mite extract also contains a variety of 
Chapter 3: Strain studies 
172 
 
other protein components that have been linked with inducing neutrophilia but yet to be 
explored as a contributor in the current model. For example, chitin proteins are a major 
component of house dust mites and fungal spores and can activate neutrophils to secrete 
chitinases and other proteases403. HDM extracts also contain a variety of intrinsic proteases or 
agonists of protease activated receptors (PAR) that can directly mediate neutrophil activation 
and chemoattraction404. Additionally, PAR activation on stromal cells such as epithelial cells 
and local leukocytes such as alveolar macrophages could mediate the release of neutrophil 
chemokines404. PAR-2 is expressed on a variety of cell types including mast cells and Th2 
cells404 and one study identified that anti-PAR-2 antibody administration inhibited AHR, 
cytokine production and cellular infiltration in mice challenged and sensitised with OVA and 
allergen, cockroach extract405. It would be interesting to assess the function of PAR-2 in an 
allergen challenge model such as the HDM model of AAD. 
PGP is a collagen-derived peptide fragment that functions as a chemoattractant for neutrophils. 
It has been previously been shown that administration of PGP peptide into the airways of mice 
induces neutrophilic inflammation, with sustained administration ultimately leading to an 
emphysematous phenotype132. Surprisingly, significant quantities of PGP were detectable 
within the HDM extract. The ECM is evolutionary conserved with ECM constituents found 
even within bacterial species381. Whilst ECM components and matrikines differ greatly 
between arthropods, such as house dust mite, and mammals, it could be speculated that PGP 
may be present in the HDM extract and thus alter the inflammatory response upon 
administration. Not much is known about the preparation of the HDM extract and possible 
contamination with human skin could also be attributable to the existence of PGP within 
extracts. Interestingly, HDM extract was also demonstrated to possesses an intrinsic 
aminopeptidase activity that degrades PGP. This degrading activity was perturbed by addition 
of EDTA or heat treatment, suggestive that this intrinsic aminopeptidase is a 
metalloproteinases. Whether this aminopeptidase activity within the extract has a biological 
function and physiological relevance within house dust mite remains unknown. However, this 
intrinsic aminopeptidase function could affect the methodology in which HDM extracts are 
handled and stored during the dosing period. Current storage conditions of reconstituted HDM 
at 4 ºC maintains aminopeptidase activity, and I have observed that sustained storage of HDM 
at this temperature reduces intrinsic PGP over time, and interestingly elicits a reduced 
neutrophilic response when administered to mice. It is thus feasible that PGP, endogenously 
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present in the HDM extract, may contribute the TLR-4 independent neutrophilic inflammation 
observed in the model of AAD. 
3.6 Conclusions 
In conclusion, this study has shown that administration of HDM triggers inflammation and 
remodelling in all strains of mice with significant divergence in the type and amplitude of 
pathological changes observed between strains. This Chapter has demonstrated that 129/S2 
mice exhibit prominent remodelling and AHR accompanied with a robust type 2 inflammation 
compared to the other strains of mice. Conversely, Balb/c mice exhibit a mixed granulocytic 
type of inflammation composed of significant eosinophilic and neutrophilic inflammation – 
and thus represent the optimal strain for subsequent dissection of the role of neutrophils in 
AAD. C57BL/6 mice displayed an intermediary inflammatory response between those of 
Balb/c mice and 129/S2 mice. This Chapter also noted that a prophylactic administration of 
corticosteroid, budesonide, largely ameliorated many aspects of Th2 inflammation but only 
partially reduced the neutrophilic inflammation. Importantly, in this model of AAD, the results 
from these series of experiments have shown that neutrophilia is not dependent on TLR4 and I 
speculate that neutrophil chemoattractant, PGP, endogenous within HDM extract, may 
contribute to the HDM-induced neutrophilic inflammation in the in-house HDM model. 
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4 Chapter 4: The role of neutrophils in AAD 
4.1 Introduction 
There is  clear clinical evidence reporting the presence of neutrophils in the lung 
parenchyma275, BAL275 and induced sputum269 of asthmatic patients, particularly those with 
more severe forms of disease275,337. Neutrophil products such as MMP-9285 and neutrophil 
elastase57 have also been shown to be elevated in BAL and exhaled breath condensates of 
asthmatic patients. Despite the circumstantial association between neutrophils and severe 
asthma, the precise role of neutrophils in defining the pathophysiology of disease remains 
unclear. Although the consensus has been that neutrophils are detrimental to disease outcome 
owing to the indiscriminate tissue degrading capacity of their products406, there have 
paradoxically been recent reports indicating that neutrophils may actually have a protective 
role. For example, neutrophil chemokines have been shown to be associated with improved 
lung function301, and  neutrophil-derived proteases have been shown to degrade mucin 
components302 facilitating the removal of excessive mucus aggregates in airways273. 
Additionally, my colleagues has previously highlighted that neutrophil localisation may be 
critical in defining disease outcome, with increased numbers of intra-epithelial neutrophils 
associated with improved FEV1 measurements and symptom control in children with severe 
therapy resistant asthma300.  
Various clinical strategies have been deployed to ameliorate neutrophilic inflammation in 
asthma but have displayed disappointing results – leading to further uncertainty as to the 
pathological role of neutrophils. BLT-1 antagonist administration to mild atopic asthmatic 
patients did not improve clinical parameters such as lung function recordings and AHR during 
an allergen challenge trial355. Initial results from CXCR2 antagonist trials with severe 
asthmatics showed a reduction in neutrophil numbers and exacerbations, but FEV1 
measurements were not improved359. Whilst these disappointing results may in some instances 
reflect the selection of sub-optimal patient groups or clinical endpoints and neutrophil-
independent actions of the drugs tested, there remains uncertainty as to whether neutrophils are 
detrimental or protective in the context of asthma.  
Given this clinical uncertainty surrounding the role of neutrophils in asthma, animal models of 
AAD have been utilised to dissect their function. Previous strategies to deplete neutrophils such 
as cyclophosphamide treatment and administration of a monoclonal antibody to, Gr-1 (RB6-
8C5) have been criticised for their lack of specificity. Studies utilising the ovalbumin mouse 
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model of AAD and a chemical induced asthma model have shown that RB6-8C5 administration 
resulted in improvements in lung function measurements75,295. However, it is now recognised 
that these strategies are non-specific and target multiple immune populations in addition to 
neutrophils. RB6-8C5 targets cells expressing surface markers, Ly6C and Ly6G. Ly6C has 
been shown to be present on subsets of dendritic cells78, monocytes77 and CD8+ T cells79. Ly6G 
however, has thus far, exclusively been shown to be present on the surface of neutrophils80. 
Accordingly, The Ly6G-specific antibody, 1A8, has subsequently been deployed to selectively 
deplete neutrophils80.  
In the previous chapter, I demonstrated that the Balb/c strain of mouse exhibited a mixed 
granulocytic infiltration, composed of eosinophils and neutrophils, in their airways and lung 
tissue in the in-house HDM model of AAD. Accordingly, I aimed to dissect the role of 
neutrophils in the in-house model of AAD by administering the 1A8 neutrophil depleting 
antibody to HDM-exposed Balb/c mice.  
4.2 Hypothesis 
I hypothesise that neutrophils and their products drive inflammatory and remodelling changes 
observed in the HDM model of AAD. Thus, depletion of neutrophils will lead to a reduction 
in inflammation and cardinal remodelling features associated with asthma. 
4.3 Aims 
The objective of this chapter is to determine the specific role of neutrophils in defining the 
development of inflammatory and remodelling changes in the murine model of AAD.   
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4.4 Results 
4.4.1 HDM administration promotes pulmonary neutrophilic 
inflammation, peaking at 1 week, in the in-house model of AAD. 
As demonstrated in the previous chapter, Balb/c mice exhibit a robust mixed granulocytic 
inflammation in their lungs and airways after 3 weeks of HDM exposure, concomitant with 
airway remodelling and AHR. To further establish the kinetics of neutrophilic inflammation in 
this AAD model, mice were analysed at 24 hours, 1 week and 3 weeks of HDM exposure 
(Figure 4.1 A). Neutrophil numbers in the lung and airways peaked at the 1 week time point 
(Figure 4.1 B-C). In the lung, neutrophilic inflammation remained stable until 3 weeks, whereas 
neutrophil numbers in the BAL had partially receded by 3 weeks of HDM administration. As 
expected, eosinophils become the predominant granulocyte in the lung and BAL by 3 weeks 
(Figure 4.1 B-C). Neutrophil derived proteases MMP-9 (Figure 4.1 D) and MPO (Figure 4.1 
F) peaked at 1 week in lung homogenate in keeping with neutrophilic inflammation. BALF 
MPO also peaked at the 1 week time point (Figure 4.1 G), but BALF MMP-9 continued to rise 
until 3 weeks (Figure 4.1 E) – likely attributable to other cellular sources of MMP-9 abundant 
in the airways at this time.  
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Figure 4.1: Balb/c mice display significant neutrophilic inflammation upon HDM administration. 
Female Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 24 hours, 1 week or 
3 weeks (A). At 24 hours post final HDM/PBS exposure, the number of eosinophils and neutrophils in the lung 
and BAL were assessed by flow cytometry. (B) Lung neutrophils and eosinophils at all timepoints. (C) BAL 
neutrophils and eosinophils at all timepoints. At 24 hours post final HDM/PBS exposure, lung tissue and BALF 
was collected for analysis of neutrophil proteases by ELISA. (D) Lung homogenate MMP-9 at all time points. (E) 
BALF MMP-9 at all time points. (F) Lung homogenate MPO at all time points. (G) BALF MPO at all time points. 
Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test.   
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4.4.2 Administration of anti-Ly6G antibody, 1A8, selectively and robustly 
depletes neutrophils in HDM model of AAD.  
The anti-Ly6G antibody, 1A8, was used to deplete neutrophils in the in-house HDM model of 
AAD. Since neutrophils are classically identified by flow cytometry using the fluorochrome-
tagged 1A8 antibody, it was necessary to devise a novel strategy to identify neutrophils 
independent of Ly6G expression. Previous studies have identified neutrophils as CD11b+ 
CD11clo, F480- and Ly6Cintermediate407. Therefore, we utilised a similar strategy to identify 
neutrophils independently of Ly6G - and then validated the purity of the neutrophil population 
utilising the Ly6G antibody (Figure 4.2 B).  
Having demonstrated that it was possible to identify neutrophil populations by flow cytometry 
independent of Ly6G, we next assessed the ability of the neutrophil-depleting antibody, 1A8, 
to ablate neutrophils after 1 dose of HDM (24 hrs). At 24 hrs prior to the HDM, mice were 
administered 1A8 at different doses and routes, as previously described in the current 
literature407,408, to assess the optimal strategy for neutrophil depletion (Figure 4.2 A). The 
lowest dose of 1A8 (100 µg i.p.) largely ablated neutrophils in the lung and airways elicited by 
one administration of HDM (Figure 4.2 C-G) – a finding validated from analysis of cytospins 
(Figure 4.2 H).  
The exact mechanism by which 1A8 depletes neutrophils remains unknown. Localised 
reduction in neutrophil numbers with 1A8 treatment, was not attributable to a blockade in 
extravasation into the lung as numbers were also ablated in the blood upon depleting antibody 
administration (Figure 4.3 A and B). It has previously been suggested that neutrophil numbers 
systemically reduce upon 1A8 administration as a result of neutrophil retention within the 
spleen409. However, the number of neutrophils within the spleen were also ablated upon 
administration of 1A8 (Figure 4.3 C and D).  Administration of 1A8 also significantly reduced 
the number of bone marrow neutrophils albeit not completely (Figure 4.3 E and F), suggesting 
that treatment was not effecting neutrophil egress from this site. Although no mechanism for 
depletion was defined in these studies, a recent paper has suggested that 1A8 triggers neutrophil 
phagocytosis by local macrophages81. Thus a dose of 100 µg 1A8 via an i.p. route was sufficient 
to reduce the number of neutrophils in the lung, BAL and other compartments such as the 
spleen, blood and bone marrow. 
Whilst this 1A8 treatment regimen could ablate neutrophil numbers after one HDM 
administration (24hrs), it was important to assess that this strategy was still effective after 
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multiple HDM administrations at 1 week – a time of peak neutrophilic inflammation in this 
model. Furthermore, it was important to assess how long neutrophil depletion persisted after 
each antibody administration Therefore, mice were administered PBS or HDM over the course 
of 1 week, concomitant with 100 µg neutrophil depleting antibody, 1A8, or isotype control 
antibody, 2A3, administered 24 hours prior to each HDM/PBS dose. The mice were harvested 
2 days, 4 days or 7 days post the final 1A8/2A3 dose (Figure 4.4 A). As already observed, 
HDM administration for 1 week significantly increased the number of neutrophils in the lung 
and airways (Figure 4.4 B-E). Administration of 1A8 largely ablated the number of neutrophils 
in the lung and BAL up to 4 days post the final HDM administration (Figure 4.4 B-E).  
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Figure 4.2: Administration of 1A8 ablates neutrophils in the lung and airways after a single dose of HDM. 
Balb/c mice were administered a single of dose of PBS or HDM. At 24 hours prior to the HDM dose, mice were 
administered either 100 µg i.p. 1A8, 500 µg i.p. 1A8, or 500 µg i.p. and 200 µg i.n. 1A8 in combination (A). At 
24 hours post PBS/HDM, lung tissue and BAL were collected to assess neutrophil numbers by flow cytometry. 
Ly6G independent identification of neutrophils by flow cytometry was achieved by first gating on a CD11c 
negative and CD11b positive population. This CD11b+ CD11c- population was then assessed for Ly6C and F480 
expression. Neutrophils were F480- and Ly6Cint which was further confirmed by Ly6G staining when applicable 
(B). (C) Representative Ly6C vs F480 flow cytometry plots (after initial CD11b+ CD11c- gating) of lung and BAL 
cells from a control or neutrophil depleted mouse administered HDM. The number (D and F) and percentage (E 
and G) of neutrophils in the lung (D and E) and airways (F and G) was determined by flow cytometry. (H) BAL 
cells were also spun onto glass slides and stained with Wright Giemsa for cytospin analysis. Representative image 
of different cell populations from the BAL of control and neutrophil depleted mice. Results depicted as mean ± 
SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. (H) Scale bar = 25 µm 
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Figure 4.3: Administration of 1A8 systemically reduced numbers of neutrophils after a single dose of HDM.
Balb/c mice were administered a single of dose of PBS or HDM. At 24 hours prior to the HDM, mice were 
administered either 100 µg i.p. 1A8, 500 µg i.p. 1A8, or 500 µg i.p. and 200 µg i.n. 1A8 in combination. At 24 
hours after the PBS/HDM dose, spleen, blood and bone marrow were collected to assess the percentage and 
number of neutrophils by flow cytometry. (A) Number of blood neutrophils. (B) Percentage blood neutrophils. 
(C) Number of spleen neutrophils. (D) Percentage spleen neutrophils. (E) Number of bone marrow neutrophils. 
(F) Percentage bone marrow neutrophils. Results depicted as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, 
**** P<0.0001 using Mann–Whitney statistical test. 
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Figure 4.4: Neutrophil depletion imparted by 1A8 treatment is maintained after 1 week of HDM exposure.
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 week and 24 hours prior to 
each dose, mice were administered either 100 µg of neutrophil depleting antibody, 1A8, or isotype control, 2A3. 
At 2 days, 4 days or 7 days after the final 2A3/1A8 dose, lung and BAL was collected for analysis of neutrophils 
by flow cytometry (A). (B) Number of lung neutrophils. (C) Percentage lung neutrophils. (D) Number of BAL 
neutrophils. (E) Percentage BAL neutrophils. Results depicted as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 
using Mann–Whitney statistical test. 
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4.4.3 Administration of 1A8 led to a consistent reduction in neutrophils over 
the course of the 3 week HDM time course. 
 The devised 1A8 dosing strategy was subsequently applied throughout a 3 week HDM study, 
with harvests performed at 24 hours, 1 week and 3 week time points (Figure 4.5 A). 
Administration of 1A8 to HDM treated mice largely ablated neutrophils in the lung (Figure 4.5 
B) and BAL (Figure 4.5 C) at all time points. The concentration of proteases MMP-9 and MPO 
are often used as surrogates for neutrophilic inflammation in clinical studies, and were assessed 
in the HDM model following neutrophil depletion (Figure 4.5 D-G). At the 1 week time point 
lung homogenate MMP-9 and BALF MPO were significantly reduced in neutrophil depleted 
mice, but BALF MMP-9 and lung homogenate MPO were comparable between 2A3 and 1A8 
treated mice (Figure 4.5 D-G). However, at 3 weeks of HDM exposure, the levels of MMP-9 
and MPO were indistinguishable between 1A8 and 2A3 treated mice in both BALF and lung 
homogenate (Figure 4.5 D-G). The disconnect between neutrophil numbers and MMP-9/MPO 
would suggest other cell types are producing these proteases throughout the HDM time course 
(discussed in Chapter 3).  
 
4.4.4 Neutrophil depletion did not alter AHR in the in-house HDM model of 
AAD, but did cause an increase in baseline resistance. 
As previously demonstrated, 3 weeks of HDM administration is sufficient to induce AHR. As 
expected, administration of HDM led to an increase in airway resistance and reduction in lung 
compliance in mice administered isotype control antibody, 2A3 (Figure 4.6 A-F). Interestingly, 
baseline airway resistance measurements were increased in neutrophil depleted mice 
administered HDM (Figure 4.6 B). However, airway resistance measurements to increasing 
doses of methacholine were comparable to that of mice administered HDM and 2A3.  
Airway remodelling encompassed by gross morphological changes such as excessive mucus 
production, collagen and smooth muscle deposition, are important features of HDM-induced 
allergic airway inflammation. To dissect the effects that neutrophil depletion may have on 
goblet cell metaplasia, lung sections were cut for PAS staining (Figure 4.7 A). Administration 
of HDM led to an increase in mucus production, as defined by PAS scoring of the sections 
(Figure 4.7 B). In keeping with the comparable lung function measurements there were no 
differences in the PAS scores between control and neutrophil depleted mice administered 
HDM. Assessment of sections stained for smooth muscle actin and Sirius red revealed no 
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differences in smooth muscle and collagen deposition, respectively, between control and 
neutrophil-depleted mice (data not shown). 
 
 
Figure 4.5: Administration of 1A8 effectively depletes lung and BAL neutrophils throughout a 3 week HDM 
time course. 
(A) Balb/c mice were administered HDM intranasally (i.n.) 3 times per week for up to  3 weeks, and at 24 hours 
prior to each HDM administration, mice were dosed with either 100  µg of neutrophil depleting antibody, 1A8, 
or isotype control antibody, 2A3. At 24 hours, 1 week and 3 week time points, lung tissue for homogenisation 
(LH) and BALF was collected to measure the number of neutrophils by flow cytometry and proteases by ELISA. 
(B) Lung neutrophil numbers at all time points. (C) BAL neutrophil numbers at all time points. (D) Lung 
homogenate MMP-9 at all time points. (E) BALF MMP-9 at all time points. (F) Lung homogenate MPO at all 
time points. (G) BALF MPO at all time points. Results depicted as mean ± SEM. *P<0.05, **P<0.01, 
***P<0.001, **** P<0.0001 using Mann–Whitney statistical test. 
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Figure 4.6: Neutrophil depletion for 3 weeks did not affect HDM-induced AHR. 
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks and at 24 hours prior 
to each HDM treatment, mice were dosed with either 100 µg of neutrophil depleting antibody, 1A8 or isotype 
control antibody, 2A3. (A) Airway Resistance (R) to increasing doses of methacholine (Mch) was measured 24 
hrs post the final HDM/PBS exposure. (B) Airway resistance at baseline. (C) Airway Resistance at 100 mg/ml 
methacholine. (D) Lung Compliance (C) to increasing doses of methacholine (Mch) was measured 24 hours post 
the final HDM/PBS exposure. (E) Lung Compliance at baseline. (F) Lung Compliance at 100 mg/ml 
methacholine. Results depicted as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 using Mann–Whitney statistical 
test. 
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Figure 4.7: HDM administration induces comparable mucus production in the lung between control and 
neutrophil depleted mice. 
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks and 24 hours prior 
to each dose, mice were administered either 100 µg of neutrophil depleting antibody, 1A8 or isotype control, 2A3. 
24 hours post the final HDM/PBS administration, lung tissue was harvested and sections cut for PAS staining to 
assess mucus production. (A) Representative PAS stained sections from control and neutrophil depleted mice 
administered PBS or HDM. PAS sections were also scored to quantify the level of goblet cell metaplasia per 
mouse (B). Results depicted as mean ± SEM. (A) Scale bar = 50 µm. 
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4.4.5 Neutrophil depleted mice exhibit a more pronounced Th2 
inflammation in response to HDM. 
Total inflammatory cell infiltrate was assessed at all time points in the lung and BAL. 
Administration of HDM led to an increase in total lung and BAL cell counts, as previously 
demonstrated (Figure 4.8 A and B). Total cell numbers in the BAL were significantly reduced 
in neutrophil depleted mice at 1 week (Figure 4.8 B), in keeping with the observation that 
neutrophils are the dominant granulocyte in the airways at this time point. Interestingly, despite 
the fact that neutrophils are completely depleted, total cell numbers in the airways of HDM-
exposed 1A8 treated mice were comparable at 3 weeks, and numbers in the lung were actually 
significantly increased (Figure 4.8 A and B) – suggesting that in the absence of neutrophils 
other populations are augmented.  
To specifically probe which cell types were increased in neutrophil depleted mice, differential 
cell analysis was performed by flow cytometry. HDM-exposed mice depleted of neutrophils 
displayed a trend towards an increase in the number of eosinophils in their lungs by 3 weeks 
(Figure 4.8 C), though numbers in the airways were comparable between 2A3 and 1A8 treated 
mice (Figure 4.8 D).  
In keeping with the general increase in eosinophil numbers, ILC2s expressing T1ST2 were 
significantly increased in the lungs of neutrophil depleted mice compared to respective controls 
at 3 weeks (Figure 4.9 A). Similarly, the number of lung (Figure 4.9 C) and BAL (Figure 4.9 
E) Th2 (CD4+ T1ST2+) cells were also significantly increased in HDM-exposed neutrophil 
depleted mice by 3 weeks. Whilst the number of lung ILC2s (Figure 4.9 B) and lung (Figure 
4.9 D) and BAL (Figure 4.9 F) T cells producing IL-13 were generally higher in neutrophil 
depleted mice, this failed to reach significance.   
Total and HDM-specific antibody levels were subsequently measured in the serum at 3 weeks 
by ELISA. HDM administration led to an increase in total and HDM specific IgE (Figure 4.10 
A-B) and IgG1 (Figure 4.10 C-D). Interestingly, the levels of total and HDM-specific IgE and 
IgG1 were strikingly elevated in neutrophil depleted mice administered HDM compared to 
control treated animals, in keeping with the heightened Th2 inflammation. 
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Figure 4.8: Increased total cell infiltrate in the lung tissue of neutrophil depleted mice administered HDM 
for 3 weeks. 
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks, and at 24 hours 
prior to each HDM treatment mice were dosed with either 100 µg of neutrophil depleting antibody, 1A8, or isotype 
control antibody, 2A3. At 24 hours post final HDM/PBS exposure, total cell numbers in the lung and BAL were 
assessed by trypan blue exclusion. (A) Total cell numbers in the lung at all time points. (B) Total cell numbers in 
the BAL at all time points. At 24 hours post final HDM/PBS exposure, lung and BAL was collected to measure 
the number of eosinophils by flow cytometry. (C) Lung eosinophils at all time points. (D) BAL eosinophils at all 
time points. Results depicted as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 using Mann–Whitney statistical 
test. 
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Figure 4.9:  Increased ILC2 and Th2 numbers in the lung and BAL of neutrophil depleted mice after 3 
weeks of HDM administration. 
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks and at 24 hours prior 
to each HDM treatment, mice were dosed with either 100 µg of neutrophil depleting antibody, 1A8 or isotype 
control antibody, 2A3. At 24 hours post final HDM/PBS exposure, lung and BAL was collected to measure the 
number of ILC2s and Th2 CD4+ T cells by flow cytometry. (A) Lung ILCs expressing T1ST2 at all time points. 
(B) Lung ILCs producing IL-13 at all time points. (C) Lung CD4+ T cells expressing T1ST2 at all time points. 
(D) Lung CD4+ T cells producing IL-13 at all time points. (E) BAL CD4+ T cells expressing T1ST2 at all time 
points. (F) BAL CD4+ T cells producing IL-13 at all time points. Results depicted as mean ± SEM. *P<0.05, 
**P<0.01 using Mann–Whitney statistical test. 
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Figure 4.10: Increased antibody levels in the serum of neutrophil depleted mice after 3 weeks of HDM 
administration. 
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks and at 24 hours prior 
to each HDM treatment, mice were dosed with either 100 µg of neutrophil depleting antibody, 1A8 or isotype 
control antibody, 2A3. At 24 hours post final HDM/PBS exposure, serum was collected for detection of 
antibodies. Levels of total (A) and HDM-specific IgE (B), and total (C) and HDM-specific IgG1 (D) were 
measured by ELISA. Results depicted as mean ± SEM. *P<0.05, **P<0.01, ****P<0.0001 using Mann–Whitney 
statistical test. 
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4.4.6 Neutrophil depleted mice exhibit a striking increase in BALF Th2 
cytokines at 1 week of HDM exposure. 
Given the general increase in Th2 inflammation observed in HDM-exposed neutrophil depleted 
mice, soluble levels of type 2 cytokines in the lung homogenate and BALF were subsequently 
assessed at all time points. As expected, HDM administration led to an increase in the 
concentrations of IL-4 (Figure 4.11 A and B), IL-5 (Figure 4.11 C and D) and IL-13 (Figure 
4.11 E and F) in the lung homogenates and BALF. Intriguingly, despite an increase in the 
number of ILC2s and Th2 cells in neutrophil depleted mice at 3 weeks of HDM exposure, the 
concentrations of these cytokines were similar in the lung homogenate and BALF at this time 
point, with the exception of BALF IL-13 that was greater in neutrophil depleted animals. 
However, at 1 week of HDM exposure, the levels of IL-4, IL-5 and IL-13 were strikingly 
augmented in neutrophil depleted mice, particularly in the BALF (Figure 4.11 B, D and F). 
This exacerbated cytokine response at 1 week may contribute to the augmented type 2 
inflammatory cell infiltrate and antibody production observed at 3 weeks.  
4.4.7 ILC2s in HDM-exposed neutrophil depleted mice produce more IL-13 
on a per cell basis relative to control mice. 
The prominent increase in levels of Th2 cytokines in HDM-exposed neutrophil depleted mice 
at 1 week, led us to question their cellular source. Therefore, lung epithelial (CD45- EpCAM+), 
endothelial (CD45- EpCAM- CD31+) and leukocyte cell populations (CD45+) in the lung were 
sorted from control and neutrophil depleted mice administered PBS or HDM for 1 week with 
the help of flow cytometry (Figure 4.12 A) to assess the expression of Th2 cytokines. 
Additionally, to decipher if this increased cytokine production originated from a cell type 
located in the airways, the whole BAL cell pellet from each mouse was taken and assessed for 
Th2 cytokine expression. IL-4, IL-5 and IL-13 gene expression was measured by qPCR in each 
cell population. None of the Th2 cytokines were detected in epithelial cells and endothelial 
cells derived from any mice (Figure 4.12 E-J). Th2 cytokines however, were detected in lung 
CD45+ cells. HDM administration expectedly led to an increase in the expression of Th2 
cytokines in CD45+ cells (Figure 4.12 B-D). Despite not reaching significance, the gene 
expression of IL-4 and IL-13 were generally higher in the lung CD45+ cells of neutrophil 
depleted mice administered HDM (Figure 4.12 B-D). Furthermore, Th2 cytokine expression in 
the whole BAL cell pellet of neutrophil depleted mice administered HDM was significantly 
greater compared to respective controls (Figure 4.12 K-M) – in keeping with changes in soluble 
cytokine levels being more prominent in BALF. Thus, hematopoietic cells seem to be the 
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prominent source of the Th2 cytokines in our HDM model at 1 week, and this production is 
elevated in HDM-exposed neutrophil depleted mice, particularly within the airways. 
Subsequently, to further deduce the source of these Th2 cytokines at 1 week in the BAL, we 
used IL-13 gfp-reporter mice.  Using the reporter mice, it was clear that airway eosinophils, 
neutrophils and CD8+ T cells produced no IL-13 in the HDM model (Figure 4.13 A).  BAL 
CD4+ T cells produced some IL-13, but BAL ILC2s were the predominant source of IL-13 at 
1 week HDM exposure (Figure 4.13 A). The number and percentage of IL-13+ CD4+ T cells 
were comparable in control and neutrophil depleted mice after 1 week of HDM exposure 
(Figure 4.13 B and C). Whilst the total number of IL-13+ CD4+ T cells were comparable 
between control and neutrophil depleted mice, it is possible that CD4+ T cells may be producing 
more IL-13 on a per cell basis, and thus the geometric mean of IL-13 expression was assessed. 
However, once again no differences were seen in the relative amounts of IL-13 being produced 
between control and neutrophil depleted mice (Figure 4.13 D). The number and percentage of 
IL-13+ ILCs were again similar between control and neutrophil depleted mice administered 
HDM (Figure 4.13 E and F). Intriguingly, however, the geometric mean of IL-13 expression 
in ILCs was significantly greater in neutrophil depleted mice (Figure 4.13 G). Therefore, ILC2s 
from neutrophil depleted mice were seemingly producing more cytokines on a per cell basis 
compared to those from respective control animals administered HDM. 
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Figure 4.11: Augmented Th2 cytokine levels in the BALF of neutrophil depleted mice administered HDM. 
Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks and at 24 hours prior 
to each HDM treatment, mice were dosed with either 100 µg of neutrophil depleting antibody, 1A8, or isotype 
control antibody, 2A3. At 24 hours post final HDM/PBS exposure, lung tissue and BALF was collected to measure 
Th2 cytokine levels by ELISA. (A) Lung homogenate IL-4 at all time points. (B) BALF IL-4 at all time points. 
(C) Lung homogenate IL-5 at all timepoints. (D) BALF IL-5 at all timepoints. (E) Lung homogenate IL-13 at all 
time points. (F) BALF IL-13 at all time points. Results depicted as mean ± SEM. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001  using Mann–Whitney statistical test. 
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Figure 4.12: Cells in the BAL express more levels of Th2 cytokines in neutrophil depleted mice administered 
HDM. 
Female Balb/c mice were administered HDM intranasally (i.n.) 3 times per week for 1 week. At 24 hours prior to 
each HDM administration, mice were treated with either 100 µg of neutrophil depleting antibody, 1A8, or isotype 
control antibody, 2A3. At 24 hours post final HDM/PBS exposure, lung tissue was collected to sort different cell 
populations by flow cytometry. Live cells were initially gated with the help of a live dead dye. Lung leukocyte 
populations were sorted by the expression of CD45. Epithelial cells were identified as CD45- EpCAM+. Cells that 
were EpCAM- CD45- were gated for CD31 expression and CD31+ cells were identified as endothelial cells (A). 
Gene expression of IL-4, IL-5 and IL-13 were measured in each sorted cell population by qPCR. (B) IL-4 gene 
expression in lung CD45+ cells. (C) IL-5 gene expression in lung CD45+ cells. (D) IL-13 gene expression in lung 
CD45+ cells. (E) IL-4 gene expression in epithelial cells. (F) IL-5 gene expression in epithelial cells. (G) IL-13 
gene expression in epithelial cells. (H) IL-4 gene expression in endothelial cells. (I) IL-5 gene expression in 
endothelial cells. (J) IL-13 gene expression in endothelial cells. BAL was also performed on the mice and gene 
expression was measured in the whole BAL cell pellet. (K) IL-4 gene expression in BAL pellet. (L) IL-5 gene 
expression in BAL pellet. (M) IL-4 gene expression in BAL pellet. *P<0.05, **P<0.01 using Mann–Whitney 
statistical test. 
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Figure 4.13: ILC2s from HDM-exposed neutrophil depleted mice produce more IL-13 on a per cell basis. 
Female IL-13 gfp-reporter mice were administered HDM intranasally (i.n.) 3 times per week for 1 week. At 24 hours 
prior to each dose, mice were administered either 100 µg of neutrophil depleting antibody, 1A8, or isotype control, 
2A3. At 24 hours post final HDM exposure, BAL was collected to assess IL-13 expression by different cell types by 
flow cytometry. (A) Representative histogram of IL-13 gfp-reporter mouse administered HDM for 1 week depicting 
IL-13 expression by CD4+ T cells, CD8+ T cells, eosinophils, neutrophils, and ILCs. Number (B) and percentage (C) 
of IL-13+ CD4+ T cells. (D) Geometric mean of IL-13 expression by lung CD4+ T cells. Number (E) and percentage 
(F) of IL-13+ ILCs. (G) Geometric mean of IL-13 expression by lung ILCs. Results depicted as mean ± SEM. *P<0.05 
using Mann–Whitney statistical test. 
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4.4.8 Neutrophil depletion results in an increase in the number of lung 
monocytes and ensuing antigen presenting cells.  
The elevated type 2 cytokines levels are linked to the elevated Th2 CD4+ T cell response and 
allergen specific IgG1/IgE observed at 3 weeks in HDM-exposed neutrophil depleted animals. 
Presentation of antigen by APCs is critical to the development of the Th2 CD4+ T cell response. 
Interestingly, neutrophil depletion in HDM-exposed mice resulted in an increase in the number 
of monocytes present in the lung (Figure 4.14). Traditionally monocyte cell populations were 
identified according to the expression of the cell surface marker, Ly6C. Ly6Chigh monocytes 
are thought to be more inflammatory in function and possess the potential to differentiate into 
macrophages and dendritic cells410. Ly6Clow monocytes are not noted for their inflammatory 
role but have been shown to have an important function in patrolling the endothelium and 
endothelial cell repair411. 
In light of the appreciation that Ly6Chigh monocytes can differentiate into macrophage and 
dendritic cells by up-regulating MHC2 and subsequently down-regulating Ly6C366, I aimed to 
further define these monocyte subsets by assessing differential expression of Ly6C versus 
MHC2. Based on this previously defined gating strategy366, 4 monocyte populations are 
identified as: Ly6Clow MHC2- monocytes, Ly6Chigh MHC2- monocytes, Ly6Chigh MHC2+ 
monocytes and Ly6Clow MHC2+ monocytes (Figure 4.14 A). Interestingly, neutrophil depletion 
resulted in a significant increase in the number of Ly6Clow MHC2- monocytes (Figure 4.14 B), 
Ly6Chigh MHC2- monocytes (Figure 4.14 C), Ly6Chigh MHC2+ monocytes (Figure 4.14 D), and 
Ly6Clow MHC2+ monocytes (Figure 4.14 E). Monocyte infiltration in the lung primarily peaked 
at the 1 week timepoint. Interestingly, PBS control neutrophil depleted mice also exhibited an 
increase in the number of monocyte subsets compared to respective control mice, suggestive 
that neutrophils may naturally regulate monocyte numbers within the lung. 
To further probe whether this increase in monocytes affected subsequent antigen presentation, 
control and neutrophil depleted mice were administered HDM for 1 week. Concomitant with 
the final dose of HDM, mice were also administered Alexa Fluor 700-tagged OVA to assess 
its transportation and presentation in local lymph nodes. Monocyte-derived dendritic cells 
(MoDCs) and CD11b+ cDCs have been characterised as key dendritic cell subsets that are 
important in transporting antigen to the lymph node in the HDM model of AAD320. Therefore, 
the number of moDCs and CD11b+ cDCs that were positive for OVA were assessed in the 
lymph node. Interestingly, the number of OVA+ moDCs (Figure 4.15 A) were significantly 
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increased in neutrophil depleted mice. To assess the antigen presenting capacity of these DCs 
the geometric mean expression of CD86 was measured. CD86 expression was also significantly 
higher in the moDCs of neutrophil depleted mice (Figure 4.15 B). The number of OVA+ 
CD11b+ cDCs (Figure 4.15 C) were not increased in number in neutrophil depleted mice 
compared to respective controls, however CD86 expression was significantly higher in the 
CD11b+ cDCs of mice lacking neutrophils (Figure 4.15 D). With an increase in the number of 
DCs presenting antigen in the lymph node, I next assessed if the T cells in the lymph nodes of 
neutrophil depleted mice displayed an altered phenotype. Therefore surface expression of 
different T cell activation markers were assessed by measuring their geometric expression. 
ICOS412 and CD44413 are classical T cell activation markers and the geometric mean of ICOS 
(Figure 4.15 E) and CD44 (Figure 4.15 F) were significantly increased in neutrophil depleted 
mice. PD1 is a marker for T cells that have been presented antigen by local APCs414 and in 
keeping with increased moDC trafficking, PD1 expression was increased in neutrophil depleted 
mice (Figure 4.15 G). T cell expansion is also another indicator of increased antigen 
presentation, therefore the number of Ki-67+ T cells were assessed. In keeping with the 
monocyte and T cell phenotype, the number of Ki-67+ T cells were also strikingly increased in 
neutrophil depleted mice (Figure 4.15 H). Therefore, antigen presentation within local lymph 
nodes is enhanced in neutrophil depleted mice and is likely to be caused by the monocytosis 
exhibited by these mice. 
4.4.9 Neutrophil depletion leads to an increase in the number of bone 
marrow monocyte progenitors. 
To rationalise the increase in lung monocyte numbers observed in mice depleted of neutrophils, 
the concentrations of monocyte chemokines, CCL2 (MCP-1) and CX3CL1 (fractalkine), were 
assessed in the lung homogenate at the 1 week time point. HDM administration led to an 
increase in the levels of lung homogenate CCL2 (Figure 4.16 A) and CX3CL1 (Figure 4.16 B). 
However, the concentrations of these chemokines were comparable between HDM-exposed 
control and neutrophil depleted mice.  
To address whether neutrophil depletion could affect the production of monocytes, monocyte 
progenitor numbers within the bone marrow were assessed. The monocyte dendritic cell 
progenitor (MDP) is known to be important in the formation of monocytes within the bone 
marrow415. Recently, it has been suggested that MDPs can differentiate into common dendritic 
cell progenitor cells (CDPs)415 which are the first committed dendritic cell progenitor to give 
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rise to pre-DCs. Therefore, the numbers of these progenitor cell subsets were assessed by flow 
cytometry at the 1 week timepoint. In keeping with the exacerbated monocytosis, neutrophil 
depleted mice exhibited an increase in the percentage of MDPs (Figure 4.16 C). Intriguingly, 
a similar trend was observed in the CDP (Figure 4.16 D) and pre-DC (Figure 4.16 E) dendritic 
cell progenitors. This heightened progenitor cell development was also observed in neutrophil 
depleted mice administered PBS, indicating a role for neutrophils in regulating bone marrow 
monocyte and dendritic cell progenitor production even at steady-state.  
4.4.10 Neutrophil depletion in HDM-exposed mice results in an increase in 
serum and lung homogenate G-CSF levels. 
Depletion of neutrophils causes an increase in the percentage of monocyte bone marrow 
progenitors. To identify potential mediators that could be regulating this enhanced monocyte 
production in neutrophil depleted animals, serum and lung homogenates from mice exposed to 
HDM for 1 week were analysed by a proteome profiler - an array that can detect up to 111 
cytokines, chemokines and proteases. 
Representative blots of serum from HDM-exposed control and neutrophil depleted mice are 
shown in Figure 4.17 A. Pixel density from each cytokine was determined and expressed as a 
fold change (Table 4.1) in serum cytokines (Figure 4.17 B), chemokines and neutrophil 
proteases relative to the HDM/2A3 group (Figure 4.17 C). Standout changes were an increase 
in IL-17A, G-CSF, CCL6 and KC in neutrophil depleted mice.  Reassuringly, neutrophil 
derived protease MMP-9 was reduced in neutrophil depleted mice. Representative blots of lung 
homogenate from HDM-exposed control and neutrophil depleted mice are shown in Figure 
4.18 A. Once again pixel density from each cytokine was determined and expressed as a fold 
change (Table 4.2). Interestingly G-CSF was again strikingly elevated in the lung homogenate 
of neutrophil depleted mice (Figure 4.18 B). G-CSF administration to mice and patients to 
promote neutrophil granulopoiesis also results in increased monocyte numbers416. Therefore 
serum, lung homogenate and BALF G-CSF levels were measured by ELISA. In keeping with 
the proteome profiler data, G-CSF concentrations were increased in neutrophil depleted mice 
in serum (Figure 4.17 D), lung homogenate (Figure 4.18 D) and BALF (Figure 4.18 E).  
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Figure 4.14: Increased lung monocyte numbers in HDM-exposed neutrophil depleted mice. 
Female Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for up to 3 weeks. At 24 
hours prior to each HDM administration, mice were given either 100 µg of neutrophil depleting antibody, 1A8, 
or isotype control antibody, 2A3. At 24 hours post the final HDM/PBS exposure, lung was collected to assess 
different monocyte subsets by flow cytometry. Monocyte subsets were divided based on the expression of surface 
markers Ly6C and MHC2. (A) Representative flow cytometry plots of monocyte subsets from control and 
neutrophil depleted mice administered HDM for 1 week. (B) Lung Ly6Clow MHC2- monocytes at all time points. 
(C) Ly6Chigh MHC2- monocytes at all time points. (D) Ly6Chigh MHC2+ monocytes at all time points. (E) Ly6Clow
MHC2+ monocytes at all time points. Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney 
statistical test. 
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Figure 4.15: Increased antigen presentation by dendritic cells in the lymph nodes of neutrophil depleted 
mice. 
Female Balb/c mice were administered HDM intranasally (i.n.) 3 times per week for 1 week. The final HDM dose 
was admixed with 100 µg OVA labelled with Alexa Fluor 700. At 24 hours prior to each HDM administration, 
mice were treated with either 100 µg of neutrophil depleting antibody, 1A8, or isotype control antibody, 2A3. At 
24 hours post final HDM exposure, mediastinal lymph nodes were collected to assess DC trafficking to the lymph 
node by flow cytometry. (A) Number of OVA+ MoDCs. (B) Geometric mean of CD86 expression by MoDCs. 
(C) Number of OVA+ CD11b+ cDCs. (D) Geometric mean of CD86 expression by CD11b+ cDCs. T cells were 
also examined within the lymph node to assess their activation status via measuring geometric mean expression 
by flow cytometry. (E) Geometric mean of ICOS expression by CD4+ T cells. (F) Geometric mean of CD44 
expression by CD4+ T cells. (G) Geometric mean of PD1 expression by CD4+ T cells. (H) Number of Ki-67+
CD4+ T cells. Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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Figure 4.16: Neutrophil depleted mice exhibit increased numbers of monocyte progenitors in their bone 
marrow after 1 week of HDM administration. 
Female Balb/c mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 1 week. At 24 hours 
prior to each HDM administration, mice were treated with either 100 µg of neutrophil depleting antibody, 1A8, or 
isotype control antibody, 2A3. At 24 hours post final HDM/PBS exposure, lung tissue was collected to measure the 
concentration of CCL2 (A) and CX3CL1 (B) by ELISA. At 24 hours post final HDM/PBS exposure, bone marrow 
femurs were flushed to enumerate monocyte and dendritic cell progenitors by flow cytometry. (C) Percentage bone 
marrow MDPs. (D) Percentage bone marrow CDPs. (E) Percentage bone marrow pre-DCs. pre-DCs.  
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Figure 4.17: HDM-exposed neutrophil depleted mice display greater G-CSF serum levels. 
Female Balb/c mice were administered HDM intranasally (i.n.) 3 times per week for 1 week. At 24 hours prior to 
each HDM administration, mice were treated with either 100 µg of neutrophil depleting antibody, 1A8, or isotype 
control antibody, 2A3. At 24 hours post final HDM exposure, serum was collected for proteome profiler and 
ELISA analysis. (A) Representative images of the proteome profiler blots from control and neutrophil depleted 
mice administered HDM for 1 week. (B) Fold change in serum cytokine pixel density in HDM-exposed neutrophil 
depleted mice over respective control mice. (C) Fold change in serum chemokine and protease pixel density in 
HDM-exposed neutrophil depleted mice over respective control mice. (D) Serum concentration of G-CSF as 
determined by ELISA. Results depicted as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 using Mann–Whitney 
statistical test. Red boxes in (A) denote the location of the G-CSF spots. 
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Figure 4.18: HDM-exposed neutrophil depleted mice display greater G-CSF levels in lung homogenate. 
Female Balb/c mice were administered HDM intranasally (i.n.) 3 times per week for 1 week. At 24 hours prior to 
each HDM administration, mice were treated with either 100 µg of neutrophil depleting antibody, 1A8, or isotype 
control antibody, 2A3. At 24 hours post final HDM exposure, lungs were collected for proteome profiler analysis. 
(A) Representative images of lung homogenate proteome profiler blots from control and neutrophil depleted mice 
administered HDM for 1 week. (B) Fold change in lung homogenate cytokine pixel density in HDM-exposed 
neutrophil depleted mice over respective control mice. (C) Fold change in lung homogenate chemokine and 
protease pixel density in HDM-exposed neutrophil depleted mice over respective control mice. (D) lung 
homogenate concentration of G-CSF, (E) BALF concentration of G-CSF as determined by ELISA. Results 
depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. Red boxes in (A) denote the 
location of the G-CSF spots. 
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Mediator 
Fold change 
over 
HDM+2A3 
Mediator 
Fold 
change 
over 
HDM+2A3 
Mediator 
Fold change 
over 
HDM+2A3 
Adiponectin/Acrp30 1.04 DPPIV/CD26 0.98 IL-27p28 1.25 
Amphiregulin 1.22 EGF 0.93 IL-28A/B 1.25 
Angiopoietin-1 0.53 Endoglin/CD1
05 
1.20 IL-33 0.50 
Angiopoietin-2 1.15 Endostatin 1.07 LDL R 1.21 
Angiopoietin-like 3 0.81 Fetuin 
A/AHSG 
0.95 Leptin 0.99 
BAFF/BLyS/TNFSF13B 1.02 FGF acidic 0.80 LIF 0.49 
C1qR1/CD93 0.66 FGF-21 0.72 Lipocalin-2/NGAL 1.63 
CCL2/JE/MCP-1 0.50 Flt-3 Ligand 0.79 LIX 0.77 
CCL3/CCL4/MIP-
1alpha/beta 
1.13 Gas 6 0.97 M-CSF 1.03 
CCL5/RANTES 1.11 G-CSF 2.74 MMP-2 0.86 
CCL6/C10 1.91 GDF-15 1.36 MMP-3 1.04 
CCL11/Eotaxin 1.09 GM-CSF 0.69 MMP-9 0.23 
CCL12/MCP-5 0.98 HGF 0.95 Myeloperoxidase 1.06 
CCL17/TARC 0.87 ICAM-1/CD54 1.07 Osteopontin (OPN) 0.96 
CCL19/MIP-3beta 0.43 IFN-gamma 0.99 Osteoprotegerin/TNFRSF11B 2.65 
CCL20/MIP-3alpha 1.39 IGFBP-1 0.87 PD-ECGF/Thymidine 
phosphorylase 
1.23 
CCL21/6Ckine 0.86 IGFBP-2 1.08 PDGF-BB 0.37 
CCL22/MDC 0.99 IGFBP-3 0.68 Pentraxin 2/SAP 1.46 
CD14 1.13 IGFBP-5 0.47 Pentraxin 3/TSG-14 1.55 
CD40/TNFRSF5 0.82 IGFBP-6 1.05 Periostin/OSF-2 0.65 
CD160 1.37 IL-1alpha/IL-
1F1 
0.70 Pref-1/DLK-1/FA1 0.56 
Chemerin 0.70 IL-1beta/IL-
1F2 
0.85 Proliferin 0.81 
Chitinase 3-like 1 0.87 IL-1ra/IL-1F3 1.34 Proprotein Convertase 
9/PCSK9 
1.15 
Coagulation Factor 
III/Tissue Factor 
1.20 IL-2 1.00 RAGE 0.11 
Complement 
component C5/C5a 
0.58 IL-3 1.09 RBP4 0.96 
Complement Factor D 1.01 IL-4 1.23 Reg3G 1.02 
C-reactive Protein/CRP 0.92 IL-5 1.35 Resistin 1.05 
CX3CL1/Fractalkine 0.45 IL-6 1.20 E-Selectin/CD62E 0.61 
CXCL1/KC 2.05 IL-7 0.86 P-Selectin/CD62P 0.84 
CXCL2/MIP-2 0.83 IL-10 0.87 Serpin E1/PAI-1 0.54 
CXCL9/MIG 0.76 IL-11 0.77 Serpin F1/PEDF 0.88 
CXCL10/IP-10 0.75 IL-12p40 0.71 Thrombopoietin 0.62 
CXCL11/I-TAC 1.50 IL-13 0.79 TIM-1/KIM-1/HAVCR 1.68 
CXCL13/BLC/BCA-1 1.31 IL-15 0.88 TNF-alpha 0.60 
CXCL16 1.08 IL-17A 1.87 VCAM-1/CD106 0.88 
Cystatin C 0.62 IL-22 1.04 VEGF 1.15 
DKK-1 0.56 IL-23 0.60 WISP-1/CCN4 0.99 
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Table 4.1: Proteome profiler data for serum. 
Female Balb/c mice were administered HDM intranasally (i.n.) 3 times per week for 1 week. At 24 hours prior to 
each HDM administration, mice were treated with either 100 µg of neutrophil depleting antibody, 1A8, or isotype 
control antibody, 2A3. At 24 hours post final HDM exposure, serum was collected for proteome profiler analysis. 
Data shown as fold change in pixel density of mice administered HDM and 1A8 over mice administered HDM 
and 2A3. 
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Mediator 
Fold change 
over 
HDM+2A3 
Mediator 
Fold change 
over 
HDM+2A3 
Mediator 
Fold change 
over 
HDM+2A3 
Adiponectin/Acrp30 19.60 DPPIV/CD26 1.37 IL-27p28 1.60 
Amphiregulin 1.28 EGF 0.84 IL-28A/B 0.60 
Angiopoietin-1 1.79 Endoglin/CD105 0.61 IL-33 1.37 
Angiopoietin-2 2.18 Endostatin 1.20 LDL R 1.48 
Angiopoietin-like 3 5.14 Fetuin A/AHSG 3.49 Leptin 0.67 
BAFF/BLyS/TNFSF13
B 1.56 FGF acidic 0.76 LIF 1.05 
C1qR1/CD93 1.62 FGF-21 0.44 Lipocalin-2/NGAL 0.62 
CCL2/JE/MCP-1 1.10 Flt-3 Ligand 0.65 LIX 5.82 
CCL3/CCL4/MIP-
1alpha/beta 
0.77 Gas 6 0.83 M-CSF 1.11 
CCL5/RANTES 0.84 G-CSF 2.33 MMP-2 1.99 
CCL6/C10 1.02 GDF-15 1.90 MMP-3 1.88 
CCL11/Eotaxin 0.98 GM-CSF 0.95 MMP-9 0.36 
CCL12/MCP-5 2.54 HGF 1.58 Myeloperoxidase 1.34 
CCL17/TARC 1.88 ICAM-1/CD54 1.28 Osteopontin (OPN) 3.77 
CCL19/MIP-3beta 0.95 IFN-gamma 1.11 Osteoprotegerin/T
NFRSF11B 
1.15 
CCL20/MIP-3alpha 1.95 IGFBP-1 1.37 
PD-
ECGF/Thymidine 
phosphorylase 
1.76 
CCL21/6Ckine 1.58 IGFBP-2 3.65 PDGF-BB 0.75 
CCL22/MDC 1.19 IGFBP-3 2.93 Pentraxin 2/SAP 1.94 
CD14 0.72 IGFBP-5 2.05 
Pentraxin 3/TSG-
14 1.06 
CD40/TNFRSF5 0.76 IGFBP-6 3.98 Periostin/OSF-2 2.43 
CD160 1.30 IL-1alpha/IL-1F1 1.07 Pref-1/DLK-1/FA1 1.05 
Chemerin 1.63 IL-1beta/IL-1F2 1.64 Proliferin 1.47 
Chitinase 3-like 1 1.62 IL-1ra/IL-1F3 1.12 
Proprotein 
Convertase 
9/PCSK9 
2.70 
Coagulation Factor 
III/Tissue Factor 1.04 IL-2 0.85 RAGE 0.81 
Complement 
component C5/C5a 
1.00 IL-3 2.66 RBP4 5.77 
Complement Factor D 10.16 IL-4 2.47 Reg3G 3.08 
C-reactive 
Protein/CRP 
13.28 IL-5 1.32 Resistin 2.39 
CX3CL1/Fractalkine 1.24 IL-6 1.10 E-Selectin/CD62E 1.21 
CXCL1/KC 0.84 IL-7 1.42 P-Selectin/CD62P 2.40 
CXCL2/MIP-2 0.91 IL-10 1.31 Serpin E1/PAI-1 0.69 
CXCL9/MIG 0.84 IL-11 1.71 Serpin F1/PEDF 1.31 
CXCL10/IP-10 0.90 IL-12p40 1.05 Thrombopoietin 1.15 
CXCL11/I-TAC 0.97 IL-13 1.62 
TIM-1/KIM-
1/HAVCR 
1.30 
CXCL13/BLC/BCA-1 0.67 IL-15 1.18 TNF-alpha 1.54 
CXCL16 1.35 IL-17A 0.95 VCAM-1/CD106 6.90 
Cystatin C 3.34 IL-22 1.06 VEGF 1.39 
DKK-1 1.13 IL-23 1.22 WISP-1/CCN4 0.85 
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Table 4.2: Proteome profiler data for lung. 
Female Balb/c mice were administered HDM intranasally (i.n.) 3 times per week for 1 week. At 24 hours prior to 
each HDM administration, mice were treated with either 100 µg of neutrophil depleting antibody, 1A8, or isotype 
control antibody, 2A3. At 24 hours post final HDM exposure, lungs were collected for proteome profiler analysis. 
Data shown as fold change in pixel density of mice administered HDM and 1A8 over mice administered HDM 
and 2A3. 
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4.4.11 G-CSF administration results in enhanced monocyte recruitment into 
the lung tissue of neutrophil depleted mice.  
G-CSF is typically linked with inducing neutrophil granulopoieses and bone marrow egress1. 
However, excessive G-CSF production can stimulate monocytosis416. To ascertain whether G-
CSF could drive augmented monocyte numbers in neutrophil depleted mice, mice were 
administered recombinant G-CSF or PBS i.p. daily for 4 days in combination with 2A3/1A8 
(Figure 4.19 A).  
Administration of recombinant G-CSF to control mice expectedly led to an increase in the 
number (Figure 4.19 B) and percentage (Figure 4.19 C) of neutrophils in the lung which was 
reduced upon 1A8 administration. G-CSF also led to a modest increase in the number of 
Ly6Clow MHC2- monocytes (Figure 4.19 D), Ly6Chigh MHC2- monocytes (Figure 4.19 E) and 
Ly6Clow MHC2+ monocytes (Figure 4.19 G). However, the levels of these monocyte 
populations were significantly increased yet further when G-CSF was administered to 
neutrophil depleted mice. G-CSF administration did not affect the number of Ly6Chigh MHC2+ 
monocytes in the lung (Figure 4.19 F). To elucidate whether G-CSF may have an effect on 
respective bone marrow progenitors of monocytes, the percentage of MDPs and CDPs were 
assessed by flow cytometry. G-CSF administration caused an increase in the percentage of 
MDPs (Figure 4.19 H) in the bone morrow but CDPs were unaffected (Figure 4.19 I).  
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Figure 4.19: G-CSF administration induces monocyte production and infiltration into the lung. 
(A) Female Balb/c mice were administered i.p. recombinant G-CSF/PBS daily for 4 days.  Concomitantly, mice 
received 100 µg of neutrophil depleting antibody, 1A8, or isotype control antibody, 2A3. At 24 hours post the 
final G-CSF/PBS treatment, lung was collected to assess the number of monocyte subsets by flow cytometry. (B) 
Number of lung neutrophils. (C) Percentage of total lung cells that are neutrophils. (D) Number of lung Ly6Clow 
MHC2- monocytes, (E) Ly6Chigh MHC2- monocytes, (F) Ly6Chigh MHC2+ monocytes (G) and Ly6Clow MHC2+ 
monocytes. At 24 hours post final G-CSF/PBS dose, bone marrow femurs were flushed and progenitor subsets 
identified by flow cytometry. (H) Percentage of total bone marrow cells that are MDPs. (I) Percentage of total 
bone marrow cells that are CDPs. Results depicted as mean ± SEM. *P<0.05, **P<0.01 using Mann–Whitney 
statistical test. 
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4.4.12 Anti-G-CSF administration reduced lung monocyte numbers in HDM 
treated neutrophil depleted mice. 
HDM-exposed neutrophil depleted mice displayed an increase in G-CSF levels, and I have 
subsequently demonstrated that G-CSF administration to neutrophil depleted animals can 
augment monocyte numbers within the lung. To determine whether the increased G-CSF levels 
in HDM-exposed neutrophil depleted mice was responsible for the increased lung monocytes, 
mice exposed to HDM for 1 week were concomitantly treated with 2A3/1A8 and anti-G-CSF 
neutralising antibody/control (Figure 4.20 A). As consistently reported previously, neutrophil 
depletion in HDM exposed mice resulted in an increase in the number of lung Ly6Clow MHC2-
monocytes (Figure 4.20 B), Ly6Chigh MHC2- monocytes (Figure 4.20 C), Ly6Chigh MHC2+ 
monocytes (Figure 4.20 D) and Ly6Clow MHC2+ monocytes (Figure 4.20 E). However, this 
augmented monocytic infiltrate seen in neutrophil depleted animals was completely ablated by 
concomitant administration of anti-G-CSF antibody. 
4.4.13 Increased Th2 cytokine production by ILC2s in HDM-exposed 
neutrophil depleted mice is G-CSF dependent. 
Previously it was demonstrated that HDM-exposed neutrophil depleted mice exhibited a 
prominent increase in Th2 cytokine levels at 1 week, which was attributable to augmented 
production on a per cell basis by ILC2s. Intriguingly, whilst BALF IL-4 (Figure 4.21 A), IL-5 
(Figure 4.21 B) and IL-13 (Figure 4.21 C) were again elevated in neutrophil depleted mice 
administered HDM, this enhanced production was largely ablated when anti-G-CSF was 
administered to 1A8 treated animals. Thus both the elevated monocyte numbers and the 
augmented ILC2-driven type 2 cytokine response observed in HDM-exposed neutrophil 
depleted mice was G-CSF dependent.   
Since G-CSF neutralisation was able to reduce Th2 cytokine levels in the BALF of HDM-
exposed neutrophil depleted mice, it was postulated that G-CSF treatment may be modulating 
ILC2s. Therefore, the levels of IL-13 expressed by ILC2s, on a per cell basis, was assessed by 
flow cytometry in HDM-administered mice following neutrophil depletion and G-CSF 
neutralization. As previously observed, ILC2s from HDM-exposed neutrophil depleted mice 
produced more IL-13 on a per cell basis relative to ILC2s HDM/2A3 from control mice (Figure 
4.21 D). Interestingly, however, upon anti-G-CSF administration to neutrophil depleted mice, 
this augmented IL-13 production was ablated (Figure 4.21 D). Therefore, G-CSF was directly 
or indirectly modulating the release of IL-13 from ILC2s in neutrophil depleted mice. 
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These studies have thus far revealed that G-CSF is modulating ILC2 IL-13 production in 
neutrophil depleted mice administered HDM. To assess whether G-CSF directly affects ILC2s 
and modulates their cytokine expression, human ILC2s were cultured and treated with either 
media or 100 ng/ml or 10 ng/ml recombinant G-CSF for 24 hours, with the number of IL-13+ 
and IL-17+ ILC2s measured by flow cytometry. Treatment with G-CSF resulted in increased 
IL-13 production by ILCs (Figure 4.22 A and B). IL-17 production by ILC2s was, as expected, 
minimal and largely unaltered by exposure to G-CSF (Figure 4.22 C and D).  
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Figure 4.20: Anti-G-CSF administration attenuates 1A8-induced lung monocytosis. 
(A) Female Balb/c mice were administered HDM intranasally (i.n.) 3 times per week for 1 week. At 24 hours 
prior to each HDM administration, mice were treated with either 100 µg of neutrophil depleting antibody, 1A8, 
or isotype control antibody, 2A3. To neutralise G-CSF, mice were also administered 100 µg anti-G-CSF or isotype 
control at 24 hours prior to each HDM/PBS dose. At 24 hours post final HDM/PBS administration, lung was 
collected to assess the number of monocyte subsets by flow cytometry. (B) Ly6Clow MHC2- monocytes. (C) 
Ly6Chigh MHC2- monocytes. (D) Ly6Chigh MHC2+ monocytes. (E) Ly6Clow MHC2+ monocytes. Results depicted 
as mean ± SEM. *P<0.05, **P<0.01m using Mann–Whitney statistical test. 
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Figure 4.21: Anti-G-CSF administration attenuates 1A8-induced augmentation in BALF 
Th2 cytokine levels after 1-week of HDM exposure. 
Female Balb/c mice were administered HDM intranasally (i.n.) 3 times per week for 1 week. 
At 24 hours prior to each HDM administration, mice were treated with either 100 µg of 
neutrophil depleting antibody, 1A8, or isotype control antibody, 2A3. To neutralise G-CSF, 
mice were also administered 100 µg anti-G-CSF or isotype control at 24 hours prior to each 
HDM/PBS dose. At 24 hours post final HDM/PBS administration, BALF was collected to 
measure the concentration of Th2 cytokines by ELISA. (A) BALF IL-4. (B) BALF IL-5. (C) 
BALF IL-13. (D) At 24 hours post final HDM/PBS exposure, lung was collected to assess the 
geometric mean of IL-13 expression on ILCs by flow cytometry. Results depicted as mean ± 
SEM. *P<0.05, **P<0.01 using Mann–Whitney statistical test. 
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Figure 4.22: G-CSF induces increased expression of IL-13 by human ILCs. 
Human ILCs were isolated from peripheral blood and exposed to normal growth media, 100 ng/ml recombinant 
G-CSF or 10 ng/ml recombinant G-CSF for 24 hours. After 24 hours of stimulation, ILCs were the assessed for 
the percentage and geometric mean of of IL-13 and IL-17 expression by flow cytometry.  Percentage of ILC2s 
that were IL-13+ (A) and the geometric mean of this expression (B). Percentage of ILC2s that were IL-17+ (C) 
and the geometric mean of this expression (D). Results depicted as mean ± SEM. 
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4.5 Discussion 
A large proportion of severe asthmatic patients that are unresponsive to conventional steroid 
treatment display prominent neutrophilia in clinical samples272,273. Despite this overwhelming 
evidence suggestive of neutrophil presence in asthma, the exact role of neutrophils remains 
speculative with protective and detrimental roles of these cells suggested in various studies 
(Refer to 1.3.6). Therefore, these series of studies were specifically designed to dissect the role 
of neutrophils in the HDM model of AAD. We performed this by depleting neutrophils in mice 
administered PBS or HDM utilising the neutrophil depleting antibody, 1A8. Depletion of 
neutrophils consequentially induced an augmented Th2 inflammation after 3 weeks of HDM 
administration. This exacerbated Th2 inflammation may be due to an over-exuberant Th2 
cytokine production by airway ILC2s and increased antigen-presentation within local lymph 
nodes invoked by monocytosis. This Chapter has identified G-CSF as the central mediator in 
inducing monocytosis via an action on monocyte progenitors and directly stimulating Th2 
cytokine production from ILC2s.  
As reported in the previous chapter, Balb/c mice administered HDM displayed a significant 
neutrophil infiltration into the lung and airways. This data recapitulates the findings of a 
previous study performed within my research group323. I devised a strategy to effectively 
deplete neutrophils in mice with a repeated administration of just 100 µg of 1A8. The strategy 
by which 1A8 depletes neutrophils remains unknown, however it has identified that 1A8 
administration reduces neutrophil numbers in the spleen, blood and bone marrow. Thus, in my 
hands 1A8 does not halt neutrophil egress from the bone marrow or retention in spleen as 
previously suggested409. During the course of the project, one study identified that 1A8 
promotes neutrophil phagocytosis by local macrophages by an Fc-receptor mediated 
mechanism81. Interestingly, it was observed that despite depleting neutrophils, airway levels of 
MPO and MMP-9 were still increased upon HDM administration. As discussed in the previous 
chapter, MPO and MMP-9 can be derived from other cell types such as monocytes and 
macrophages that are indeed increased in number upon HDM administration.  This raises the 
question as to whether MPO and MMP-9 are useful clinical biomarkers for neutrophilic 
inflammation.  
HDM-exposed mice depleted of neutrophils exhibited augmented Th2 inflammation at 3 weeks 
and an elevated release of IL-4, IL-5 and IL-13, particularly in the BALF, at 1 week. IL-4 is 
credited with invoking the production of Th2 cells in addition to stimulating the class switching 
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of antibodies by B cells213, rationalizing the heightened Th2 cell infiltration and antibody 
production observed at 3 weeks of HDM. Furthermore, IL-5 has extensively been shown to 
promote eosinophil accumulation into target tissues which also explains the trends towards an 
increase in the number of eosinophils417. ILC2s within the airways were shown to be the likely 
source of these elevated Th2 cytokines in neutrophil depleted mice at 1 week and we have 
revealed that excessive concentrations of G-CSF in these mice can directly induce ILC2s to 
produce more IL-13 on a per cell basis. The direct effect of G-CSF on ILC2s is entirely novel 
and future studies should look to validate and extend these findings to ascertain the specific 
mechanism by which G-CSF modulates cytokine production. Assessment of csfr3 gene 
expression and subsequent analysis of transcription factors in ILC2s post G-CSF incubations 
may further decipher such mechanisms. The exact reason as to why Th2 cytokines are 
indistinguishable between control and neutrophil depleted mice at 3 weeks remains unknown, 
but may reflect the utilisation of these mediators by cells elevated in the neutrophil depleted 
mice or the timings of ILC2 recruitment and / or G-CSF release.  
Another feature of the neutrophil depletion and elevated G-CSF levels in HDM-exposed mice 
was a striking augmentation in monocyte numbers and ensuing development of APCs that 
facilitate the increased Th2 inflammation. G-CSF is recognised as being important in triggering 
granulopoieses and mobilisation of neutrophils in the bone marrow4. However, G-CSF is also 
known to trigger monocytosis416 and is a common observation in patients administered this 
protein therapeutically418. A previous study has also demonstrated the potential of G-CSF to 
regulate monocytosis416. Sivakumaran et al. depleted CD11c+ cells in a CD11c DTR mouse 
and observed an increase in monocytes and neutrophils416, which was dependent upon G-CSF. 
This study also demonstrated that G-CSF increased the activation status of Ly6Chigh 
monocytes416, and this is something that could be addressed further in the model. Although 
studies have identified that G-CSF induces monocytosis, not much is known about the 
mechanism by which this occurs. I have shown that G-CSF may promote monocytosis in 
neutrophil depleted mice by increasing the progenitors of monocytes in the bone marrow. 
Although, this Chapter identified an increase in the number of MDPs in mice lacking 
neutrophils, the exact cell type within the progenitor cell pool on which G-CSF is acting 
remains to be elucidated and future studies should investigate G-CSF receptor expression on 
these populations. One study identified that neutrophil depleted mice displayed an increase in 
G-CSF and an increased shift in the formation of GMPs, the precursor to MDPs compared to 
control mice419. Thus, it is possible that G-CSF is acting further upstream to MDPs.  
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G-CSF is clearly the central mediator that defines the elevated Th2 inflammation observed in 
HDM-exposed neutrophil depleted mice. Previous studies have also demonstrated that 
depletion of neutrophils with specific depleting antibodies invoked an increase in G-CSF 
concentrations419 but the mechanism by which this occurs remains incompletely understood. It 
is known that the bone marrow acts as a sink for different growth factors, which are taken up 
by various resident cell types - and consequently removal of one of these populations can 
disrupt homeostasis within the bone marrow420. Thus, depletion of neutrophils within the bone 
marrow, although partial with my depletion strategy, may ‘free up’ unbound G-CSF to act on 
progenitor cell pools such as MDPs. Stark et al. demonstrated that phagocytosis of apoptotic 
neutrophils by local macrophages and DCs reduced the secretion of IL-23 and ensuing IL-17 
by T cells, which is known to regulate G-CSF production421. Thus, a loss of neutrophils in the 
lung may results in increased IL-23, IL-17 and G-CSF. This effect was indeed highlighted in a 
study performed by Bugl et al. when IL-23 and IL-17 were increased in mice after neutrophil 
depletions, which subsequently resulted in excessive production of G-CSF from an unknown 
cellular source419. Given these findings, it is interesting that another study previously attributed 
a protective role to G-CSF  in a mouse model of  OVA-induced AAD422. In this OVA model 
of AAD, G-CSF pre-treatment reduced total cell infiltrate, AHR and cytokine production422. It 
is possible that the utilisation of the OVA model, which requires an alternate dosing strategy 
and differential cellular inflammation compared to the current HDM model of AAD may 
highlight a possible difference between the findings of both studies. 
Overall this Chapter suggests a regulatory role for neutrophils in AAD. Depletion of 
neutrophils unexpectedly triggered an exacerbated type 2 inflammation. Elevated Th2 
inflammation has been anticipated to drive AHR and airway remodelling150. However, despite 
the increased Th2 inflammation in HDM-exposed neutrophil depleted mice, there were no 
changes in lung function and airway remodelling compared to HDM/2A3 control mice at 3 
weeks. However, in contrast to the current observations, De Vooght et al. previously observed 
that 1A8 administration ablated toluene-2, 4-diisocyanate (TDI)-induced AHR and 
remodelling which is in contrast to the current observations75. Interestingly, this study 
identified that neutrophil depletion significantly reduced total cell counts in the airways. This 
effect may in part be due to the use of TDI, a chemical compound that triggers a predominantly 
neutrophilic inflammation upon a single challenge which in contrast to the current HDM 
model, triggers a mixed granulocytic inflammation post repeated challenges.  
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4.6 Conclusions 
In conclusion, Ihave shown that neutrophil depletion in the in-house model of AAD results in 
an exacerbated Th2 inflammation consisting of heightened Th2 CD4+ cells and ILC2 
recruitment concomitant with an exacerbated antibody response after 3 weeks of HDM 
exposure. Underlying this exacerbated Th2 inflammation in neutrophil depleted animals was a 
pronounced increase in ILC2-derived Th2 cytokines and a monocytosis that led to augmented 
APC development and antigen presentation.  This in turn was mediated by augmented levels 
of G-CSF in neutrophil depleted mice, which subsequently acted directly on ILC2 to modulate 
Th2 cytokine production, and indirectly on monocyte progenitors in the bone marrow. This 
study highlights the complexities of targeting neutrophils in AAD, and suggests that 
neutrophils may fulfil a beneficial role in limiting inflammation.  
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5 Chapter 5: The dual role of Leukotriene A4 Hydrolase in AAD 
5.1 Introduction 
Asthma is a chronic inflammatory disease of the conducting airways characterised clinically 
by AHR and reversible airway obstruction. The cardinal features of asthma that drive this AHR 
are airway inflammation and airway structural changes (termed remodelling). Whilst asthma 
has classically been perceived to be a disease that manifests with Type-2 inflammation and 
airway eosinophilia, it is now acknowledged to be heterogeneous in nature with up to 50% of 
patients exhibiting minimal evidence of Th2 inflammation273,369. Similarly, airway remodelling 
(encompassing epithelial hypertrophy, goblet cell hyperplasia, subepithelial reticular basement 
membrane thickening, increased airway smooth muscle (ASM) mass and angiogenesis377,423) 
is also recognised to be extremely variable within this heterogenous patient group. It had 
traditionally been hypothesised that chronic inflammation was driving the airway remodelling 
in asthma, but it is increasingly accepted that these features of disease can develop in parallel 
and remodelling can even develop independently of the inflammation167. Consequently, the 
mediators and mechanisms that instigate airway remodelling in asthma are still completely 
understood.  Thus, it is clear that asthma encompasses variable inflammatory and remodelling 
phenotypes and defining the underlying instigators of these facets of disease will dictate future 
efforts to develop personalised treatment strategies.  
Leukotriene B4 (LTB4) is a powerful pro-inflammatory lipid mediator implicated in a myriad 
of diseases, including asthma103,424. LTB4 is generated by the epoxide hydrolase activity of the 
enzyme leukotriene A4 hydrolase (LTA4H)425 within an intracellular environment, and upon 
release LTB4  may bind to receptors BLT1 or BLT2 – though all physiological functions 
ascribed to LTB4 are seemingly mediated through BLT1426. The rationale for LTB4 in driving 
asthma pathogenesis is derived from its capacity to function as a potent chemotactic factor and 
activator for an array of inflammatory cells implicated in disease progression106,109,426,427. 
Additionally, LTB4 has been demonstrated to promote proliferation and migration of ASM 
cells428.  Numerous studies have reported the increased levels of LTB4 in the sputum, BAL, 
urine, exhaled breath condensate and blood of asthmatic patients429–433. In addition, LTA4H 
levels are increased in circulating neutrophils and bronchial biopsies of patients with 
asthma434,435 and genetic polymorphisms in genes encoding LTB4-synthesizing enzymes are 
associated with asthma severity436–438. Animal models have also supported a pathological role 
for LTB4 in asthma, with mice deficient in BLT-1 or treated with a BLT-1 antagonist displaying 
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signs of reduced inflammation, remodelling and AHR439–442. Furthermore, administration of a 
BLT-1 antagonist to primates reduced AHR induced by multiple antigen challenges443. 
There has been significant pharmaceutical interest in ameliorating LTB4-mediated pathology 
in asthma as a therapeutic strategy, and inhibitors have thus been developed to target LTA4H. 
Accordingly, Johnson & Johnson demonstrated that their selective LTA4H inhibitor, JNJ-
26993135, attenuated airway inflammation and AHR in a murine ovalbumin (OVA) model of 
AAD354. Subsequent development of this compound led to the assessment of JNJ-40929837 in 
a bronchial allergen challenge model of asthma357, but despite JNJ-40929837 demonstrating 
clear target engagement and reducing LTB4, this drug failed to show any clinical benefit over 
placebo357. LTA4H inhibitors, despite demonstrating excellent pharmacokinetic properties, 
have consistently failed to demonstrate clinical efficacy444. 
Recently, my lab demonstrated that LTA4H possesses a second anti-inflammatory 
aminopeptidase activity, whereby it can degrade the tripeptide Pro-Gly-Pro (PGP)83,406. PGP is 
a neutrophil chemoattractant derived from extracellular matrix (ECM) collagen via the 
sequential enzymatic activity of matrix metalloproteinases (MMPs) and prolylendopeptidase 
(PE)133. PGP functions as a neutrophil chemoattractant by mimicking key sequences found in 
glutamic acid, leucine, arginine+ (ELR+) chemokines and binding to CXCR1/2132. My 
colleagues have demonstrated that PGP is readily degraded during episodes of acute pulmonary 
inflammation by extracellular LTA4H to facilitate the resolution of neutrophilic inflammation, 
and failure of this system culminated in augmented and prolonged inflammation with 
exacerbated pathology and illness143. Accordingly, it seems that this LTA4H-PGP degradation 
pathway is perturbed in chronic neutrophilic lung diseases, enabling PGP to accumulate and 
drive inflammation142,445. LTA4H therefore represents a highly unusual enzyme with 
dichotomous and directly opposing pro- and anti-inflammatory activities that dictate the 
amplitude and persistence of inflammation, potentially accounting for the failure of LTA4H 
inhibitors in a clinical setting.  
5.2 Hypothesis 
I hypothesise that LTB4 is a critical mediator in the induction of AAD, but global deletion of 
LTA4H will result in exacerbated disease owing to accumulation of PGP. 
Chapter 5: The dual role of Leukotriene A4 Hydrolase in AAD 
224 
 
5.3 Aims 
The objective of this chapter is to dissect the dual roles of LTA4H on the development of 
inflammatory and remodelling changes in the HDM model of AAD. 
5.4 Results 
5.4.1 Loss of LTB4 signalling ameliorates HDM-induced AHR and 
remodelling. 
To dissect the significance of the dual roles of LTA4H in the context of asthma, I utilised the 
well-established in-house 3 week murine model of HDM-driven AAD that recapitulates many 
of the cardinal features of the clinical disease (Figure 5.1 A)368. Primarily, I looked to define 
the specific role of LTB4 in the pathogenesis of disease by utilizing mice deficient in its 
physiological receptor, BLT1 (Figure 5.1 B).  In keeping with previous studies that have clearly 
ascribed a pathological role to LTB4 in asthma, HDM-treated blt1-/- mice displayed a 
significant reduction in airway resistance relative to littermate controls (Figure 5.1 C-D). 
Furthermore, analysis of hemotoxylin and eosin (H and E) stained lung sections clearly 
demonstrated a marked reduction in pulmonary inflammation in HDM-exposed blt1-/- mice 
relative to controls (Figure 5.1 E). Thus, in the current murine model, in keeping with previous 
studies, LTB4 seemingly contributes to the development of inflammatory and AHR changes in 
HDM-exposed animals.  
5.4.2 An absence of LTA4H leads to exacerbated AHR, yet reduced airway 
inflammation, in a HDM model of AAD. 
Given the pathological role of LTB4, I subsequently investigated the phenotype of HDM-
exposed lta4h-/- mice, which cannot generate LTB4 but at the same time cannot degrade PGP 
(Figure 5.2 A). Intriguingly, despite being unable to produce LTB4, the lta4h-/- mice 
administered HDM displayed a striking increase in airway resistance compared to their wild 
type littermate counterparts (Figure 5.2 B-C) and a modest, yet significant reduction in airway 
compliance (Figure 5.2 D-E).  To determine the underlying cause of the exacerbated AHR in 
HDM-exposed lta4h-/- mice, cellular infiltration into the airways and lung tissue were 
investigated. Despite displaying an exacerbated AHR, HDM-exposed lta4h-/- mice exhibited 
reduced total cellular infiltrate into their airways (Figure 5.2 F) and comparable cell numbers 
in their lung tissue relative to littermate controls (Figure 5.2 G). A cardinal feature of AAD in 
this model is a robust eosinophilic infiltrate, but once again the numbers of eosinophils in the 
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airways of lta4h-/- mice were reduced relative to controls (Figure 5.2 H), and lung eosinophils 
were comparable (Figure 5.2 I). Moreover, numbers of alveolar macrophages were comparable 
between HDM-administered lta4h-/- and littermate controls (Figure 5.2 J), and Ly6Chi 
monocytes were actually reduced in lta4h-/- mice (Figure 5.2 K). Type 2 innate lymphoid cells 
(ILC2s) have more recently been implicated as instigators of pathology in AAD, yet again their 
numbers were comparable between HDM-treated lta4h-/- and littermate controls (Figure 5.3 
A-B). Th2 cells expressing T1/ST2 (Figure 5.3 C) and IL-13+ CD4+ T cells (Figure 5.3 D) were 
again reduced in the airways of HDM-treated lta4h-/- mice relative to controls, whilst lung 
numbers of these cells were comparable between groups (Figure 5.3 E-F).  
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Figure 5.1: HDM treated blt1-/- mice show ameliorated AHR and airway inflammation relative to wild type 
controls. 
(A) Schematic depicting how the loss of BLT1 abolishes LTB4 signalling.  Wild type and blt1-/- mice were 
administered HDM or PBS intranasally (i.n.) 5 times per week for 3 weeks. (B) Airway Resistance (R) to 
increasing doses of methacholine (Mch) was measured 24 hrs post the final HDM/PBS exposure (C). (D) Airway 
resistance at 100 mg/ml methacholine. (E) Representative H&E stained lung sections from wild type and blt1-/-
mice administered PBS or HDM. Results depicted as mean ± SEM. *P<0.05 using Mann–Whitney statistical test. 
(E) Scale bar = 50 µm 
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Figure 5.2:  Augmented airway resistance in HDM treated lta4h-/- mice despite reduced airway 
inflammation. 
Wild type and lta4h-/- mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks. (A) 
Schematic depicting the opposing pro- (LTB4 generation) and anti-inflammatory (PGP degradation) activities of 
LTA4H.  Abrogation of LTA4H activity (red crosses) will result in reduced LTB4 but increased PGP. (B) Airway 
Resistance (R) to increasing doses of methacholine (Mch) was measured 24 hrs post the final HDM/PBS exposure. 
(C) Airway resistance at 100 mg/ml methacholine. (D) Lung compliance to increasing doses of methacholine 
(Mch) was measured 24 hrs post the final HDM/PBS exposure. (E) Lung compliance at 100 mg/ml methacholine. 
At 24 hrs post final HDM/PBS exposure, total cell numbers in the BAL (F) and lung (G) were assessed by trypan 
blue exclusion, and airway eosinophils (H), lung eosinophils (I), alveolar macrophages (J) and lung Ly6Chi
monocytes (K) were assessed by flow cytometry. Figures present combined data from 2 independent experiments 
with 4-6 mice per group and are representative of 4 independent experiments. Results depicted as mean ± SEM.
*P<0.05, **P<0.01, ***P<0.001 using Mann–Whitney statistical test. 
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Figure 5.3: HDM treated lta4h-/- mice possess comparable ILC2 infiltrate relative to their littermate 
controls. 
Wild type and lta4h-/- mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks. The 
number of ILCs in the lung expressing T1ST2 (A) and IL-13 (B) were assessed by flow cytometry. Flow cytometry 
was also utilised to measure the number of CD4+ T cells expressing T1ST2 in the airways (C), IL-13 in the in 
airways (D), T1ST2 in the lung (E) and IL-13 in the lung (F). Results depicted as mean ± SEM. *P<0.05, 
**P<0.001, ***P<0.0001 using Mann–Whitney statistical test. 
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5.4.3 HDM-exposed lta4h-/- mice exhibit a pronounced reduction in 
classical drivers of AHR. 
Th2 cytokines IL-4, IL-5 and IL-13 are implicated in driving the inflammation, remodelling 
and ultimately AHR in the in-house murine model of AAD150,223, and thus their levels were 
assessed in BALF and lung homogenate of HDM-treated lta4h-/- mice and littermate controls. 
Whilst these Th2 cytokines were markedly increased in lung homogenate (Figure 5.4 A-C) and 
BALF (Figure 5.4 D-F) of wild type mice upon HDM exposure, their levels were strikingly 
lower in HDM-exposed lta4h-/- mice.  Similarly, levels of the potent eosinophil 
chemoattractant eotaxin-2 were significantly reduced in the lung homogenate (Figure 5.5 A) 
and BALF (Figure 5.5 B) of HDM-treated lta4h-/- mice relative to littermate controls. Mast 
cells are a hallmark feature of AAD with their products potentially driving pathology, and yet 
again levels of mast cell protease-1 (MCPT-1) were lower in the serum of HDM-treated lta4h-
/- mice relative to littermate controls (Figure 5.5 C). Oedematous airways tend to be narrower 
and prone to airway hyperactive behaviour446,447 and thus BALF albumin levels were assessed, 
as a measure of oedema, in HDM-treated mice. However, HDM-administered lta4h-/- mice 
demonstrated a marked reduction in BALF albumin relative to controls (Figure 5.5 D). 
Furthermore, levels of pro-inflammatory cytokines TNF-α (Figure 5.5 E) and IL-6 (Figure 5.5 
F) were reduced in HDM-exposed lta4h-/ mice, whilst levels of IL-17 were comparable 
between wild types and knockouts (Figure 5.5 G). Finally, total (Figure 5.6 A-B) and HDM-
specific (Figure 5.6 C-D) levels of IgE and IgG1 were assessed in the serum of HDM-treated 
mice and found to be comparable between wild types and lta4h-/- mice. Therefore, cellular and 
soluble mediators of inflammation most commonly associated with AAD were generally 
reduced in lta4h-/- mice, most likely owing to the absence of LTB4, despite these animals 
presenting with a striking exacerbation in AHR. Thus, there is a clear disconnect between 
inflammation and AHR.  
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Figure 5.4: HDM treated lta4h-/- mice exhibit reduced levels of Th2 inflammatory mediators relative to 
their littermate controls. 
Wild type and lta4h-/- mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks, and 
BALF and lung homogenate collected 24 hrs post the final HDM/PBS exposure. Levels of lung homogenate IL-
4 (A), lung homogenate IL-5 (B), lung homogenate IL-13 (C), BALF IL-4 (D), BALF IL-5 (E), BALF IL-13 (F) 
were assessed by ELISA. Results depicted as mean ± SEM. **P<0.01, ***P<0.001 using Mann–Whitney 
statistical test. 
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Figure 5.5: HDM treated lta4h-/- mice exhibit reduced levels of soluble inflammatory mediators relative to 
their littermate controls. 
Wild type and lta4h-/- mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks, and 
BALF, lung homogenate and serum collected 24 hrs post the final HDM/PBS exposure. Levels of lung homogenate 
eotaxin-2 (A), BALF eotaxin-2 (B), serum MCPT-1 (C), BALF Albumin (D), lung homogenate TNF-α (E), lung 
homogenate IL-6 (F) and lung homogenate IL-17A (G) were assessed by ELISA. Results depicted as mean ± SEM. 
**P<0.01, ***P<0.001 using Mann–Whitney statistical test. 
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Figure 5.6: HDM treated lta4h-/- mice exhibit comparable antibody levels despite the exacerbated AHR 
compared to their littermate controls. 
Wild type and lta4h-/- mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks, and 
serum collected 24 hrs post the final HDM/PBS exposure. Levels of total serum IgE (A), total IgG1 (B), HDM-
specific IgE (C) and HDM-specific IgG1 (D) were assessed by ELISA. Results depicted as mean ± SEM. 
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5.4.4 Loss of LTA4H did not increase other lipid mediators in the 
arachidonic acid pathway. 
Loss of LTA4H can consequentially lead to the build-up of substrate LTA4. It has been 
suggested that this accumulated LTA4 can be shunted towards other arms of the arachidonic 
acid pathway and result in accumulation of other potentially pathological mediators. For 
example, it has been speculated that loss of LTA4H can lead to a shunting of the arachidonic 
acid pathway to produce more pro-remodelling cysteinyl leukotrienes356. To rule this out, 
BALF from WT and lta4h-/- mice administered PBS or HDM was assessed for LTC4 levels. 
Interestingly, lta4h-/- mice displayed a reduction in BALF LTC4 levels compared to respective 
wild type mice (Figure 5.7 A). Other lipid mediators in the BALF were measured by mass 
spectrometry. Prostaglandin E2 (PGE2) is linked with immunomodulatory effects of a variety 
of immune cells448, and whilst HDM administration led to an augmentation in PGE2 levels, 
they were indistinguishable between WT and lta4h-/- mice (Figure 5.7 B). Various 
Hydroxyeicosatetraenoic acids (HETEs) were also measured in the BALF by mass 
spectrometry and levels found to be comparable between WT and respective knockout mice 
when administered HDM (Figure 5.7 C-E). Anti-inflammatory lipoxins were also measured in 
the BALF but were undetectable in all groups of mice. 
5.4.5 HDM-treated lta4h-/- mice exhibit PGP accumulation but comparable 
neutrophil numbers. 
It seemed counter-intuitive that HDM-exposed lta4h-/- mice exhibited an exacerbated AHR yet 
reduced inflammation. To further ascertain what may underlie the changes in lung function in 
these mice, it was considered the secondary anti-inflammatory action of LTA4H, in degrading 
PGP. Levels of key PGP-generating enzymes, MMP-9 and PE, were assessed in the BALF of 
the mice. Administration of HDM resulted in an elevation in the BALF levels of MMP-9 and 
PE (Figure 5.8 A-B), but their levels were comparable between lta4h-/- mice and littermate 
controls. However, whereas no PGP was detectable in the BALF of wild type mice, significant 
concentrations were detectable in HDM-treated lta4h-/- mice when assessed by mass 
spectrometry (Figure 5.8 C). In keeping with the previous observations, this PGP accumulation 
was attributable to an inability of lta4h-/- mice to degrade the peptide, with these animals 
lacking the extracellular PGP-degrading LTA4H activity observed in HDM-treated wild type 
mice (Figure 5.8 D-E).  
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Given the capacity of PGP to function as a neutrophil chemoattractant, I questioned whether 
accumulation of PGP in the HDM-treated lta4h-/- mice may function to promote a more 
neutrophilic asthma – a phenotype associated with more severe forms of the disease. 
Surprisingly however, in the context of AAD, the accumulation of PGP did not lead to 
enhanced neutrophil numbers in the lung tissue (Figure 5.8 F) or airways (Figure 5.8 G) of 
HDM-treated lta4h-/- mice relative to their littermate controls. It should be stressed that this 
model of AAD is predominantly eosinophilic with a minimal neutrophilic infiltrate (Figure 5.9 
A-B) – with airway neutrophil numbers less than 1% of eosinophil numbers after 3 weeks of 
HDM (Figure 5.9 A-B). Comparable neutrophil numbers between HDM-exposed lta4h-/- mice 
and littermate controls were also apparent at earlier time points (Figure 5.9 A-B). Whilst the 
neutrophil chemoattractant PGP is elevated in HDM-treated lta4h-/- mice, it should be 
remembered that these animals cannot generate neutrophil the chemoattractant LTB4 (Figure 
5.9 C) - thus the two mediators may differentially compensate. Levels of classical neutrophil 
chemokines, KC and MIP-2, were assessed and found to be modestly elevated in HDM-
exposed animals but no differences were apparent between wild type and lta4h-/- mice (Figure 
5.9 D-E). Finally, I considered whether neutrophil activation may be altered owing to the 
presence of PGP, leading to augmented release of potentially pathological products. However, 
levels of both primary granule-derived protease MPO (Figure 5.9 F-G) and tertiary granule-
derived protease MMP-9 (Figure 5.8 A and Figure 5.9 G) were comparable between HDM-
administered lta4h-/- mice and littermate controls.  
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Figure 5.7: HDM treated lta4h-/- mice exhibit comparable BALF lipid profiles to littermate controls. 
Wild type and lta4h-/- mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks, 
and 24 hrs after post the final HDM/PBS, BALF was collected to measure the concentration of lipid mediators. 
Concentrations of BALF LTC4 (A) were measured by ELISA. Concentrations of BALF PGE2 (B), BALF 11-
HETE (C), BALF 12-HETE (D), BALF 15-HETE (E) were measured by mass spectrometry. Results depicted 
as mean ± SEM. 
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Figure 5.8: HDM treated lta4h-/- mice exhibit PGP accumulation but comparable neutrophil infiltrate 
relative to littermate controls. 
Wild type and lta4h-/- mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks, and
BALF and lung tissue collected 24 hrs post the final HDM/PBS exposure. Amounts of total MMP-9 in BALF 
were assessed by ELISA (A) and PE by Western blot (B). The concentration of PGP in BALF was determined 
by ESI-LC/MS/MS (C). BALF was incubated with PGP and degradation assessed after 2 hours by mass 
spectrometry (D) or release of free proline (E). The number of neutrophils recruited into the lung tissue (F) and 
airways (G) was determined by flow cytometry. Results depicted as mean ± SEM. ***P<0.001 using Mann–
Whitney statistical test. 
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Figure 5.9: Comparable neutrophilic inflammation and mediators in HDM-exposed wild type and lta4h-/- 
mice. 
Wild type and lta4h-/- mice were administered HDM or PBS intranasally (i.n.) 3 times per week for up to 3 weeks. 
BALF and lung tissue collected at 24 hrs, 1 week and 3 weeks of HDM/PBS for downstream analysis. The number 
of neutrophils and eosinophils recruited into the lung tissue (A) and airways (B) was determined by flow cytometry 
at each time point. Levels of BALF LTB4 at 3 weeks were assessed by ESI-LC/MS/MS (C). Levels of KC (D), 
MIP-2 (E), MPO (F) and MMP-9 (G) in lung homogenate at 3 weeks HDM exposure were assessed by ELISA. 
Results depicted as mean ± SEM.  
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5.4.6 HDM-administered lta4h-/- mice display a striking epithelial 
remodelling phenotype. 
Airway remodelling is a cardinal feature of AAD that contributes to the development of AHR 
and thus it was postulated that airway structural changes may account for the exacerbated 
airway resistance observed in the lta4h-/- mice administered HDM. Accordingly, observation 
of H and E stained lung sections revealed that the height of airway epithelial cells was 
significantly augmented in the HDM-treated lta4h-/- mice relative to littermate controls, with 
epithelial cells strikingly elongated and projecting out to occlude the lumen of the airways 
(Figure 5.10 A-B). This striking observation was consistently observed in lta4h-/- mice (Figure 
5.11). Furthermore, many of the airways of lta4h-/- mice administered HDM were filled with 
mucus (Figure 5.10 A and Figure 5.11) and PAS staining of lung sections clearly demonstrated 
enhanced mucus production by the airway epithelia of HDM-treated lta4h-/- mice relative to 
littermate controls (Figure 5.10 C-D). Subsequently, I questioned whether other aspects of 
airway remodelling were also altered in the lta4h-/- mice, but no differences were apparent in 
airway smooth muscle or collagen deposition (Figure 5.12 A-D). Thus, the remodelling 
phenotype is seemingly restricted to the airway epithelia. This striking epithelial remodelling 
observed in HDM-treated lta4h-/- mice would clearly limit airflow and thus account for the 
striking exacerbation in airway resistance observed in these animals. 
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Figure 5.10: HDM treated lta4h-/- mice exhibit augmented airway epithelial remodelling relative to littermate 
controls. 
Wild type and lta4h-/- mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks, and 
24 hrs after post the final HDM/PBS exposure lungs were removed for histological examination. (A) Representative 
H&E stained lung sections from wild type and lta4h-/- mice administered PBS or HDM. (B) Epithelial cell height 
around medium-sized conducting airways was assessed from H&E stained lung sections. Data presented are an 
average per mouse. (C) Representative PAS stained lung sections from wild type and lta4h-/- mice administered 
PBS or HDM. (D) Goblet cells were scored from PAS stained sections. The sum of airway scores from each lung 
was divided by the number of airways examined and expressed as mucus cell score in arbitrary units. *P<0.05, 
***P<0.001 using Mann–Whitney statistical test. (A, C) Scale bar = 50 µm 
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Figure 5.11: HDM treated lta4h-/- mice exhibit augmented airway epithelial remodelling relative to 
littermate controls. 
Wild type and lta4h-/- mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks, and 
24 hrs after post the final HDM/PBS exposure lung were removed for histological examination. Representative 
H&E stained lung sections depicted from wild type and lta4h-/- mice administered HDM. Scale bar = 50 µm 
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Figure 5.12: Comparable smooth muscle and collagen deposition in HDM treated wild type and lta4h-/- 
mice. 
Wild type and lta4h-/- mice were administered HDM or PBS intranasally (i.n.) 3 times per week for 3 weeks, and 
24 hrs after post the final HDM/PBS exposure lung were removed for histological examination and lung 
homogenisation to measure soluble collagen determined by Sircoll assay. (A) Representative smooth muscle actin 
stained lung sections from wild type and lta4h-/- mice administered PBS or HDM. (B) Thickness of smooth 
muscle actin around medium-sized conducting airways was assessed from stained   lung sections, with data 
presented as an average per mouse. (C) Intensity of Sirius Red staining in lung sections from wild type and lta4h-
/- mice administered PBS or HDM, with data presented as an average per mouse. (D) Lung homogenate soluble 
collagen. Results depicted as mean ± SEM. (A) Scale bar = 50 µm 
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5.4.7 A novel role for PGP in driving airway epithelial remodelling and 
AHR in the context of AAD. 
HDM-exposed lta4h-/- mice exhibited a pronounced airway epithelial remodelling that led to 
exacerbated AHR, but developed seemingly independently of inflammation – with many of the 
classical mediators that drive airway structural changes reduced in these animals. Increasingly, 
it is becoming apparent that PGP may exert functions independent of its effect on neutrophils, 
with a recent study highlighting the capacity of PGP to act directly on endothelial cells to 
promote vascular permeability449. Given that type IV collagen of the basement membrane, 
lying juxtaposed to the airway epithelium, is a prime substrate for PGP generation, I postulated 
that the PGP that accumulated in HDM-treated lta4h-/- animals may drive the epithelial 
remodelling and ensuing exacerbated AHR. The tripeptide arginine-threonine-arginine (RTR; 
tetramerised onto a di-lysine core) exhibits a direct mirror image hydropathy profile to PGP, 
as defined by the molecular recognition theory, and thus functions to bind and neutralise PGP 
both in vitro and in vivo136,450–452.  HDM-exposed wild type and lta4h-/- mice were therefore 
administered RTR or control peptide, ASA, to directly probe the role of PGP in driving the 
remodelling and lung function changes (Figure 5.13 A). HDM-treated lta4h-/- mice again 
exhibited increased airway resistance (Figure 5.13 B-C), epithelial height (Figure 5.13 D-E) 
and epithelial mucus production (Figure 5.13 F-G) relative to littermate controls. However, 
administration of RTR to HDM-exposed lta4h-/- mice strikingly reduced airway resistance 
(Figure 5.13 B-C), epithelial height (Figure 5.13 D-E) and epithelial mucus production (Figure 
5.13 F-G) demonstrating that all these changes were clearly mediated through a novel action 
of PGP.  
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Figure 5.13: PGP neutralization attenuates the heightened airway resistance and epithelial remodelling 
observed in HDM-exposed lta4h-/- mice. 
(A) Wild type and lta4h-/- mice were administered HDM intranasally (i.n.) 3 times per week for 3 weeks. Mice 
were concomitantly administered PGP antagonist, RTR, or control peptide, ASA. (B) Airway Resistance (R) to 
increasing doses of methacholine (Mch) was measured 24 hrs post the final HDM/PBS exposure. (C) Airway 
resistance at 100 mg/ml methacholine. (D) Representative H&E stained lung sections from wild type and lta4h-/-
mice administered HDM with either RTR or ASA. (E) Epithelial cell height around medium-sized conducting 
airways was assessed from H&E stained lung sections. Data presented are an average per mouse. (F) 
Representative PAS stained lung sections from wild type and lta4h-/- mice administered HDM with either RTR 
or ASA. (G) Goblet cells were scored from PAS stained sections. The sum of airway scores from each lung was 
divided by the number of airways examined and expressed as mucus cell score in arbitrary units. Results depicted 
as mean ± SEM. *P<0.05, **P<0.01, using Mann–Whitney statistical test. (D, F) Scale bar = 50 µm 
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5.4.8 Direct application of PGP induces epithelial remodelling and mucus 
production. 
I subsequently assessed whether this epithelial remodelling effect of PGP was a consequence 
of a direct, sustained interaction of the peptide with epithelial cells. Normal bronchial epithelial 
cells in air-liquid-interface (ALI) were therefore cultured in media or media supplemented with 
PGP (in the basolateral compartment) for 7 days. Analysis of H&E stained sections of these 
cells after 7 days demonstrated that PGP treatment resulted in an increase in epithelial height 
(Figure 5.14 A-B). Additionally, PGP supplementation enhanced mucus production in apical 
supernatants collected at day 1 and day 7 of culture (Figure 5.14 A, C).  
To further define the effect of PGP on epithelia, normal primary bronchial epithelial cells in 
submerged culture were treated with different concentrations of peptide and visualised over a 
period of 72 hours using a JuLI™ Stage automated cell imaging system. PGP caused a 
significant increase in epithelial cell confluence at all concentrations of peptide tested (Figure 
5.15 A-E) with this phenotype prominent at PGP concentrations as low as 10 ng/ml (Figure 
5.15 A, E). The increase in confluence was in part attributable to an increase in cellular 
proliferation in response to PGP, with a significant increase in the proportion Ki-67 positive 
cells after 72 hours of peptide stimulation (Figure 5.16 A- B). At later time points in particular, 
PGP treated cells also began to display striking morphological changes with prominent 
lamellipods indicative of enhanced cellular motility and some evidence of a loss of contact 
inhibition of locomotion (Figure 5.16 B).  Thus, PGP directly elicits profound functional and 
morphological changes in bronchial epithelial cells that could rationalise the epithelial 
phenotype observed in HDM treated animals.  Together these studies highlight an entirely 
novel capacity of a matrikine, generated during inflammation, to subsequently drive a 
pathological airway remodelling, which in turn accounts for the striking disconnect between 
airway inflammation and lung function.  
 
 
 
 
 
 
 
Chapter 5: The dual role of Leukotriene A4 Hydrolase in AAD 
246 
 
 
 
 
Figure 5.14: PGP induces remodelling of human bronchial epithelial cells. 
Normal human bronchial epithelial cells were cultured in airway liquid interface (ALI). Respective wells were 
supplemented with basolateral media or media with 10 μg/ml PGP for 7 days. Apical supernatants were collected 
and cells were fixed for histological analysis. (A) Representative H&E and PAS stained sections of ALI culture 
epithelium after 7 days treatment. (B) Epithelial cell height was assessed from H&E stained sections, with data 
presented as an average per well. (C) Apical supernatant Muc5AC was assessed by ELISA at days 1 and 7 post 
treatment. Results depicted as mean ± SEM.  *P<0.05, **P<0.01, ***P<0.001 using Mann–Whitney statistical 
test (C) or ANOVA with Bonferroni correction (D and F). (A) Scale bar = 25 µm 
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Figure 5.15: PGP induces remodelling of human bronchial epithelial cells. 
Normal human bronchial epithelial cells were cultured in media or media supplemented with different 
concentrations of PGP and visualized over a period of 72 hours using a JuLI™ Stage automated cell imaging 
system. (A) Fold change in cell confluence over 72 hour period relative to media control. (B) Intra-group fold 
change in % cell confluence of cells cultured in media or 10 µg/ml PGP at 72 hours relative to 0 hours. (C) Intra-
group fold change in % cell confluence of cells cultured in media or 1 µg/ml PGP at 72 hours relative to 0 hours. 
(D) Intra-group fold change in % cell confluence of cells cultured in media or 100 ng/ml PGP at 72 hours relative 
to 0 hours. (E) Intra-group fold change in % cell confluence of cells cultured in media or 10 ng/ml PGP at 72 
hours relative to 0 hours. Results depicted as mean ± SEM.  *P<0.05, **P<0.01, ***P<0.001 using ANOVA with 
Bonferroni correction. 
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Figure 5.16: Direct application of PGP to bronchial epithelial cell increases cell proliferation. 
Normal human bronchial epithelial cells were cultured in media or media supplemented with different 
concentrations of PGP and visualized over a period of 72 hours using a JuLI™ Stage automated cell imaging 
system. After 72 hours the cells were fixed and stained for Ki-67 with Ki-67 positive cells expressed as a 
percentage of DAPI positive cells (A).  (B) Representative Bright Field images and images of cells stained for 
DAPI and KI-67 after 72 hours of culture in media or 10 ng/ml PGP. Results depicted as mean ± SEM.  *P<0.05, 
**P<0.01, ***P<0.001 using ANOVA with Bonferroni correction. (B) Scale bar = 25 µm 
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5.5 Discussion 
LTA4H represents a highly unusual enzyme with dual, seemingly opposing activities: 1. To 
generate the potent pro-inflammatory lipid mediator LTB4; 2. To degrade the classically pro-
neutrophilic matrikine PGP. These series of experiments have dissected the dual roles of 
LTA4H in driving the inflammatory and remodelling aspects of AAD. LTB4 is a powerful pro-
inflammatory mediator strongly implicated in the pathology of asthma, and as such represents 
an attractive therapeutic target106,109,426,427,432. Accordingly, there has been a concerted effort 
by pharmaceutical companies to develop inhibitors to the enzyme LTA4H, the rate limiting 
step in LTB4 biosynthesis. This has culminated in the assessment of potent LTA4H inhibitor, 
JNJ-40929837, in a bronchial allergen challenge of asthma, which despite showing target 
engagement failed to demonstrate efficacy357. My lab have previously identified a novel anti-
inflammatory role for LTA4H in degrading the neutrophil chemoattractant PGP and 
rationalised that the persistent ineffectiveness of LTA4H inhibitors in the clinic may be 
attributable to the inadvertent inhibition of this PGP-degrading aminopeptidase activity of 
PGP83,406. Consequently, I have assessed the dual roles of LTA4H in a physiologically relevant 
murine model of AAD. 
In accordance with the weight of literature439,441–443, selective abrogation of LTB4 signalling 
(blt1-/- mice) resulted in a reduction in airway inflammation, remodelling and AHR in the in-
house murine model. Conversely, lta4h-/- mice, despite lacking LTB4 and ensuing 
inflammation, exhibited a striking exacerbation in airway resistance. The exacerbated AHR 
observed in HDM-exposed lta4h-/- animals seems paradoxical given the absence of LTB4 and 
the striking reduction of inflammatory cells and mediators that have classically been implicated 
in the pathophysiology of AAD. Specifically, eosinophils, Th2 CD4+ T cells and levels of IL-
4, IL-5, IL-13 were all markedly reduced in lta4h-/- animals, despite having previously been 
shown to be fundamental for disease progression224,453,454. Markers of oedema and mast cell 
activation, which have also been implicated in pathology of AAD446,447,455, were also reduced 
in lta4h-/- mice – indeed all classical cellular and soluble mediators assessed in HDM-exposed 
knock out animals were lower or at least comparable to their littermate controls. Thus the lta4h-
/- mice exhibited a striking disconnect between airway inflammation and lung function 
changes. 
One inflammatory mediator that was able to accumulate in HDM-treated lta4h-/- mice was 
PGP owing to complete inability of these animals to degrade the peptide, as previously 
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reported83,406. Though PGP is classically considered a neutrophil chemoattractant132, numbers 
of neutrophils in the lungs and airways were comparable between lta4h-/- mice and littermate 
controls. Instead, I identified a novel neutrophil-independent, remodelling activity for PGP 
whereby the peptide elicited striking epithelial hyperplasia and mucus production leading to 
occlusion of the airways and limitation of airflow. Accordingly, neutralization of PGP in HDM-
exposed lta4h-/- mice, with the compound RTR, reduced epithelial height, mucus cell 
metaplasia and airway resistance - supportive of the notion that it is these profound remodelling 
changes that underlie the exacerbated AHR.  
Given the accumulation of PGP in HDM-treated lta4h-/- mice it is perhaps surprising that no 
increase in neutrophilic inflammation was observed in these animals. PGP has been 
demonstrated to function as a neutrophil chemoattractant by mimicking key sequences found 
in ELR+ CXC neutrophil-specific chemokines and binding to receptors CXCR1/2132. 
Previously, my colleagues have shown that a failure of LTA4H-mediated PGP degradation in 
the context of acute, self-resolving pulmonary neutrophilic models results in an exacerbated 
neutrophilic infiltrate, protease imbalance and illness143. Accordingly, PGP degradation by 
LTA4H is seemingly perturbed in chronic neutrophilic lung diseases, such as COPD, in a 
manner that enables accumulation of the peptide83,445. However, in the context of this Th2-
dominant AAD model, it seems that PGP accumulation does not promote an augmented 
neutrophilia or release of neutrophil-derived proteases. Within this model, HDM 
administration to wild type mice results in a hyper-eosinophilic inflammation with minimal 
neutrophil recruitment (over 100 fold more airway eosinophils than neutrophils at 3 weeks 
HDM), and it may be that this profoundly Th2 environment is less conducive to neutrophil 
recruitment or persistence. Furthermore, whilst PGP may accumulate in lta4h-/- mice, LTB4 
will be absent and may thus counteract the increase in PGP in the context of AAD. Given that 
the levels of PGP described in this study are generally lower than those reported previously in 
neutrophilic inflammatory models or diseases, it is also feasible that the concentration of 
peptide is insufficient to promote a robust neutrophil infiltrate – conversely the airway 
epithelium is positioned juxtaposed to the PGP-rich basement membrane, which may thus form 
a localised reservoir of the peptide that can directly act upon the epithelium.  Neutrophils are a 
robust source of the proteases (MMPs133 and PE456) that generate PGP from collagen, which 
may explain the lower concentrations of the peptide in this model that displays minimal 
neutrophilic inflammation. These studies also therefore dispel a previous misconception that 
neutrophils must be present in order to generate PGP. The MMPs and PE that generate PGP 
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from collagen are released by an array of cells other than neutrophils135,457,458 and thus we must 
be vigilant to the potential adverse effects of PGP accumulation even in the setting of non-
neutrophilic inflammation.  
Whilst PGP has classically been viewed as a neutrophil chemoattractant, it is increasingly 
becoming apparent that this peptide can also modulate the behaviour of other cells. A recent 
study demonstrated that PGP is able to act on endothelial cells, via CXCR2, to promote 
vascular permeability449. Indeed, it was demonstrated that direct application of PGP to primary 
human bronchial epithelial cells promoted their proliferation and radial spreading, and 
recapitulated the in vivo phenotype when the cells were cultured in ALI.  Furthermore, PGP 
induced striking morphological changes in epithelial cells with prominent lamellipods 
indicative of enhanced cellular motility and some evidence of a loss of contact inhibition of 
locomotion. It is feasible that PGP is eliciting an epithelial response that is conducive to 
localised wound repair, however, if PGP persists as a result of aberrant LTA4H activity then 
this response becomes pathological. Airway epithelial cells, like their endothelial counterparts, 
have extensively been shown to possess CXCR2358,451,459. As previously alluded to, interaction 
of airway epithelial cells and endothelial cells with PGP is extremely likely given the proximity 
of the basement membrane and thus potentially high localised concentrations of this peptide. 
The precise mechanism by which PGP drives this epithelial remodelling phenotype are as yet 
to be defined. However, it is pertinent that neutrophil-specific chemokines, IL-8 and Gro-α, 
have previously been suggested to be capable of driving epithelial cell migration and 
proliferation459–462. Additionally, in-vivo studies utilising CXCR2 antagonists have established 
a link between CXCR2 and mucus hypersecretion and AHR in models of  LPS-induced airway 
inflammation463, cigarette smoke464 and RSV infection465. Given that PGP functions by 
mimicking key sequences in these chemokines, it is plausible that the high localised 
concentration and persistence of PGP in an environmental niche juxtaposed to the epithelium 
would promote its capacity to function as a mitogenic and pro-remodelling factor for these 
cells.  Thus whilst it is recognised that fragments generated from the ECM can modulate the 
inflammatory response, Chapter 5 now demonstrate that the matrikine PGP also exhibits a 
remarkable and potent capacity to directly drive airway remodelling.   
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5.6 Conclusion 
In conclusion, I have identified a novel pro-remodelling role for the matrikine PGP in driving 
airway epithelial hyperplasia and mucus release. Accordingly, this chapter demonstrates that a 
failure of lta4h-/- mice to degrade PGP in a physiologically relevant murine model of AAD 
leads to severe adverse effects and exacerbated AHR, despite the absence of LTB4. These 
findings have direct implications for the assessment of LTA4H inhibitors, which have entered 
the clinic and failed to demonstrate efficacy444, and that my colleagues have recently shown to 
abrogate PGP degrading activity of LTA4H87. The recent failure of JNJ-40929837 to 
demonstrate efficacy in a human bronchial allergen challenge model of asthma, despite clearly 
reducing levels of LTB4357, could be attributable to a confounding increase in PGP. 
Furthermore, whilst no PGP was detectable in HDM-exposed wild type mice, human severe 
asthma is a heterogeneous disease with variable inflammatory, remodelling and clinical 
phenotypes, and PGP may naturally be present and contributing to pathology in a subset of 
patients. Severe asthma phenotypes have been described that exhibit pronounced neutrophilic 
inflammation, which would lead to elevated PGP generation275,280,337. Furthermore, airway 
epithelial thickness and proliferation have been demonstrated to be greater in severe asthmatics, 
and contribute to progressive decline in lung function466, but the mediator/s that drive this 
epithelial phenotype are unclear.  My lab have demonstrated the capacity of tobacco smoke to 
abrogate LTA4H-mediated PGP degradation83,144, and thus it is pertinent that smoke exposure 
has been demonstrated to be a major risk factor for severe asthma, and is associated with greater 
airflow obstruction and AHR467. Additionally, my colleagues have demonstrated that 
respiratory viral83 and bacterial143 infections can spike PGP generation; relevant given that 
infectious exacerbations of asthma are associated with augmented neutrophilia and mucus 
release210,468,469. Finally, it has previously demonstrated that PGP is a biomarker for chronic 
neutrophilic lung diseases such as COPD and CF133,445.  Aberrant epithelial remodelling with 
excessive mucus production is hallmark of these diseases that could in part be attributable to 
the previously unappreciated role for PGP now identified in this study.  
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6 Chapter 6: General Discussion 
It is known that a significant proportion of asthmatics display prominent neutrophilic 
inflammation in the lung and airways272,273,275. Furthermore, neutrophilic proteases and 
chemokines are elevated in various clinical samples derived from patients with 
asthma57,272,273,285. The exact role that neutrophils are playing in defining disease 
pathophysiology, however, remains unknown. Therefore, the aim of this thesis was to dissect 
the role of neutrophils and their proteases in AAD.  
In Chapter 3, I demonstrated that different strains of mice display distinct inflammatory and 
remodelling changes upon HDM exposure. Specifically, Balb/c mice exhibited a mixed 
granulocytic infiltrate with a significant neutrophilic component, whereas 129/S2 mice 
displayed a hyper-eosinophilic inflammatory phenotype that was associated with more 
pronounced airway remodelling and an exacerbated AHR.  
Chapter 4 directly dissected the role of neutrophils in in-house murine model of AAD through 
the administration of a specific neutrophil depleting antibody. Surprisingly, neutrophil depleted 
HDM-exposed mice displayed a more pronounced Th2 inflammation and increased baseline 
airway resistance. In defining the mechanism, I revealed that neutrophils play an important 
homeostatic role in regulating systemic levels of G-CSF. Subsequently, depletion of 
neutrophils resulted in augmented G-CSF levels, which in turn led to heightened type 2 
cytokine production from ILC2s, and a monocytosis that resulted in greater antigen 
presentation. 
Chapter 5 dissected the role of LTA4H in AAD – an enzyme that has been targeted by the 
pharmaceutical sector in asthma to reduce levels of pro-neutrophilic mediator LTB4. However, 
my group has recently demonstrated that LTA4H possesses a secondary anti-inflammatory role 
in degrading another pro-neutrophilic mediator, PGP. I demonstrated that genetic deletion of 
LTA4H resulted in reduced inflammation but a profound epithelial remodelling and 
exacerbated AHR. This latter phenotype was demonstrated to be attributable to PGP 
accumulation and a novel pro-remodelling role for this matrikine in promoting epithelial 
hypertrophy and mucus production. 
Though these findings have specifically been addressed in respective chapters, many general 
concepts have arisen that could merit further consideration. However, in this final discussion I 
will address the following: 
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1. Neutrophils – good, bad or indifferent in asthma 
2. Asthma heterogeneity in mouse and man 
3. The relationship between inflammation, remodelling and lung function 
4. The importance of the ECM and matrikines in inflammation and remodelling 
5. Therapeutically targeting neutrophils in asthma – the implications 
6.1 Neutrophils – good, bad or indifferent in asthma. 
A significant number of asthmatic patients display neutrophilic inflammation, particularly 
patients with severe disease that respond poorly to steroid treatment272,273. Neutrophil proteases 
such as MMP-9 and MPO are also elevated in subsets of asthmatics and correlate with 
neutrophil numbers57,285. Despite the clear indication that neutrophils can be a prominent 
component of the allergic response, their significance and relative contribution to the 
development and pathophysiology of asthma remain unclear. Nonetheless, the general 
consensus is that neutrophils are detrimental and indicate a worse prognosis: neutrophilic 
inflammation is prominent in asthmatics post exacerbations and hospitalisation280 and is  
generally associated with enhanced severity of disease, diminished responsiveness to 
corticosteroids, lower lung function and is a feature of rapid onset asthmatic deaths280,337,369.  
Direct interrogation of the role of neutrophils in animal models of AAD have been surprisingly 
lacking. Neutrophil depletion with an anti-Gr-1 monoclonal antibody in an OVA murine model 
significantly reduced the magnitude of the LAR295. Additionally, in a mouse model of chemical 
induced asthma it was demonstrated that neutrophil depletion prevented AHR, lung epithelial 
damage and reduced airway inflammation75. In a steroid-insensitive Th17 cell adoptive transfer 
model of AAD, neutrophil depletion reduced airway inflammation and improved lung 
compliance but did not improve AHR to methacholine301. Thus, whilst the physiological 
relevance of some of these models to human disease and the specificity by which neutrophils 
are targeted can be debated, there is enough to argue that neutrophils can contribute to asthma 
pathophysiology. Nonetheless, detailed mechanisms underlying any detrimental effects of 
neutrophils in asthma are predominantly speculative. 
As already noted, products released by neutrophils, such as proteases and reactive oxygen 
species, possess a marked capacity to cause direct non-specific tissue damage and thus it is 
easy to rationalise the pathological contribution of these cells when deregulated in the asthmatic 
lung. This likely represents an oversimplified view, however, of the probable multifaceted and 
complex role of neutrophils in AAD. Neutrophil products such as neutrophil elastase470, 
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MPO57,471 and MMP-9285 have been associated with reduced lung function in asthmatic 
patients. The potential of MMP-9 to drive asthma related pathophysiology is reinforced by the 
finding that MMP-9 deficient mice exhibit impaired mononuclear cellular infiltration and 
bronchial hyperresponsiveness in a model of allergen-induced airway inflammation472. NE 
possesses the potential to promote many of the pathophysiological features of asthma, with a 
purported capacity to promote epithelial damage, vascular permeability, mucus gland 
metaplasia and mucus hypersecretion, eosinophil cationic protein (ECP) release from 
eosinophils, smooth muscle cell proliferation, collagen deposition and airway wall thickening 
and ultimately bronchoconstriction and bronchial hyperreactivity57,473,474. 
Although there is certainly evidence suggesting neutrophils are pathological in the context of 
asthma, there is also accumulating evidence that neutrophilic inflammation may paradoxically 
be associated with a beneficial outcome. Could their presence in the more severe forms of 
asthma represent an effort to control inflammation, restore homeostasis and promote tissue 
repair? Whilst this concept may seem unlikely, it is not beyond the realms of possibility that 
neutrophils may fulfil some favourable role. Neutrophils have the capacity to phaocytose and 
clear apoptotic cells and debris and are a source of pro-resolving lipid mediators, anti-
inflammatory and immunomodulatory cytokines, decoy receptors and cytokine 
scavengers304,475–480. As discussed above, there is strong circumstantial evidence that MMP-9 
is elevated in asthma and may contribute to pathology of disease; however two studies in 
animal models have suggested that MMP-9 may actually serve a positive role in limiting and 
resolving AAD298,299. Another study has demonstrated a positive role for neutrophil derived 
proteases in the destruction of mucus plugs that are an important cause of airway obstruction 
in severe asthma302. In keeping with these findings, neutrophil chemokines have been 
associated with better clinical outcomes in a subset of patients with severe neutrophilic 
asthma301. Furthermore, increased intra-epithelial neutrophil numbers are associated with 
improved FEV1 recordings in children with severe therapy resistant asthma300.  
Various clinical confounders might result in increased neutrophilic inflammation in certain 
subsets of asthmatic patients. Many of the patients with severe asthma are on high doses of 
corticosteroids, which function to inhibit neutrophil apoptosis – suggesting that the steroid 
treatment itself actually accounts for the elevated neutrophilia481,482. Additionally, smoking and 
bacterial and viral infections are prominent in asthmatic patients and are often associated with 
exacerbations and neutrophilic inflammation483,484. The relationship between neutrophilic 
asthma and smoking status is unclear and previous studies have suggested that if data are 
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controlled for corticosteroid use and smoking then a neutrophilic asthma phenotype does not 
exist485,486.  
The results of this thesis do not support the concept that neutrophils are pathological in the 
context of AAD and even suggest a potential protective role in the HDM model. Circumstantial 
evidence to support this notion comes from Chapter 3, whereby 129/S2 mice displayed minimal 
neutrophilic inflammation relative to Balb/c mice, and yet exhibited a more pronounced airway 
remodelling and AHR. Furthermore, whilst budesonide administration ablated Th2 
inflammation, remodelling and AHR in HDM-exposed Balb/c mice, neutrophil numbers were 
only modestly reduced in the lungs and airways. Thus, the presence of neutrophils in the lung 
and airways does not seem to necessarily equate to more severe remodelling and AHR. More 
specifically, in Chapter 4 I demonstrated that neutrophil depletion actually increased Th2 
inflammation and baseline airway resistance upon HDM administration - suggesting that 
neutrophils may actually have a protective role in AAD. However, such a global neutrophil 
depletion strategy may cause baseline homeostatic changes that are not relevant to strategies 
utilised in the clinic to target neutrophils. Clearly, therefore, an alternate therapeutically 
relevant strategy should be utilised to determine the specific role of neutrophils in AAD. 
Accordingly, I have performed preliminary studies whereby HDM-treated mice were 
administered a CXCR2 antagonist, SB52002 to block neutrophil recruitment into the lung (data 
not shown). SB52002 treatment resulted in increased AHR despite a reduction in the number 
of neutrophils and comparable levels of Th2 inflammation. Further studies are required to 
identify a possible mechanism by which CXCR2 antagonist treatment augments AHR. 
Given the classical opinion of neutrophils as indiscriminate protagonists of tissue destruction 
and the clear indication that neutrophils are a prominent inflammatory cell in a subset of 
asthmatics with an often severe and corticosteroid refractory phenotype, then it is unsurprising 
that the neutrophil has been cast as the villain that drives disease pathology and that should be 
therapeutically targeted at all costs. Whilst this viewpoint is not without merit, we should 
discard the outdated and common misconception of neutrophils as primitive and purely 
pathological. Instead, we should acknowledge a cell that at times can exhibit a pronounced 
awareness and plasticity, an impressive and broad biosynthetic capacity, and a marked potential 
to influence and shape the inflammatory environment to which it enters. Furthermore, we 
should consider the neutrophil in the asthmatic lung as a potentially heterogeneous population 
and in the context of location, comorbidities and intrinsic and extrinsic confounders. In this 
complex setting, there is the clear need to define and dissect precisely what role the neutrophil 
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is playing rather than infer its role from circumstantial evidence and obsolete misgivings of the 
neutrophil as a harbinger of doom. It is feasible, and perhaps probable, that the neutrophil 
exhibits pleiotropic and potentially conflicting roles in defining asthma pathophysiology– some 
almost certainly detrimental and some potentially beneficial – that may be variable in a context 
and patient specific setting. 
6.2 Asthma heterogeneity in mouse and man. 
Asthma is increasingly recognised as a heterogeneous disease with patients displaying distinct 
clinical and immunopathological profiles. Consequently, devising treatment strategies for 
severe asthmatics can prove challenging257, and it is becoming increasingly apparent that 
therapeutics need to be tailored to target the patient-specific pathological profiles. While 
environmental factors clearly have a role in driving disease heterogeneity, the individual’s 
genetic profile also defines the disease phenotype. This project identified that different inbred 
mouse strains exhibit remarkably different inflammatory and remodelling profiles to one 
another after HDM administration. Genetic difference between inbred mouse studies that 
define these differential responses are also relevant to human disease. For example, CD23 
polymorphisms that are found in the 129/S2 strain of mouse are associated with greater Th2 
inflammation, and have also been observed in asthmatic patients and associated with elevated 
IgE production394,395. 
Reliable biomarkers are essential for disease diagnosis and consequently for tracking disease 
progression, with specific biomarkers now being utilised to help define specific subsets of 
asthmatic patients. For example, blood levels of periostin and exhaled FeNO have previously 
been used to identify patients with significant Th2 inflammation, and subsequently those that 
could respond to anti-IL-13 treatment338,342. It would be interesting to assess these markers in 
the 129/S2 strain of mice utilised in some studies described in this thesis. Biomarkers for 
neutrophilic asthma remain lacking, but MPO and MMP-9 have been utilised as surrogates for 
neutrophilic inflammation in the clinic. Many studies have indeed highlighted correlations 
between these neutrophil proteases and neutrophil counts57,285. However, in these mouse 
studies, these proteases did not always correlate with neutrophilic inflammation. For example, 
129/S2 mice display similar levels of MPO and MMP-9 in lung homogenate and BALF Balb/c 
mice despite possessing significantly lower neutrophilic inflammation. Likewise, neutrophil 
depleted mice display increased levels of MPO and MMP-9 upon HDM administration. This 
may in part be due to the fact that other cell types are sources of these proteases, with MMP-9 
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being produced by a plethora of cells and isolated human blood monocytes capable of secreting 
MPO and MMP-9487. Therefore, although MPO and MMP-9 are derived from neutrophils, it is 
important to appreciate that they may not always correlate with neutrophilic inflammation and 
thus caution should be applied when using them as biomarkers in the clinic.  
Despite the obvious discrepancies between mouse and man, these studies raise the question as 
to whether distinct inbred mouse strains could be utilised to mimic certain facets of asthma 
phenotypes observed in the clinic. I demonstrated that different mouse strains certainly mimic 
many facets of the inflammation and remodelling exhibited by asthmatic patients, with 
differential inflammatory profiles, remodelling and AHR apparent between different strains. 
For example, 129/S2 mice display a hyper-eosinophilic response to HDM whereas Balb/c mice 
exhibit a mixed granulocytic response – two distinct subsets of patients observed in the clinic. 
It is impossible to expect mouse strains to faithfully mimic multifaceted disease manifestations 
observed in man, and to incorporate the complex effects of heterogeneous environmental 
influences such as smoking, exposure to pollutants and infection history. However, awareness 
of the distinct immunopathological profiles observed by different inbred mice could be utilised 
to ensure that the most appropriate strain is used to probe hypotheses into distinct facets of 
asthma, such as those focused on interrogating specific cell types, inflammatory mediators or 
biomarkers. For example, it is clear that Balb/c mice need to be utilised to dissect aspects of 
neutrophilic inflammation in the HDM model.  
Consequently, a limitation of some studies described in this thesis is that genetically modified 
mice are on distinct genetic backgrounds. For example, lta4h-/- mice were of a 129/S2 
background whereas blt1-/- were on a C57/BL6 background. HDM-exposed lta4h-/- mice 
exhibited PGP accumulation but did not show an augmented neutrophilic response – potentially 
owing to this strain of mouse naturally eliciting minimal neutrophilia in the in-house AAD 
model. Additionally, neutrophils are a prominent source of enzymes that generate PGP143 and 
thus lta4h-/- mice, on a 129/S2 background, display lower levels of PGP generation which may 
not support additional neutrophil recruitment. It would be interesting in future therefore to 
assess the effect of LTA4H gene deletion or inhibition in the HDM model in a Balb/c strain of 
mouse – which may support a greater neutrophilic inflammation.  
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6.3 The relationship between inflammation, remodelling and lung function. 
Classically, inflammation has been considered to be the instigator of and precursor to  airway 
remodelling and AHR in asthmatic patients145,150,338. Supporting this notion, mouse models of 
AAD have demonstrated that inflammatory changes generally drive the increased airway 
remodelling and AHR150. For example, in-vivo studies have highlighted the key significance of 
IL-13, produced by inflammatory cells in the asthmatic lung, in driving mucus production and 
lung function223,224. Furthermore, manipulation of IL-4 and IL-5 signalling can significantly 
attenuate the induction of AHR in murine models of AAD150. Likewise, experiments 
performing an adoptive transfer of  activated CD4+ T cells that produce a spectrum of Th2 
cytokines can induce many features of AAD150.  
More recently, however, this dogma of inflammation driving remodelling and AHR has been 
challenged, and some asthmatic patients clearly display airway remodelling and AHR in the 
absence of inflammation488. Bossley et al. performed biopsies and BAL on children with severe 
paediatric asthma489, and showed airway remodelling despite no observable increase in  BALF 
IL-4, IL-5 and IL-13 levels489. Another study revealed that pre-school children with severe 
wheeze exhibited significant airway remodelling, but this again did not correlate with 
inflammation490. Murine studies have also shown that airway remodelling and AHR can 
develop independently of inflammation. Overexpression of epithelial Smad2 in mice resulted 
in increased AHR, smooth muscle and collagen deposition but no changes in airway 
inflammation and Th2 cytokine secretion compared to wild type mice administered HDM491. 
ADAM33 is a protein primarily expressed by stromal cells, such as airway smooth muscle and 
fibroblasts, as opposed to leukocytes488. Independent of inflammation, ADAM33 -/- mice 
exhibit an amelioration of HDM-induced AHR and remodelling changes488. A recent study has 
also questioned the importance of antibody production and mast cell activation in inducing 
AHR in allergen challenge models. With the aim of specifically avoiding peripheral 
sensitisation, Mcknight et al. administered HDM to IgE- or FcεRIα-deficient and observed 
comparable tissue pathology and AHR relative to wild type mice492. 
Several studies that form part of this thesis have supported the concept that there can be a 
disconnect between inflammation and airway remodelling and AHR. Most notably in Chapter 
5, HDM-exposed lta4h-/- mice displayed a significant reduction in airway inflammation 
relative to littermate controls, but a striking increase in epithelial remodelling (epithelial 
hypertrophy and mucus production) and AHR. In this instance, the loss of LTB4-induced 
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inflammation was overridden by the increase in PGP driven remodelling. Additionally, in 
Chapter 4 the depletion of neutrophils in HDM-exposed mice resulted in increased Th2 
inflammation but comparable airway remodelling and AHR. Thus, it is clearly apparent that 
inflammation, airway remodelling and AHR can be divorced and it is likely that distinct 
mechanisms are more prevalent and driving disease in discrete subsets of asthmatic patients. 
6.4 The importance of the ECM and matrikines in inflammation and 
remodelling. 
The ECM has classically been thought of as a key component in providing structural support 
to solid organs,  with ECM components such as elastin, laminin, collagen and hyaluronan all 
acting as a scaffold for constituent cells134,381. ECM remodelling during development, 
inflammation and tissue repair requires the co-ordinated action of specific proteases such as 
elastases, collagenases, metalloproteases and hyaluronidases to ensure ECM turnover is tightly 
regulated throughout the animal’s development and lifetime134,381. Recently, however, it has 
been demonstrated that ECM components do not just provide a scaffold but are able to signal 
to proximal cells and shape their behaviour. For example, collagen can bind to discoidin 
receptors that are present on many leukocytes with this interaction shown to lead to the 
activation of cells such as lymphocytes and macrophages493. Additionally, proteolytic 
processing of ECM components can lead to the release of bioactive fragments, termed 
matrikines, which can act as signalling molecules for a multitude of cells. Maquart et al. were 
the first to coin the term ‘matrikine’ after characterising the function of “ECM-derived 
peptides”, GHK and CNYYSNS494. GNK was shown to be a potent trigger of ECM synthesis 
and via its ability to activate fibroblasts and CBYYSNS was demonstrated to inhibit neutrophil 
activation494. Subsequently, matrikines have become increasingly recognised as important 
modulators of inflammation and repair. Senior et al. demonstrated that elastases generated a 
monocyte chemoattractant from elastin fragments128. Subsequently, Houghton et al. showed 
that MMP-12 deficient mice were protected from cigarette smoke-induced emphysema due to 
their inability to produce these chemotactic elastin fragments129. Collagen-derived peptides had 
been shown to possess chemotactic potential for monocytes and fibrolasts128, and of course 
more recently neutrophils132. Hyaluronan-derived fragments have also been shown to function 
as signalling molecules, having been shown to elicit MIP-2 release from macrophages495. 
Recently, hyaluronan expression was demonstrated to be associated with increased epithelial 
cell renewal, with the abrogation of hyaluronan expression promoting the development of 
fibrosis in mice administered bleomycin496. 
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It is evident that matrikines serve as important localised signalling mediators that shape 
inflammation and ensuing tissue repair. Matrikines are essentially perfectly placed to act as 
“DAMPs” and sense localised tissue injury and co-ordinate an appropriate inflammatory 
response. Thus, as inflammatory cells are recruited to the site of infection/injury, they will 
release proteases that target ECM components to facilitate their migration through the dense 
matrix. Subsequently, matrikines will be liberated to efficiently guide subsequent inflammatory 
cells to the specific site of infection/injury whilst minimalizing unnecessary tissue damage. 
Following an inflammatory insult, matrikines are well placed to instigate an appropriate 
reparative and remodelling process and restore homeostasis. Indeed, in Chapter 5 I identified a 
novel epithelial remodelling role for PGP, dispelling the current dogma that it is only a 
neutrophil chemoattractant. Whilst high or persistent levels of PGP may drive pathological 
remodelling, it could be speculated that low, transient production can drive an epithelial 
reparative response. Similarly, it could be speculated that other matrikines function in a co-
ordinated manner to ensure the adequate resolution of inflammation and initiation of tissue 
repair and restoration of homeostasis.  
Neutrophils are a prominent source of the key proteases that degrade ECM components and 
generate matrikines, being a rich repository of MMP-8 and MMP-9 that can degrade collagen 
and laminins134,381, and  neutrophil elastase that can degrade elastin57. Accordingly, neutrophils 
are key players in defining the location and magnitude of inflammatory responses and the 
ensuing remodelling. Chronic lung diseases such as COPD445 and CF141,497 are characterised 
by persistent neutrophilic inflammation and a protease imbalance that destroys the tissue 
architecture. Furthermore, the excessive matrikine production can function to further 
perpetuate inflammation and accentuate pathology. Accordingly, matrikines such as PGP are 
abundant in these diseases and are associated with disease severity381. The role of matrikines, 
such as PGP, is yet to be fully explored in asthmatic patients but may play a key role in driving 
inflammation and remodelling, particularly in those individuals displaying a prominent 
neutrophilic component.  
Whilst no PGP was detectable in HDM-exposed wild type mice, I demonstrated that 
accumulation of this peptide in lta4h-/- mice drove pathological epithelial remodelling and 
mucus production. Human severe asthma is a heterogeneous disease with variable 
inflammatory, remodelling and clinical phenotypes.  Severe asthma phenotypes have been 
described that exhibit pronounced neutrophilic inflammation, which would lead to elevated 
PGP generation337. Furthermore, airway epithelial thickness and proliferation have been 
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demonstrated to be greater in severe asthmatics, and contribute to progressive decline in lung 
function466, but the mediator/s that drive this epithelial phenotype are unclear.  I have recently 
generated preliminary data suggesting that AcPGP is exclusively elevated in the sputum of 
severe asthmatics, suggesting that this could be a critical mediator in driving the pathological 
inflammatory and remodelling changes seen in these patients.  
6.5 Therapeutically targeting neutrophils in asthma – the implications. 
Therapeutically targeting neutrophilic inflammation in asthma has been of great interest in 
recent years. Various strategies have been deployed to reduce the levels of mediators that 
directly or indirectly drive neutrophil recruitment. 
LTB4 has represented an attractive target for the pharmaceutical sector for the treatment of 
severe asthma. Whilst LTB4 is a potent neutrophil chemoattractant, it is also recognised to act 
on a multitude of other inflammatory cells103 – as demonstrated in the HDM model in Chapter 
5.  Despite clear evidence from clinical and animal studies supporting the assertion that LTB4 
is a key pathophysiological mediator in asthma, drugs that have reduced its production have 
yielded disappointing results in clinical trials in asthmatic patients. This is exemplified by the 
LTA4H inhibitor JNJ-40929837 that despite showing target engagement and reducing LTB4 in 
a bronchial allergen challenge model of asthma, failed to improve FEV1357. As demonstrated in 
Chapter 5, perturbing the function of LTA4H in asthma could have deleterious repercussions 
by driving the accumulation of pro-remodelling PGP. My lab have demonstrated that inhibitors 
of LTA4H inhibit both hydrolytic and aminopeptidase functions of LTA4H and cause PGP 
accumulation in vivo87. Subsequently, my colleagues have generated substrate specific LTA4H 
inhibitors that prevent LTB4 generation, whilst still enabling PGP87. These specific inhibitors 
may represent an attractive therapeutic for the manipulation of LTB4 in AAD compared to 
previous non-selective strategies. 
Classical neutrophil chemokines also represent attractive targets for ameliorating neutrophilic 
inflammation in asthma. As discussed in Chapter 3, chemokine KC may be an important driver 
of the robust neutrophil infiltration in the lung and airways of HDM-exposed Balb/c mice. In 
humans, IL-8 is noted as a key neutrophil chemokine that signals via receptors CXCR1 and 
CXCR225. CXCR2 antagonists are currently being trialled in asthma, with one trial has showing 
reduced neutrophil numbers and the number of mild exacerbations in severe asthmatics359. 
However, FEV1 and symptom control were unchanged by CXCR2 treatment359. As discussed 
above, CXCR2 antagonist administration exacerbated AHR in the in-house HDM model of 
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AAD. It will be important in future to dissect why CXCR2 antagonists resulted in exacerbated 
lung function in the in-house HDM model as this may rationalise the somewhat disappointing 
effects of these therapeutics in the patients.  
Given the capacity of PGP to drive persistent neutrophilia and pathological remodelling, and 
my recent observations that this matrikine is elevated in severe asthmatics, then it may 
represent an attractive therapeutic target for severe asthma and other chronic lung diseases498. 
Aforementioned CXCR1/2 antagonists would be anticipated to block PGP-mediated 
neutrophilic inflammation, though it is yet to be determined whether the epithelial remodelling 
phenotype imparted by PGP is CXCR1/2 dependent498. Additionally, the broad expression of 
CXCR1/2, their multiple ligands, and the previously discussed adverse effects of antagonism 
of this receptor may make this strategy unappealing. Another strategy would be to reduce PGP 
levels through the use of inhibitors that target PGP-generating enzymes MMP-9 and PE138. 
However, these enzymes have pleiotropic functions and thus inhibition may result in 
undesirable off-target effects. Finally, it may be desirable to target PGP itself, with neutralizing 
antibodies or complementary neutralizing peptides such as RTR136. Macrolides are currently 
being explored for the treatment of severe neutrophilic asthma (Section 1.4.7). Accordingly, it 
is intriguing that another study demonstrated that administration of the macrolide azithromycin 
to COPD patients resulted in reduced PGP levels140. Whilst the mechanism by which 
macrolides may reduce PGP is unclear, it is feasible that these compounds could consequently 
reduce PGP-mediated neutrophilic inflammation and pathological epithelial remodelling in 
asthmatic patients. 
 
 
 
 
 
 
Chapter 7: Future work 
264 
 
7 Chapter 7: Future work 
7.1 Determine how inflammatory and remodelling parameters observed 
in distinct mouse strains correlate with those observed in discrete subsets of 
asthmatics. 
It is now apparent that asthma is a heterogeneous disease with different subsets of patients 
presenting with very different pathophysiologies. From the studies described in Chapter 3 it is 
apparent that different inbred mouse strains also present with very distinct inflammatory and 
remodelling profiles upon HDM exposure. In future, it will be of interest to interrogate more 
fully the extent to which certain facets of the AAD phenotype observed in different mouse 
strains mimics the corresponding parameters in discrete subsets of asthmatics; thus, 
rationalizing the utilisation of specific strains of mouse to identify biomarkers and investigate 
tailored subset-specific therapeutics for patients. 
I ascertained that HDM-exposed 129/S2 mice exhibited a robust type 2 response with 
substantial Th2 cytokine production, hyper-eosinophilia and mucus hypersecretion. Though 
speculative, it would be intriguing to further probe whether this phenotype mimics aspects of 
disease observed in asthmatics that present with hyper-eosinophilia. Specifically, it has been 
demonstrated that this subset of patients display pronounced levels of lung TGF-β192 and serum 
periostin342, and thus it should be ascertained whether these too are a hallmarks of the AAD 
presentation seen in 129/S2 mice. Furthermore, these hyper-eosinophilic asthmatic patients 
have also been reported to exhibit intense basement membrane thickening264. Although mice 
fail to develop such profound basement membrane thickening, it would be of interest to assess 
collagen levels and deposition in HDM-exposed 129/S2 mice by Sircoll assay and Sirius red 
staining of lung sections, respectively. 
Conversely, upon HDM administration, Balb/c mice displayed a mixed granulocytic airway 
inflammation with a robust neutrophilic infiltrate.  Subsets of asthmatic patients present with a 
neutrophilic or mixed granulocytic inflammation, and it is this group that are often refractory 
to conventional treatments and remain a significant unmet clinical need. Reliable biomarkers 
and mechanisms underlying pathology in these patients remain poorly defined. The levels of 
classical neutrophil chemokines, KC and MIP-2 were significantly elevated in Balb/c mice, 
supportive of reports indicating elevated levels of Gro family257 and IL-8257,280 in subsets of 
asthmatics that present with a neutrophilic infiltrate.  It would be of interest to more fully 
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characterise the levels of other neutrophil chemoattractants in the Balb/c mouse strain and 
patients with neutrophilic asthma, with LTB4 and PGP particularly pertinent given other studies 
described in this thesis. Interrogation of the mechanisms that drive a robust neutrophilic 
infiltrate in HDM-exposed Balb/c mice may facilitate our understanding of disease processes 
in this specific subset of patients. Accordingly, it would be of interest to ascertain the cellular 
source of these neutrophil chemoattractants in HDM exposed Balb/c mice, by analysis of RNA 
in isolated populations such as macrophages and epithelial cells. Subsequently, ex vivo analysis 
of these isolated populations upon exposure to HDM could reveal whether their augmented 
pro-neutrophilic response is imparted by intrinsic mouse-strain specific differences in the 
isolated population of cells or by alterations in the lung microenvironment in which the cells 
reside. If, for example, alveolar macrophages were shown to be the prominent source of the 
neutrophil chemoattractants then these cells could be adoptively transferred499–501 between 
Balb/c and 129/S2 mice to infer the effect on ensuing HDM-driven neutrophilic inflammation. 
Dissected mechanisms could then be interrogated in isolated populations from subsets of 
asthmatic patients.  
7.2 Assessment of therapeutic budesonide treatment in HDM model. 
The series of studies detailed in Chapter 3 also demonstrated the beneficial effects of a 
prophylactic dosing regimen of budesonide in the HDM model of AAD in reducing 
inflammation, remodelling and AHR in all strains of mice. In the clinic, asthmatics presenting 
with neutrophilic airway inflammation have often been shown to be refractory to budesonide 
treatment257,338, with steroids shown to promote neutrophil survival257. The neutrophilic 
inflammation observed in HDM-treated Balb/c mice was reduced by prophylactic budesonide 
treatment but incompletely, being significantly more resistant to budesonide than other 
inflammatory components. However, it must be stressed that asthmatic patients receiving 
budesonide therapy would already have established disease145, and thus a prophylactic 
treatment regimen is not reflective of the clinical scenario. In future, it will therefore be 
important to assess the consequence of therapeutic budesonide treatment in HDM-exposed 
Balb/c and 129/S2 mice to infer whether inflammatory, remodelling and lung function changes 
are still responsive to this delayed treatment in different strains of mice – and specifically if 
neutrophilic inflammation is altered. In this instance, a 5 week HDM model would be utilised, 
whereby HDM is administered throughout the entire 5 weeks with budesonide administered 
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concomitantly for the final 2 weeks (a time when inflammation, remodelling and AHR are 
already established). 
7.3 Identification of HDM components that drive neutrophilic 
inflammation. 
As highlighted previously, HDM contains an array of components with the potential to promote 
neutrophil recruitment. I have demonstrated that neutrophilia in the in-house HDM model is 
seemingly TLR4 and thus LPS independent, suggestive that other components are important.  
I have previously speculated that intrinsic proteases within HDM and chitins could be 
responsible for this phenotype. There are an abundant number of proteases within the HDM 
extract, the most notable being the cysteine protease, der p 1159 which is linked to inducing 
allergenicity. HDM has also been shown to contain other serine and cysteine proteases such as 
der p 3, der p 6 and der p 9 that are known to cleave tight junction proteins and activate cell 
surface PARs502. Asthmatic patients display increased PAR-2 expression on epithelial cells 
compared to healthy controls503. As highlighted previously, neutrophil chemokine release from 
alveolar macrophages and epithelial cells can be mediated via activation of PAR-2404, thus 
proteases within HDM could indeed drive neutrophilic inflammation and would be of interest 
to dissect further. Chitins are commonly derived from exoskeletons and are abundant in HDM 
extracts159. Chitins have been shown to directly induce neutrophil activation by promoting 
chitinase secretion but can also act on alveolar macrophages to drive neutrophil chemokine 
release403. Treating isolated neutrophils, alveolar macrophages and epithelial cells with chitin 
components and the differential proteases characterised in the HDM extract159 could interrogate 
whether these components could activate neutrophils or trigger the release or factors that 
activate or recruit neutrophils. Furthermore, anti-PAR-2 antibodies or specific protease 
inhibitors could be administered to HDM-treated mice to further dissect the involvement of 
intrinsic proteases in inducing neutrophil recruitment405. 
Intriguingly, it was found that HDM extract contained endogenous PGP that could potentially 
support neutrophilic inflammation. It would be of interest to ascertain whether HDM can 
directly elicit the chemotaxis of mouse bone marrow-derived or human peripheral blood 
neutrophils in vitro, and whether PGP antagonist, RTR can abrogate this chemotaxis. 
Additionally, RTR could be admixed with HDM extract prior to administration to Balb/c mice 
and airway neutrophilia assessed. If HDM-derived PGP is contributing to the observed 
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neutrophilic inflammation in Balb/c mice then this raises the question as to why minimal 
neutrophils are seen in the 129/S2 strain. Do different strains of mice possess different levels 
of extracellular LTA4H that degrades the PGP? 
7.4 Interrogation of the G-CSF axis in neutrophil depleted mice. 
Administration of neutrophil depleting antibody, 1A8, to HDM exposed mice resulted in 
increased Th2 inflammation that was seemingly the consequence of elevated Th2 cytokine 
production by ILC2s and a monocytosis phenotype that resulted in enhanced antigen 
presentation. This evidence suggests that elevated G-CSF levels in neutrophil depleted mice 
may drive this phenotype, but there remain several unanswered questions. Firstly, why is G-
CSF so strikingly elevated in neutrophil depleted animals? It will be of interest to ascertain 
what the cellular source of G-CSF504 is and consequently whether its expression is elevated in 
neutrophil depleted animals or if the elevated levels of G-CSF protein simply reflect greater 
availability owing to the absence of neutrophils taking it up.  IL-17 has previously been shown 
to enhance the production of G-CSF in mice419. Bugl et al. later identified that depletion of 
neutrophils augmented the production of IL-17 from T cells due to elevated IL-23 levels as a 
consequence of local macrophages phagocytosing neutrophils bound to 1A8419. Additionally 
studies utilising CXCR2 -/- mice reported that CXCR2 expression on neutrophils seemingly 
inhibited the IL-17/G-CSF axis during homeostasis; thus the presence of neutrophils alone may 
be sufficient to reduce systemic levels of G-CSF505. Therefore, it is plausible that IL-17 and 
IL-23 levels may be increased in neutrophil-depleted mice and are indeed responsible for the 
heightened concentrations of G-CSF. 
These studies also suggested a novel role for G-CSF in regulating production of Th2 cytokine 
production by ILC2s. It will be necessary to confirm this assertion by FACS sorting ILC2s 
from HDM exposed control and neutrophil depleted mice and assessing gene expression of 
Th2 cytokines. I have demonstrated that G-CSF treatment increases IL-13+ production by 
cultured human ILC2s when assessed by intracellular cytokine staining. This analysis needs to 
be expanded to other Th2 cytokines and confirmed in ILC2s from more patients and verified 
at the gene expression level and cytokine release into the supernatant. The exact mechanism 
by which G-CSF modulates IL-13 production remains incompletely understood. Assessment 
of the expression of the G-CSF receptor, csfr3, on ILC2s needs to be interrogated to support 
the assertion that G-CSF is able to directly act on this cell type. Additionally, assessment of 
global changes in ILC2 gene expression post G-CSF treatment would be informative in 
Chapter 7: Future work 
268 
 
defining the mechanism of action - with changes to expression of key genes regulating cytokine 
production, such as GATA-3, being particularly pertinent.  
Neutrophil depletion in HDM-exposed mice also resulted in a monocytosis that seemingly was 
a consequence of increased numbers of MDPs in the bone marrow. As discussed previosuly, it 
remains unknown at what level in monocyte development G-CSF is acting to enhance 
progenitor numbers within the bone marrow. GMPs have previously been shown to be elevated 
post neutrophil depletion, thus there is evidence that progenitors further upstream are being 
dysregulated as a consequence of neutrophil depletion419. It would be pertinent to assess the 
gene expression of Csfr3 on different progenitor cells and assess the effects of G-CSF on the 
progenitors cells that express the receptor. 
7.5 The effects of LTA4H inhibition in the context of neutrophilic AAD 
model. 
As discussed previously, the lta4h-/- mice utilised in this project were on a 129/S2 background 
which seemingly generated hypereosinophilic inflammation with minimal neutrophil 
infiltration into the lung and airways. Neutrophilic inflammation is commonly associated with 
increased PGP levels mainly in part because neutrophils are a source of PGP-generating 
enzymes133,445. As such, the levels of PGP in the BALF of lta4h-/- mice on a 129/S2 background 
were very low and possibly not sufficient to trigger neutrophil chemoattraction. Therefore, it 
could be speculated that a neutrophilic model of AAD373 or the utilisation of Balb/c mice 
administered HDM may highlight a different effect of PGP when LTA4H function is perturbed. 
Would PGP levels be higher if lta4h-/- mice were on a Balb/c background or in a neutrophilic 
HDM model? Furthermore, could the increased PGP levels now lead to augmentation in 
neutrophil inflammation compared to the 129/S2 mouse strain?  
7.6 Dissect the effects of PGP on bronchial epithelial cells. 
In Chapter 5 I demonstrated a novel role for PGP in driving bronchial epithelial cell 
proliferation and morphological changes reminiscent to that seen in a wound healing response. 
However, PGP persistence in ALI cultures and in the in-house HDM model manifested in 
pathological epithelial remodelling with epithelial hypertrophy and mucus hypersecretion.  
These intriguing observations clearly demand further interrogation to define the mechanisms 
of action.  
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It will be important to define the effect of PGP on submerged primary healthy human bronchial 
epithelial cells (HBECs), with key findings validated in cells at airway-liquid interface. 
Epithelial repair responses could be interrogated using standard wound healing assays506 in 
real-time using Juli Stage automated cell imaging. Cardinal features of epithelial 
repair/remodelling507,508 such as cell spreading, actin cytoskeletal re-organization, focal 
adhesion formation506,509, adherens/tight junctions506 and ECM adherence should all be 
assessed.    
To define preferential activity of PGP on epithelial sub-populations, treated ALI cells can be 
stained for FoxJ1, CC10, KRT5 and MUC5AC/5B, with CXCR1/2 and Ki-67510 and detailed 
morphological changes assessed by transmission electron microscopy511. Global changes in 
PGP-induced gene expression should be determined at multiple time points by RNA-seq, with 
subsequent confirmation/interrogation of pathways. CXCR2 is expressed on epithelial cells358 
but whether PGP is acting through this receptor should be assessed. Receptor antagonists will 
ascertain CXCR1/2 dependency of PGP-induced phenotypes, and activity should be compared 
with conventional CXCR1/2 ligands. Functional consequences of PGP treatment could be 
interrogated by micro-optical tomography of ALI cells with assessment of cilia function, mucus 
depth/movement512.  
Observations and mechanisms of PGP action elucidated in vitro with bronchial epithelial cells 
can be further interrogated in HDM-exposed LTA4H-/- mice to infer whether the same PGP-
specific signature is apparent in vivo. Furthermore, epithelial cell functionality is altered in 
asthmatic patients513, and thus it will be of interest to ascertain the responsiveness to PGP of 
epithelial cells (bronchial brushing-derived) from asthmatic patients to infer if it differs to that 
seen in healthy cells. 
7.7 The function of LTA4H in asthmatic patients. 
The in-vivo studies in Chapter 5 demonstrated the severe consequences of perturbed LTA4H 
aminopeptidase activity and PGP accumulation in an AAD murine model. However, a 
limitation of this study is the current absence of corroborating clinical data dissecting PGP and 
the LTA4H pathway in asthmatic patients. Subsets of severe asthmatics present with 
neutrophilic inflammation273,337 and pathological epithelial hypertrophy466 – potential 
consequences of PGP accumulation. Whilst HDM-exposed wild type mice have intact LTA4H 
activity and thus can readily degrade PGP, it is unknown if this pathway is actually perturbed 
in patients with severe asthma.  Indeed, it is known that PGP accumulates in other chronic 
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neutrophilic lung diseases such as COPD445, cystic fibrosis141 and bronchiolitis obliterans 
syndrome142 as a consequence of aberrant LTA4H aminopeptidase activity. For example, 
components within cigarette smoke inhibit LTA4H aminopeptidase activity406. Accordingly, it 
is known that cigarette smoke exacerbates asthma150; which could potentially be attributable to 
PGP accumulation. On-going studies are beginning to investigate this pathway in asthmatic 
cohorts, with exciting data suggesting that PGP is selectively elevated in severe asthmatics. 
The reason why PGP is able to accumulate in this cohort of patients should be interrogated, 
and where possible PGP levels correlated with lung function, neutrophilic inflammation and 
epithelial remodelling. 
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